data_2kux_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kux _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.874 0 CA-C-O 120.089 -0.284 . . . . 0.0 112.811 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.518 ' HG1' ' HB3' ' A' ' 29' ' ' LEU . 17.0 p -98.83 113.25 64.29 Favored Pre-proline 0 C--O 1.224 -0.257 0 CA-C-N 117.507 0.653 . . . . 0.0 111.682 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.4 Cg_exo -49.51 128.96 22.01 Favored 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.932 2.422 . . . . 0.0 112.6 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 12.7 m -88.5 16.49 6.45 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.593 -178.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 58.72 32.57 69.94 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.892 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.586 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 32.8 tt0 -136.24 145.82 46.04 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -179.362 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.54 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -137.48 151.99 49.06 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.031 0.443 . . . . 0.0 111.874 -178.686 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 29.7 p -109.54 39.54 2.07 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.33 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.54 HG23 ' HB2' ' A' ' 7' ' ' SER . 16.5 t -72.04 -41.58 68.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.173 -179.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 19.5 m-85 -115.1 -47.95 2.84 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.647 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.573 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 34.7 pt -122.16 153.31 61.32 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.064 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -66.27 154.39 74.37 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.296 1.997 . . . . 0.0 111.768 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.586 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 72.3 m -68.04 128.24 35.8 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.287 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 61.8 mt -90.08 -44.35 14.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-O 121.359 0.599 . . . . 0.0 109.409 178.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.566 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.2 m -72.52 -23.66 61.04 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.139 179.267 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 1.011 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -52.62 -19.34 6.34 Favored Glycine 0 CA--C 1.519 0.31 0 CA-C-N 115.322 -0.853 . . . . 0.0 114.185 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 36.0 m -60.45 -18.96 17.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.871 0.336 . . . . 0.0 111.885 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.566 HG12 ' O ' ' A' ' 15' ' ' SER . 33.2 pt -79.79 -1.71 4.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.804 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 130.94 -19.4 4.95 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.403 -0.903 . . . . 0.0 112.14 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 1.011 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 56.2 m -58.58 121.92 12.16 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.301 0.572 . . . . 0.0 111.131 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 15.4 m -105.84 132.86 51.44 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.099 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.603 ' HA ' ' HA ' ' A' ' 27' ' ' CYS . 1.7 t -75.03 108.99 8.13 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.511 0.672 . . . . 0.0 111.176 -178.674 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.7 m -109.42 118.3 36.29 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.013 -0.994 . . . . 0.0 108.462 178.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.519 ' CG ' ' HZ3' ' A' ' 25' ' ' LYS . 30.9 t70 52.11 52.44 14.35 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 122.065 0.936 . . . . 0.0 110.93 -178.523 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.519 ' HZ3' ' CG ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 69.76 3.53 4.32 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.779 -1.1 . . . . 0.0 113.533 178.797 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 33.0 t -127.29 124.13 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 118.622 0.646 . . . . 0.0 110.505 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.603 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 7.3 m -75.53 124.87 27.92 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.658 0.742 . . . . 0.0 112.836 -179.193 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.448 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.4 m-85 -114.72 144.88 42.75 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.579 179.163 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.7 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 46.1 tp -92.9 81.32 4.63 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 178.519 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.9 m-80 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.449 -179.308 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.805 0 CA-C-O 120.028 -0.318 . . . . 0.0 113.271 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.583 HG21 ' HB3' ' A' ' 29' ' ' LEU . 4.9 t -106.92 118.45 54.1 Favored Pre-proline 0 C--O 1.223 -0.31 0 CA-C-N 117.755 0.778 . . . . 0.0 111.488 -179.178 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.548 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 9.5 Cg_endo -51.39 135.56 46.97 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 123.124 2.55 . . . . 0.0 112.373 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.684 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 6.7 m -93.7 7.65 43.96 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.345 -179.269 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 79.51 -25.97 2.75 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.576 -178.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.714 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 33.2 tt0 -74.06 131.2 41.11 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.5 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -112.56 154.0 26.64 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.49 0.662 . . . . 0.0 111.887 -178.744 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.7 p -122.24 44.75 2.52 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.872 -1.058 . . . . 0.0 109.688 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.655 HG21 ' HB3' ' A' ' 25' ' ' LYS . 12.9 t -72.43 -44.46 62.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.699 -178.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -112.19 -49.61 2.96 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.022 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 34.4 pt -118.76 155.59 52.45 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.391 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_exo -67.17 153.01 78.77 Favored 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 122.432 2.088 . . . . 0.0 111.753 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.714 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 62.0 m -70.82 130.97 43.07 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.54 -0.755 . . . . 0.0 111.462 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 27.7 pt -88.72 -38.04 10.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.889 0.376 . . . . 0.0 110.529 179.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.552 ' O ' HG12 ' A' ' 18' ' ' ILE . 2.8 m -74.77 -18.33 60.5 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.196 0.522 . . . . 0.0 109.895 179.245 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.939 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.08 -18.23 6.06 Favored Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.158 -0.928 . . . . 0.0 113.923 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.4 m -59.47 -19.81 17.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.925 0.393 . . . . 0.0 111.686 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.552 HG12 ' O ' ' A' ' 15' ' ' SER . 33.4 pt -79.04 -4.03 6.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.771 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 133.41 -21.61 4.04 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.994 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.939 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 50.1 m -60.52 122.28 14.25 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.342 0.592 . . . . 0.0 110.699 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.473 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.9 m -108.47 141.92 39.62 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.449 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.1 t -64.93 113.06 3.59 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.975 0.416 . . . . 0.0 110.262 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.1 m -122.57 100.27 6.84 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.086 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.441 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 23.0 t70 47.73 63.69 1.91 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.448 -0.796 . . . . 0.0 111.79 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.655 ' HB3' HG21 ' A' ' 9' ' ' VAL . 0.8 OUTLIER 72.43 -4.28 2.09 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 115.027 -0.988 . . . . 0.0 113.136 178.844 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 44.3 t -130.81 127.31 61.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 118.671 0.669 . . . . 0.0 110.718 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.473 ' HA ' ' O ' ' A' ' 21' ' ' SER . 30.6 m -80.71 127.75 32.85 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.539 0.685 . . . . 0.0 112.267 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.548 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.5 m-85 -112.27 144.72 41.2 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.255 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.684 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.8 tp -93.43 83.91 4.63 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 114.871 -1.059 . . . . 0.0 112.004 -179.61 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.792 0 CA-C-O 120.212 -0.215 . . . . 0.0 112.854 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.6 m -96.12 109.9 49.35 Favored Pre-proline 0 C--O 1.223 -0.335 0 CA-C-N 117.342 0.571 . . . . 0.0 111.077 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 71.1 Cg_exo -48.67 132.45 25.67 Favored 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 122.927 2.418 . . . . 0.0 112.663 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.533 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.3 m -92.34 3.58 55.12 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 121.164 0.507 . . . . 0.0 109.852 -179.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.82 -27.37 3.0 Favored Glycine 0 N--CA 1.448 -0.536 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 -178.253 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.464 ' H ' ' C ' ' A' ' 4' ' ' CYS . 21.9 tt0 -76.96 134.18 38.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 179.508 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -126.01 146.39 49.91 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.537 0.684 . . . . 0.0 112.18 -178.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.527 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 5.3 p -109.87 48.1 0.91 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.772 -1.103 . . . . 0.0 110.422 179.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.6 HG23 ' HB3' ' A' ' 25' ' ' LYS . 19.9 t -68.15 -38.21 79.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.699 -179.737 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -115.02 -50.27 2.77 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.661 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.527 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 32.9 pt -121.44 150.81 55.37 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.965 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -62.87 153.64 71.68 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.418 2.078 . . . . 0.0 112.258 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 61.1 m -74.66 131.06 40.59 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.396 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 12.7 tt -79.94 -34.95 15.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.791 178.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.701 ' O ' HG12 ' A' ' 18' ' ' ILE . 16.2 m -77.66 -0.09 25.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.888 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.729 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -56.7 -23.86 45.77 Favored Glycine 0 CA--C 1.519 0.336 0 C-N-CA 121.392 -0.432 . . . . 0.0 112.855 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.4 t -60.08 -26.42 36.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.962 0.41 . . . . 0.0 111.835 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.701 HG12 ' O ' ' A' ' 15' ' ' SER . 18.6 pt -80.9 5.21 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.592 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 120.51 -18.29 9.4 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.157 -1.021 . . . . 0.0 112.921 179.247 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.729 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 46.3 m -63.27 124.86 22.3 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.235 0.541 . . . . 0.0 110.624 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.468 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 12.2 m -119.57 144.46 47.07 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.156 -179.725 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 23.7 m -63.22 112.58 2.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.41 0.624 . . . . 0.0 111.833 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.2 m -120.02 95.67 4.85 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.139 -0.937 . . . . 0.0 108.588 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 48.1 t0 49.84 59.57 4.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.507 -0.769 . . . . 0.0 111.384 -178.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.6 ' HB3' HG23 ' A' ' 9' ' ' VAL . 26.6 mtmm 75.99 -9.79 1.39 Allowed 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.287 -0.869 . . . . 0.0 113.067 178.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.2 t -120.29 127.29 75.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.409 0.549 . . . . 0.0 110.517 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.542 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 69.7 m -80.64 122.74 27.46 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.561 0.696 . . . . 0.0 112.729 -179.089 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-30 -109.9 142.62 40.98 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.367 178.705 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.533 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.7 tt -89.88 84.52 6.23 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.511 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m120 . . . . . 0 C--N 1.324 -0.521 0 CA-C-N 114.591 -1.186 . . . . 0.0 110.996 -178.654 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.753 0 CA-C-O 120.206 -0.219 . . . . 0.0 112.751 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.2 m -99.28 113.4 64.75 Favored Pre-proline 0 C--O 1.221 -0.418 0 CA-C-N 117.4 0.6 . . . . 0.0 111.214 -179.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.439 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 78.9 Cg_exo -47.46 133.34 20.48 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.986 2.457 . . . . 0.0 112.845 -179.767 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.592 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 12.7 m -90.91 7.81 38.25 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.094 0.473 . . . . 0.0 110.019 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.27 -27.05 2.84 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 120.921 -0.656 . . . . 0.0 111.713 -178.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.427 ' H ' ' C ' ' A' ' 4' ' ' CYS . 61.3 tt0 -80.31 133.56 35.97 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.109 0.48 . . . . 0.0 109.719 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.477 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 0.5 OUTLIER -114.03 146.63 39.92 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.611 0.72 . . . . 0.0 112.044 -179.084 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.7 p -105.76 47.09 0.89 Allowed 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.706 -1.133 . . . . 0.0 110.208 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.531 ' HA ' ' HG3' ' A' ' 25' ' ' LYS . 21.2 t -73.77 -42.08 54.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.591 -179.048 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.6 m-85 -111.1 -48.31 3.12 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.304 -179.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.7 pt -129.9 161.41 59.83 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.264 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -66.85 152.11 81.06 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.278 1.986 . . . . 0.0 111.651 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.4 m -74.61 133.94 42.13 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.752 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 15.3 tt -74.41 -34.35 36.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.117 179.003 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.718 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.2 m -73.95 -0.82 17.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.829 179.534 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.635 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.61 -27.13 58.3 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.744 179.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.3 m -62.72 -20.88 26.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.718 HG12 ' O ' ' A' ' 15' ' ' SER . 13.6 pt -87.98 0.69 6.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.821 -0.351 . . . . 0.0 111.456 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 124.89 -18.74 7.04 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.249 -0.977 . . . . 0.0 112.638 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.635 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 61.9 m -60.88 122.88 15.99 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.398 0.618 . . . . 0.0 110.691 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.44 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.7 m -113.62 140.78 47.91 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.065 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 48.1 t -66.2 119.34 11.31 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.847 0.356 . . . . 0.0 110.162 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 22.9 m -133.96 107.68 7.95 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.17 -179.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.484 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 44.5 t0 49.06 57.86 6.0 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.507 -0.769 . . . . 0.0 111.921 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.531 ' HG3' ' HA ' ' A' ' 9' ' ' VAL . 0.0 OUTLIER 73.8 -4.45 2.25 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 113.416 0.895 . . . . 0.0 113.416 178.405 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.477 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 60.5 t -130.58 131.72 64.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 118.415 0.552 . . . . 0.0 110.749 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.44 ' HA ' ' O ' ' A' ' 21' ' ' SER . 87.5 m -81.28 129.21 34.51 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.297 0.57 . . . . 0.0 112.139 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.439 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.0 m-85 -112.74 142.83 44.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.46 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.592 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.8 tp -89.87 82.27 6.23 Favored 'General case' 0 C--N 1.31 -1.148 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.157 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.8 m120 . . . . . 0 N--CA 1.466 0.331 0 CA-C-N 114.804 -1.089 . . . . 0.0 111.286 -178.372 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.792 0 CA-C-O 120.146 -0.252 . . . . 0.0 113.004 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.452 ' HG1' ' HB3' ' A' ' 29' ' ' LEU . 17.0 p -99.19 115.35 65.79 Favored Pre-proline 0 C--O 1.223 -0.298 0 CA-C-N 117.499 0.65 . . . . 0.0 111.622 -179.179 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.417 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 68.9 Cg_exo -51.47 127.89 23.95 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.811 2.341 . . . . 0.0 112.59 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.656 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.4 m -84.09 12.78 5.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.652 -179.003 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.91 29.31 73.78 Favored Glycine 0 C--N 1.332 0.332 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -178.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.524 ' OE2' HG21 ' A' ' 14' ' ' ILE . 38.0 tt0 -129.63 149.56 51.34 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 114.504 -0.848 . . . . 0.0 109.03 -178.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.47 146.29 44.11 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.361 0.601 . . . . 0.0 111.752 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.534 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 8.6 p -117.89 50.62 1.12 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.488 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.9 t -68.02 -32.75 57.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.63 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -128.27 -50.67 1.3 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.24 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.534 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 31.5 pt -104.66 143.09 25.99 Favored Pre-proline 0 C--N 1.324 -0.511 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.093 179.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 21.2 Cg_exo -63.45 158.52 44.9 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.64 2.227 . . . . 0.0 112.44 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.494 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 10.9 m -60.72 119.78 8.8 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.904 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . 0.524 HG21 ' OE2' ' A' ' 6' ' ' GLU . 8.6 tp -78.98 -35.34 17.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 178.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.577 ' O ' HG21 ' A' ' 18' ' ' ILE . 25.3 t -82.94 3.49 29.75 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.693 178.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.56 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -56.18 -21.65 33.21 Favored Glycine 0 C--N 1.33 0.222 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.283 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.9 t -59.94 -28.4 40.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.981 0.42 . . . . 0.0 111.538 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.577 HG21 ' O ' ' A' ' 15' ' ' SER . 18.2 tt -78.93 -9.29 12.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 121.224 0.535 . . . . 0.0 111.442 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.67 -18.56 5.67 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.798 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.56 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 61.1 m -55.01 124.55 17.14 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.218 0.533 . . . . 0.0 110.628 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 20.4 m -122.79 150.01 43.38 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.879 -178.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.3 m -64.51 115.32 5.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.339 0.59 . . . . 0.0 111.717 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.6 m -125.44 96.79 4.94 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 179.002 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.457 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 47.8 t0 53.28 54.09 10.77 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.685 -178.169 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.614 ' HB2' ' HZ3' ' A' ' 25' ' ' LYS . 6.9 mtmp? 74.22 -9.82 1.22 Allowed 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 114.977 -1.011 . . . . 0.0 112.752 179.528 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 t -111.41 130.09 65.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.4 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 23.3 m -78.38 119.74 22.14 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.221 0.534 . . . . 0.0 111.366 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.499 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 2.8 m-85 -110.99 144.53 39.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.391 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.656 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 57.2 tp -96.99 83.12 3.32 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 178.37 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.495 -179.07 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.87 0 CA-C-O 120.155 -0.247 . . . . 0.0 112.909 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.522 ' HG1' ' HB3' ' A' ' 29' ' ' LEU . 16.8 p -100.58 113.32 65.53 Favored Pre-proline 0 C--O 1.223 -0.301 0 CA-C-N 117.399 0.599 . . . . 0.0 111.636 -179.15 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.472 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.5 Cg_exo -49.22 132.12 27.84 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.895 2.397 . . . . 0.0 112.584 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.653 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.4 m -91.53 5.23 50.34 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 121.011 0.434 . . . . 0.0 110.249 -179.329 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.45 -24.76 3.5 Favored Glycine 0 N--CA 1.451 -0.353 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -178.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.657 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 19.7 tt0 -72.3 133.11 44.83 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.441 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.5 p -115.32 164.44 14.24 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 121.413 0.625 . . . . 0.0 111.979 -178.66 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.6 p -139.43 43.77 2.0 Allowed 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.716 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 12.3 t -70.62 -44.62 76.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.054 -179.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -128.47 -45.11 1.35 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.818 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.496 HG21 ' HD2' ' A' ' 12' ' ' PRO . 66.4 mt -103.86 134.39 19.75 Favored Pre-proline 0 C--N 1.321 -0.638 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.027 179.38 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.496 ' HD2' HG21 ' A' ' 11' ' ' ILE . 14.9 Cg_exo -64.6 152.55 81.38 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.133 1.889 . . . . 0.0 111.775 -179.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.657 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 58.2 m -62.73 -47.29 84.22 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.669 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 78.6 mt 73.41 -55.53 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 122.893 0.477 . . . . 0.0 111.1 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.3 m -67.91 -16.23 63.98 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.3 0.571 . . . . 0.0 110.01 179.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.685 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.17 -16.36 4.47 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.061 -0.972 . . . . 0.0 113.675 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 31.2 m -58.31 -17.67 9.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.107 0.48 . . . . 0.0 111.224 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.4 tp -71.55 -15.99 18.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.145 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 144.96 -23.87 1.94 Allowed Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.685 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 55.5 m -65.67 121.13 14.26 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.445 0.64 . . . . 0.0 110.948 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.487 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.9 m -105.87 139.16 40.86 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.522 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 46.5 t -66.03 102.9 0.86 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.246 0.546 . . . . 0.0 110.423 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.2 m -112.46 106.98 15.59 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.072 -179.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 46.9 t0 47.21 59.55 3.99 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.887 -179.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 22.2 mtmm 70.68 6.27 5.76 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.246 -0.888 . . . . 0.0 113.317 178.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.441 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 45.2 t -137.83 125.93 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 118.236 0.471 . . . . 0.0 110.168 179.442 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.582 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 11.7 m -77.94 122.92 26.15 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.509 0.671 . . . . 0.0 112.292 -179.56 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.505 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 2.3 m-85 -108.69 144.36 36.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.9 179.296 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.653 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.8 tp -91.8 80.99 5.22 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.3 m-80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.554 -179.183 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.848 0 CA-C-O 120.278 -0.179 . . . . 0.0 112.741 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 23.5 m -98.42 112.89 63.39 Favored Pre-proline 0 C--O 1.22 -0.478 0 CA-C-N 117.327 0.564 . . . . 0.0 111.215 -179.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.428 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.4 Cg_exo -47.82 132.95 22.16 Favored 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 122.997 2.465 . . . . 0.0 112.863 -179.795 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.607 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 9.0 m -91.58 6.73 44.57 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.094 0.473 . . . . 0.0 110.024 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.2 -27.42 2.76 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.507 -178.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.497 ' OE2' ' HB3' ' A' ' 13' ' ' CYS . 16.3 tt0 -77.48 126.88 31.6 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.496 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 0.6 OUTLIER -109.12 151.87 25.85 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.627 0.727 . . . . 0.0 112.062 -178.577 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -114.78 51.06 0.92 Allowed 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.887 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.461 ' HA ' ' HB2' ' A' ' 25' ' ' LYS . 14.5 t -68.87 -44.9 81.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.769 -178.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -109.72 -46.86 3.44 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.218 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 30.7 pt -129.37 157.68 75.48 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.172 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -64.76 152.37 82.3 Favored 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 122.247 1.965 . . . . 0.0 111.616 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.497 ' HB3' ' OE2' ' A' ' 6' ' ' GLU . 27.1 m -71.41 132.73 45.23 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.573 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . 0.438 HG22 ' N ' ' A' ' 15' ' ' SER . 12.5 tt -74.7 -36.48 40.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.839 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.658 ' O ' HG12 ' A' ' 18' ' ' ILE . 15.3 m -75.81 -3.66 36.31 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.644 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.754 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.47 -22.66 46.12 Favored Glycine 0 C--N 1.331 0.282 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.822 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 13.7 p -61.06 -22.69 27.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.858 0.361 . . . . 0.0 111.831 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.658 HG12 ' O ' ' A' ' 15' ' ' SER . 18.5 pt -80.09 -1.03 4.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 111.839 0.311 . . . . 0.0 111.839 -179.837 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.69 -21.53 5.62 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.275 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.754 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 58.3 m -61.54 121.9 13.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.401 0.62 . . . . 0.0 110.809 -179.787 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.435 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -108.83 138.88 44.47 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.258 -179.724 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.7 t -69.63 124.02 22.86 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.849 0.357 . . . . 0.0 110.516 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 48.8 m -148.45 120.07 8.02 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.76 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 6.5 t70 50.99 57.67 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.372 0.606 . . . . 0.0 110.146 -178.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.76 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 54.15 14.68 0.77 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.028 1.331 . . . . 0.0 113.703 -179.709 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.496 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 57.6 t -137.07 131.32 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 O-C-N 122.052 -0.405 . . . . 0.0 110.247 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.466 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 73.1 m -82.54 128.02 33.9 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 121.723 -0.611 . . . . 0.0 112.044 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.428 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-85 -111.45 142.47 43.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.372 179.653 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.607 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.5 tp -89.59 82.22 6.39 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.345 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.7 m120 . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 114.726 -1.124 . . . . 0.0 111.128 -178.473 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.768 0 CA-C-O 120.008 -0.329 . . . . 0.0 113.306 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.5 t -104.73 118.7 55.75 Favored Pre-proline 0 C--O 1.224 -0.284 0 CA-C-N 117.766 0.783 . . . . 0.0 111.661 -179.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 65.8 Cg_exo -50.77 136.73 42.8 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 123.028 2.485 . . . . 0.0 112.535 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.606 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 10.0 m -93.65 5.42 51.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.072 0.463 . . . . 0.0 110.05 -179.566 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.82 -26.39 3.22 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.789 -178.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.413 ' H ' ' C ' ' A' ' 4' ' ' CYS . 50.9 tt0 -79.01 132.92 36.82 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.519 ' HB2' HG22 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -110.55 147.57 33.91 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.602 0.715 . . . . 0.0 112.055 -178.975 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.0 p -110.88 49.12 0.88 Allowed 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.847 -1.07 . . . . 0.0 110.143 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.531 ' HA ' ' HG3' ' A' ' 25' ' ' LYS . 20.7 t -72.08 -42.53 67.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.658 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -110.37 -48.06 3.21 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.932 -0.577 . . . . 0.0 111.357 -179.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.41 HG23 HD12 ' A' ' 11' ' ' ILE . 31.8 pt -130.0 161.81 57.58 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.304 -179.348 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo -66.2 152.33 81.4 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 122.321 2.014 . . . . 0.0 111.632 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 46.1 m -72.83 137.27 45.62 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.751 -179.069 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 46.4 mm -73.1 -38.57 55.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.223 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.598 ' O ' HG21 ' A' ' 18' ' ' ILE . 2.1 m -73.45 2.42 7.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.188 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.624 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.83 -25.64 56.44 Favored Glycine 0 N--CA 1.453 -0.201 0 C-N-CA 121.252 -0.499 . . . . 0.0 112.791 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.7 m -62.62 -20.96 26.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.598 HG21 ' O ' ' A' ' 15' ' ' SER . 8.7 tp -83.99 -6.35 10.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.25 0.548 . . . . 0.0 111.053 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.55 -18.51 5.72 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.514 -0.851 . . . . 0.0 111.816 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.624 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 60.3 m -59.23 122.04 12.85 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.395 0.617 . . . . 0.0 110.892 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.439 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.7 m -113.86 142.66 45.83 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.096 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.6 t -63.61 114.78 4.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.973 0.416 . . . . 0.0 110.184 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.7 m -121.51 94.48 4.34 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.038 -0.528 . . . . 0.0 109.924 -179.68 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.604 ' C ' ' HE3' ' A' ' 25' ' ' LYS . 38.7 t70 46.37 65.26 1.23 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.131 -0.941 . . . . 0.0 112.07 -179.172 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.604 ' HE3' ' C ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 78.09 -9.85 1.44 Allowed 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 178.028 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.423 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 42.2 t -130.4 128.21 63.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-N 118.496 0.589 . . . . 0.0 110.647 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.439 ' HA ' ' O ' ' A' ' 21' ' ' SER . 85.7 m -80.72 128.55 33.76 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.366 0.603 . . . . 0.0 112.475 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-85 -112.94 144.23 42.87 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.636 179.138 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.606 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.5 tt -95.92 85.69 4.14 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.7 m-80 . . . . . 0 C--N 1.327 -0.402 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.927 -179.333 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.876 0 CA-C-O 120.195 -0.225 . . . . 0.0 112.608 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 21.6 m -96.27 112.23 59.12 Favored Pre-proline 0 C--O 1.221 -0.432 0 CA-C-N 117.369 0.585 . . . . 0.0 111.395 -179.296 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.408 ' HG3' ' CE2' ' A' ' 28' ' ' TYR . 71.5 Cg_exo -49.14 127.29 17.11 Favored 'Trans proline' 0 C--N 1.346 0.44 0 C-N-CA 122.862 2.375 . . . . 0.0 112.787 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.685 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 20.3 m -86.04 14.14 6.67 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.795 -178.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.59 26.46 68.4 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.925 -0.655 . . . . 0.0 111.973 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.715 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 40.6 tt0 -132.35 131.08 41.54 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.528 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 0.6 OUTLIER -112.0 150.02 31.18 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.586 0.708 . . . . 0.0 112.236 -178.433 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.3 p -112.21 42.64 1.74 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.75 -1.114 . . . . 0.0 109.774 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 1.059 ' HA ' ' HD2' ' A' ' 25' ' ' LYS . 20.8 t -69.07 -63.71 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.847 -178.573 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.0 m-85 -91.53 -49.43 6.32 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.177 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.554 ' H ' HD11 ' A' ' 11' ' ' ILE . 0.2 OUTLIER -121.78 159.29 51.7 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.532 -179.347 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -68.25 153.99 73.23 Favored 'Trans proline' 0 N--CA 1.459 -0.538 0 C-N-CA 122.471 2.114 . . . . 0.0 111.637 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.715 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 58.6 m -69.65 132.64 46.49 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.481 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . 0.407 HG23 ' N ' ' A' ' 15' ' ' SER . 7.6 tp -89.99 -39.45 12.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.008 0.432 . . . . 0.0 109.908 178.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.537 ' O ' HG12 ' A' ' 18' ' ' ILE . 2.5 m -74.12 -24.07 59.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.815 179.074 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.974 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.11 -17.69 5.59 Favored Glycine 0 C--N 1.331 0.298 0 CA-C-N 115.144 -0.934 . . . . 0.0 114.108 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.7 p -58.8 -20.89 17.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.148 0.499 . . . . 0.0 111.356 179.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.537 HG12 ' O ' ' A' ' 15' ' ' SER . 35.5 pt -75.73 -5.21 6.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.03 -0.532 . . . . 0.0 112.32 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 135.43 -18.68 3.89 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.43 -0.89 . . . . 0.0 112.171 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.974 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 33.4 m -60.68 124.2 19.69 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.315 0.579 . . . . 0.0 110.764 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.438 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 6.5 m -104.57 139.69 39.08 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.518 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.6 t -71.37 119.51 15.62 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.12 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 38.4 m -144.45 121.79 11.62 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.7 t0 54.95 46.55 24.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 122.251 1.024 . . . . 0.0 109.98 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 1.059 ' HD2' ' HA ' ' A' ' 9' ' ' VAL . 66.4 mmtt 62.2 14.93 7.07 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 113.905 -1.498 . . . . 0.0 113.487 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.528 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 60.5 t -136.09 132.47 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.786 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.469 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 34.6 m -82.27 125.69 31.26 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.523 0.677 . . . . 0.0 112.341 -179.648 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.455 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 2.4 m-85 -111.3 142.86 42.97 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.163 179.588 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.685 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 45.3 tp -89.32 81.4 6.66 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 107.999 -1.112 . . . . 0.0 107.999 178.156 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m120 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 114.745 -1.116 . . . . 0.0 111.069 -178.316 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.649 0 CA-C-O 120.199 -0.223 . . . . 0.0 113.199 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.2 m -98.17 113.71 64.27 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 117.392 0.596 . . . . 0.0 111.315 -179.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.445 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 73.0 Cg_exo -49.19 133.08 29.37 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.861 2.374 . . . . 0.0 112.756 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.552 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 33.3 m -83.15 20.52 1.24 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.35 -179.209 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 61.59 30.21 74.03 Favored Glycine 0 C--O 1.227 -0.341 0 CA-C-N 115.972 -0.558 . . . . 0.0 113.03 179.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -162.75 151.32 14.51 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.143 0.497 . . . . 0.0 110.047 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.543 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 34.9 p -100.6 -174.52 2.66 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.157 -179.683 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.543 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 28.7 p -150.88 41.84 0.77 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.593 0.711 . . . . 0.0 109.572 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 17.4 t -69.12 -40.68 80.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.011 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -104.76 -49.52 3.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.28 -179.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.661 ' H ' HD11 ' A' ' 11' ' ' ILE . 0.2 OUTLIER -112.13 142.76 27.45 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.481 -179.695 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 18.8 Cg_exo -64.7 159.45 45.2 Favored 'Trans proline' 0 C--O 1.234 0.279 0 C-N-CA 122.738 2.292 . . . . 0.0 112.064 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 63.8 m -59.72 110.81 1.23 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.374 -179.627 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . 0.409 HD11 HG21 ' A' ' 14' ' ' ILE . 47.8 mm -63.8 -45.37 97.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.196 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.593 ' HB3' HD11 ' A' ' 18' ' ' ILE . 6.2 m -80.1 29.45 0.28 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.296 179.626 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -59.07 -34.99 81.92 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 121.228 -0.51 . . . . 0.0 112.395 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.3 p -63.94 -21.23 28.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.119 0.485 . . . . 0.0 111.181 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.593 HD11 ' HB3' ' A' ' 15' ' ' SER . 8.0 mt -84.43 -11.86 11.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.52 0.676 . . . . 0.0 110.43 179.646 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 121.13 -7.99 10.59 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.78 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.51 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 84.3 m -65.81 123.63 20.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.235 0.541 . . . . 0.0 110.711 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.3 m -129.39 148.7 51.33 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.174 -179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 19.2 m -67.38 105.8 1.9 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.465 0.65 . . . . 0.0 112.008 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.4 m -114.7 100.02 7.95 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.153 -0.931 . . . . 0.0 108.658 178.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.464 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 47.2 t0 52.52 54.07 11.23 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.527 0.68 . . . . 0.0 110.981 -178.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.787 ' HZ2' ' HB2' ' A' ' 25' ' ' LYS . 6.9 mtmp? 71.23 -0.33 3.14 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 115.185 -0.916 . . . . 0.0 113.159 179.187 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.543 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 25.6 t -120.15 134.39 63.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 118.13 0.423 . . . . 0.0 110.136 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 78.8 m -76.74 117.4 18.32 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.038 0.447 . . . . 0.0 112.197 -179.056 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.445 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.7 m-85 -112.86 142.41 45.55 Favored 'General case' 0 CA--C 1.513 -0.451 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 177.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.552 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.9 tt -101.38 86.32 2.96 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.057 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 . . . . . 0 C--N 1.325 -0.498 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.161 -178.984 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.64 0 CA-C-O 120.224 -0.209 . . . . 0.0 113.189 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.434 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 22.0 m -98.05 113.07 63.38 Favored Pre-proline 0 C--O 1.221 -0.419 0 CA-C-N 117.407 0.603 . . . . 0.0 110.806 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 8.8 Cg_endo -49.75 134.08 33.84 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 123.063 2.509 . . . . 0.0 112.49 -179.801 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.521 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 36.6 m -81.54 21.15 0.82 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.16 -179.209 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.88 28.65 72.21 Favored Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.754 -0.657 . . . . 0.0 113.235 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -161.21 152.93 19.37 Favored 'General case' 0 C--O 1.238 0.484 0 CA-C-O 121.414 0.626 . . . . 0.0 110.635 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.57 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 21.0 p -104.44 179.51 4.25 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.14 -0.937 . . . . 0.0 111.29 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.544 ' HB2' ' HA ' ' A' ' 12' ' ' PRO . 18.3 p -151.43 50.57 0.82 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.82 179.164 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.683 HG22 ' HB3' ' A' ' 25' ' ' LYS . 17.6 t -67.45 -42.39 87.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.96 -179.489 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -94.8 -48.72 5.91 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.312 -0.858 . . . . 0.0 111.694 -179.307 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.456 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 23.9 pt -135.18 142.64 42.56 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.73 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.544 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 9.6 Cg_exo -68.68 153.12 73.92 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.985 2.456 . . . . 0.0 112.493 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 97.8 m -67.27 120.77 14.36 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.931 179.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . 0.423 ' C ' ' H ' ' A' ' 16' ' ' GLY . 48.3 mm -61.61 -41.43 90.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.743 -179.751 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.651 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.0 m -76.65 22.07 0.19 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.655 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.592 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -58.83 -21.15 50.83 Favored Glycine 0 C--N 1.33 0.227 0 C-N-CA 121.467 -0.397 . . . . 0.0 112.806 179.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.5 p -60.75 -22.06 25.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.85 0.357 . . . . 0.0 111.718 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.651 HG12 ' O ' ' A' ' 15' ' ' SER . 22.4 pt -80.09 -0.59 4.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 C-N-CA 120.955 -0.298 . . . . 0.0 111.575 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.63 -20.0 7.41 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.2 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.592 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 78.3 m -63.24 124.14 20.45 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.401 0.62 . . . . 0.0 111.248 -179.767 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 17.7 m -129.14 142.03 51.0 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.376 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 23.3 m -71.99 115.77 11.6 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.486 0.66 . . . . 0.0 111.974 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.508 ' HB ' ' CD1' ' A' ' 28' ' ' TYR . 15.7 m -124.4 108.51 12.24 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.515 178.742 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 43.7 t0 47.68 57.15 6.23 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.905 -178.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.683 ' HB3' HG22 ' A' ' 9' ' ' VAL . 20.3 mtmm 68.57 8.65 6.83 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.52 0.933 . . . . 0.0 113.52 178.372 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.57 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 48.6 t -130.04 134.45 62.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 118.611 0.641 . . . . 0.0 110.23 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 97.9 m -81.02 119.42 23.51 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.214 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.529 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 37.7 m-85 -114.88 142.77 46.13 Favored 'General case' 0 CA--C 1.516 -0.342 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.521 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.8 tt -101.94 87.22 3.05 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.087 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.0 m-80 . . . . . 0 C--N 1.326 -0.442 0 CA-C-N 114.897 -1.047 . . . . 0.0 111.352 -178.955 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.684 0 CA-C-O 120.234 -0.203 . . . . 0.0 113.142 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.446 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 22.6 m -101.69 114.71 65.56 Favored Pre-proline 0 C--O 1.22 -0.45 0 CA-C-N 117.451 0.625 . . . . 0.0 111.127 -179.352 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.55 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 7.0 Cg_endo -48.75 131.86 25.2 Favored 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 123.111 2.541 . . . . 0.0 112.484 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.683 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 31.0 m -83.6 15.86 2.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.526 -179.058 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 61.45 32.2 80.22 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.004 -0.617 . . . . 0.0 112.034 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.497 ' HG3' ' SG ' ' A' ' 13' ' ' CYS . 3.8 tp10 -143.71 140.29 29.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.074 0.464 . . . . 0.0 110.012 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.589 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 11.6 p -101.3 170.19 8.4 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.455 -0.793 . . . . 0.0 112.257 -178.763 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.0 p -150.32 49.25 0.9 Allowed 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.423 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 12.1 t -68.11 -37.84 78.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.349 -178.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -125.17 -50.0 1.69 Allowed 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.401 179.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 50.0 mm -107.08 131.48 21.66 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.902 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo -69.29 151.38 71.76 Favored 'Trans proline' 0 N--CA 1.457 -0.642 0 C-N-CA 122.336 2.024 . . . . 0.0 111.66 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.497 ' SG ' ' HG3' ' A' ' 6' ' ' GLU . 9.7 m -69.19 119.4 13.41 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.148 -179.341 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 14.0 tt -64.88 -30.72 51.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.349 0.595 . . . . 0.0 110.496 179.61 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.664 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.4 p -74.76 1.99 11.15 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.529 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.636 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.33 -20.87 38.36 Favored Glycine 0 CA--C 1.518 0.26 0 CA-C-N 116.485 -0.325 . . . . 0.0 113.16 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.8 p -60.46 -23.62 28.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.96 0.41 . . . . 0.0 111.712 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.664 HG12 ' O ' ' A' ' 15' ' ' SER . 23.0 pt -81.06 0.14 3.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.453 -0.339 . . . . 0.0 111.749 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.64 -22.04 7.01 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.216 179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.636 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 83.2 m -59.84 122.6 14.63 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.531 0.681 . . . . 0.0 110.894 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.1 m -114.9 138.23 51.05 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.795 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 47.4 t -69.34 123.89 22.41 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.5 m -137.55 113.69 9.97 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.821 0.343 . . . . 0.0 110.184 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 35.4 t70 46.45 58.32 4.68 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.469 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.448 ' HE2' ' HB2' ' A' ' 25' ' ' LYS . 26.0 mtmm 72.26 4.82 5.13 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 113.783 1.031 . . . . 0.0 113.783 177.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.589 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 4.3 p -143.02 133.2 22.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 118.768 0.713 . . . . 0.0 111.343 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 93.9 m -80.78 132.16 35.48 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -178.605 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 3.1 m-85 -117.26 146.4 43.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.952 178.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.683 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 55.9 tp -99.35 84.67 3.03 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 . . . . . 0 C--N 1.327 -0.382 0 CA-C-N 115.186 -0.915 . . . . 0.0 111.602 -179.409 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.754 0 CA-C-O 120.276 -0.18 . . . . 0.0 112.728 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.412 ' HG1' ' HB3' ' A' ' 29' ' ' LEU . 14.6 p -100.74 116.6 63.98 Favored Pre-proline 0 C--O 1.222 -0.376 0 CA-C-N 117.328 0.564 . . . . 0.0 111.289 -179.361 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.446 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 82.1 Cg_exo -45.45 132.62 12.53 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 123.128 2.552 . . . . 0.0 113.084 -179.609 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.51 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 55.9 m -82.78 19.29 1.36 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.507 -179.237 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.73 30.36 76.69 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.239 -0.505 . . . . 0.0 112.741 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.3 tp10 -156.57 153.13 28.17 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.529 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 47.3 p -102.23 -176.71 3.19 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.506 0.67 . . . . 0.0 111.831 -179.317 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.1 p -151.04 41.85 0.75 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.243 179.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 13.3 t -69.93 -42.32 79.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.528 -179.016 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -115.0 -47.63 2.86 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.934 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.454 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 32.6 pt -104.59 142.9 25.6 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.82 -179.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 14.6 Cg_exo -67.15 158.69 55.66 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.715 2.277 . . . . 0.0 111.718 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 59.7 m -59.48 106.84 0.5 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.162 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . 0.794 ' H ' HD11 ' A' ' 14' ' ' ILE . 0.2 OUTLIER -62.69 -39.29 84.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.118 0.485 . . . . 0.0 110.529 179.848 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.699 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.0 m -85.57 21.7 1.75 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.571 179.237 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.416 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -59.33 -27.2 62.74 Favored Glycine 0 C--N 1.329 0.183 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.415 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.9 p -62.59 -23.63 33.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 120.856 0.36 . . . . 0.0 111.83 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.699 HG12 ' O ' ' A' ' 15' ' ' SER . 16.0 pt -90.53 3.45 6.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 C-N-CA 120.531 -0.468 . . . . 0.0 111.421 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 115.93 -12.87 17.33 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.3 -0.953 . . . . 0.0 113.25 179.181 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.416 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 71.2 m -62.58 123.38 18.21 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.467 0.651 . . . . 0.0 110.962 -179.759 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 9.1 m -117.1 142.33 47.14 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.89 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.5 t -71.91 111.36 7.1 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.069 0.462 . . . . 0.0 109.951 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 m -119.09 103.93 10.0 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.096 -179.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.448 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 19.6 t70 47.23 61.87 2.68 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.817 -179.544 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.448 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.5 OUTLIER 67.86 4.78 4.14 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 115.013 -0.994 . . . . 0.0 113.241 178.834 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.529 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 51.4 t -131.01 130.98 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 118.418 0.554 . . . . 0.0 110.577 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 84.7 m -77.73 125.42 29.32 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.446 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 4.7 m-85 -117.2 143.11 46.22 Favored 'General case' 0 CA--C 1.517 -0.317 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.234 178.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.51 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.7 tp -96.41 83.18 3.49 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.367 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 m120 . . . . . 0 N--CA 1.465 0.309 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.584 -178.586 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.74 0 CA-C-O 120.287 -0.174 . . . . 0.0 112.709 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 19.8 m -94.38 109.63 43.94 Favored Pre-proline 0 C--O 1.22 -0.453 0 CA-C-N 117.157 0.479 . . . . 0.0 111.518 -179.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.499 ' HG3' ' CE2' ' A' ' 28' ' ' TYR . 33.1 Cg_exo -58.16 134.04 59.29 Favored 'Trans proline' 0 CA--C 1.529 0.249 0 C-N-CA 122.532 2.155 . . . . 0.0 112.913 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 6.5 m -79.57 16.74 1.01 Allowed 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.272 179.294 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.9 29.91 75.65 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.101 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -153.59 156.2 37.54 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.315 0.578 . . . . 0.0 110.152 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.541 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 40.2 p -103.14 -174.73 2.62 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.544 -179.185 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 9.2 p -151.12 39.64 0.69 Allowed 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.227 179.312 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.904 HG23 ' HB3' ' A' ' 25' ' ' LYS . 10.9 t -69.99 -36.22 67.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.251 -0.886 . . . . 0.0 111.189 -179.25 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -122.7 -45.93 2.15 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.362 -179.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 35.0 pt -103.62 147.5 34.33 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.179 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo -68.64 156.21 66.28 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.715 2.277 . . . . 0.0 111.615 179.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 77.7 m -60.64 107.79 0.74 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.783 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 11.3 tt -64.96 -38.83 83.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.15 0.5 . . . . 0.0 109.976 179.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.684 ' HB3' HD13 ' A' ' 18' ' ' ILE . 6.0 m -81.62 20.72 0.88 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.024 179.325 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.543 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -60.85 -31.11 74.75 Favored Glycine 0 C--N 1.332 0.329 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.095 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 21.9 t -63.06 -23.95 34.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.324 0.583 . . . . 0.0 110.703 179.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.684 HD13 ' HB3' ' A' ' 15' ' ' SER . 6.5 mt -81.63 -12.33 12.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.413 179.666 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 118.96 -8.54 12.58 Favored Glycine 0 N--CA 1.446 -0.698 0 CA-C-N 115.715 -0.675 . . . . 0.0 112.182 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.543 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 1.8 m -70.21 127.64 33.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.726 0.774 . . . . 0.0 111.722 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 20.1 m -116.63 149.83 39.09 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.649 -1.159 . . . . 0.0 109.715 179.502 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.2 t -69.51 111.7 5.53 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.974 0.416 . . . . 0.0 110.292 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.51 ' HB ' ' CD1' ' A' ' 28' ' ' TYR . 5.9 m -119.59 103.07 9.1 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.005 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 36.2 t70 47.53 58.77 4.63 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.271 -179.502 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.904 ' HB3' HG23 ' A' ' 9' ' ' VAL . 28.4 mtmm 72.07 2.83 4.46 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 178.451 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.541 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 42.7 t -130.43 133.1 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 118.563 0.62 . . . . 0.0 110.385 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 83.9 m -80.95 120.41 24.72 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 112.724 0.639 . . . . 0.0 112.724 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.51 ' CD1' ' HB ' ' A' ' 23' ' ' THR . 57.3 m-85 -121.47 139.89 52.89 Favored 'General case' 0 CA--C 1.518 -0.288 0 CA-C-O 121.142 0.496 . . . . 0.0 110.462 178.143 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.509 ' HB2' ' SG ' ' A' ' 20' ' ' CYS . 2.7 tt -94.11 77.89 4.05 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 178.249 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.1 m-80 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.01 -178.804 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.849 0 CA-C-O 120.211 -0.216 . . . . 0.0 112.792 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.6 m -95.83 110.7 52.92 Favored Pre-proline 0 C--O 1.222 -0.363 0 CA-C-N 117.306 0.553 . . . . 0.0 111.087 -179.414 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.41 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.1 Cg_exo -49.71 130.38 26.31 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.846 2.364 . . . . 0.0 112.627 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.601 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 4.8 m -92.16 6.69 45.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.312 -179.315 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.05 -27.23 2.73 Favored Glycine 0 N--CA 1.452 -0.286 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -178.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.679 ' OE2' ' HB3' ' A' ' 13' ' ' CYS . 19.7 tt0 -69.8 131.03 43.88 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.556 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.489 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.3 p -115.75 162.79 16.78 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.471 0.653 . . . . 0.0 112.465 -178.137 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.446 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.8 p -136.01 45.45 2.38 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.576 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.628 HG22 ' HB3' ' A' ' 25' ' ' LYS . 8.1 t -70.15 -43.21 79.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.38 -178.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -127.56 -46.98 1.43 Allowed 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.282 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 35.0 pt -104.11 149.49 37.31 Favored Pre-proline 0 C--N 1.322 -0.618 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.915 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_exo -67.82 152.51 77.31 Favored 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 122.354 2.036 . . . . 0.0 111.581 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.679 ' HB3' ' OE2' ' A' ' 6' ' ' GLU . 74.3 m -64.09 -46.42 84.36 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.257 -179.394 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . 0.405 ' HB ' ' O ' ' A' ' 13' ' ' CYS . 77.2 mt 74.19 -57.07 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 C-N-CA 123.012 0.525 . . . . 0.0 111.521 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.447 ' O ' HG12 ' A' ' 18' ' ' ILE . 0.9 OUTLIER -68.46 -18.2 64.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.261 0.553 . . . . 0.0 110.084 179.351 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.728 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -52.27 -15.21 2.56 Favored Glycine 0 C--N 1.332 0.324 0 CA-C-N 115.107 -0.951 . . . . 0.0 113.887 -179.742 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 31.6 m -58.1 -18.25 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 117.07 0.435 . . . . 0.0 111.18 178.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.447 HG12 ' O ' ' A' ' 15' ' ' SER . 39.2 pt -73.95 -9.96 13.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.821 179.631 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.07 -23.25 2.59 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.681 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.728 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 38.9 m -67.76 121.86 16.87 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.514 0.673 . . . . 0.0 111.047 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.483 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -108.57 140.42 41.94 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.187 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.2 t -65.38 112.63 3.61 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.147 0.499 . . . . 0.0 110.245 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.4 m -127.61 109.4 11.65 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.016 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 21.4 t0 48.26 59.48 4.26 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.774 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.628 ' HB3' HG22 ' A' ' 9' ' ' VAL . 1.7 mptt 69.86 3.0 4.1 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.158 -0.928 . . . . 0.0 113.357 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.489 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 62.4 t -136.28 130.42 47.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 118.516 0.598 . . . . 0.0 110.815 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.58 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 5.6 m -80.2 123.32 27.82 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.502 0.668 . . . . 0.0 112.096 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.473 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 1.9 m-85 -108.42 142.34 38.92 Favored 'General case' 0 CA--C 1.519 -0.238 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.845 179.279 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.601 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.5 tt -89.78 83.48 6.21 Favored 'General case' 0 C--N 1.309 -1.165 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 178.289 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m120 . . . . . 0 C--N 1.326 -0.427 0 CA-C-N 114.649 -1.159 . . . . 0.0 111.12 -178.574 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.858 0 CA-C-O 120.231 -0.205 . . . . 0.0 112.708 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.9 m -96.27 111.5 56.83 Favored Pre-proline 0 C--O 1.221 -0.441 0 CA-C-N 117.325 0.562 . . . . 0.0 111.2 -179.419 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 89.4 Cg_exo -47.5 127.25 13.37 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.897 2.398 . . . . 0.0 113.109 -179.562 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.592 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 22.9 m -84.72 -7.62 59.15 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.425 -179.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.14 -15.99 56.8 Favored Glycine 0 N--CA 1.448 -0.506 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.04 151.52 41.68 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.248 -0.476 . . . . 0.0 110.16 179.401 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.413 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 1.6 p -128.9 150.2 50.46 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 121.84 0.828 . . . . 0.0 112.394 -179.669 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.462 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.7 p -127.18 44.37 2.93 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 114.556 -1.202 . . . . 0.0 109.698 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.9 t -74.78 -46.41 41.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.485 -179.105 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -101.75 -48.66 4.22 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.089 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.462 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 32.5 pt -132.91 164.96 40.2 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.605 -179.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -63.89 153.91 72.96 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.063 1.842 . . . . 0.0 111.684 179.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 86.8 m -61.82 139.12 58.38 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.323 -179.173 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 50.2 mm -67.22 122.81 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 115.307 -0.861 . . . . 0.0 109.657 178.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.669 ' O ' HG13 ' A' ' 18' ' ' ILE . 35.8 p 51.91 31.17 8.06 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 115.495 -0.775 . . . . 0.0 112.655 -179.48 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -55.79 -14.24 7.26 Favored Glycine 0 C--N 1.338 0.683 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.805 178.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.7 p -56.63 -17.0 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 C-N-CA 123.147 0.579 . . . . 0.0 111.37 179.039 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.669 HG13 ' O ' ' A' ' 15' ' ' SER . 55.5 mt -55.65 -30.98 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.907 0.861 . . . . 0.0 110.633 178.632 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 150.94 -18.28 0.95 Allowed Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 114.501 -1.227 . . . . 0.0 110.099 -179.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.608 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 59.2 m -68.27 120.03 13.76 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.506 0.67 . . . . 0.0 110.734 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.523 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -107.25 139.82 41.1 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.097 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.7 t -66.67 118.4 10.18 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.862 0.363 . . . . 0.0 110.148 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 16.2 m -132.21 106.13 7.76 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.049 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.556 ' CG ' ' HZ2' ' A' ' 25' ' ' LYS . 30.2 t70 48.98 58.21 5.61 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.625 0.726 . . . . 0.0 112.091 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.556 ' HZ2' ' CG ' ' A' ' 24' ' ' ASP . 6.1 mtmp? 75.09 -5.7 2.11 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 178.408 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.413 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 1.9 m -133.2 132.0 58.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.507 0.594 . . . . 0.0 111.402 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.608 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 61.1 m -81.07 129.45 34.56 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -178.654 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.431 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.3 m-85 -110.01 143.72 39.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.761 178.64 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.592 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.4 tp -89.78 81.59 6.36 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 178.398 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.7 m120 . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.969 -178.28 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.656 0 CA-C-O 120.165 -0.241 . . . . 0.0 113.309 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.0 p -100.54 119.08 59.69 Favored Pre-proline 0 C--O 1.222 -0.382 0 CA-C-N 117.5 0.65 . . . . 0.0 111.576 -179.135 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_exo -48.41 134.31 25.91 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 123.121 2.548 . . . . 0.0 112.813 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.599 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 37.1 m -82.53 19.43 1.27 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.513 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 63.75 28.8 73.16 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.235 -0.507 . . . . 0.0 112.877 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.7 tp10 -155.81 153.45 29.81 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-O 120.946 0.403 . . . . 0.0 110.064 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.621 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 44.8 p -100.14 -177.64 3.59 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.542 -0.754 . . . . 0.0 112.235 -178.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.7 p -151.54 45.45 0.79 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.113 179.229 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 10.6 t -65.9 -39.49 84.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.357 -0.838 . . . . 0.0 111.573 -178.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -128.32 -47.6 1.32 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.503 179.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.486 HD12 ' HD2' ' A' ' 12' ' ' PRO . 5.8 tp -106.92 123.62 37.93 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.416 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . 0.486 ' HD2' HD12 ' A' ' 11' ' ' ILE . 5.6 Cg_exo -73.05 153.42 52.12 Favored 'Trans proline' 0 N--CA 1.456 -0.685 0 C-N-CA 122.407 2.071 . . . . 0.0 111.49 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 86.1 m -67.29 117.04 8.74 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.125 -179.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . 0.434 ' C ' ' H ' ' A' ' 16' ' ' GLY . 47.3 mm -62.3 -40.09 86.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.593 -179.796 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.642 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.3 m -76.01 20.19 0.2 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.5 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.712 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -58.28 -21.07 46.44 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 121.508 -0.377 . . . . 0.0 112.898 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.9 m -61.42 -19.72 21.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 112.161 0.43 . . . . 0.0 112.161 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.642 HG12 ' O ' ' A' ' 15' ' ' SER . 23.1 pt -83.25 1.82 3.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.741 0.305 . . . . 0.0 111.31 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.05 -17.03 8.69 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.581 -0.818 . . . . 0.0 112.212 179.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.712 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 70.8 m -65.66 124.02 21.27 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.506 0.67 . . . . 0.0 111.373 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.5 m -128.04 142.47 51.21 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.239 -0.891 . . . . 0.0 109.262 179.485 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 46.4 t -73.27 124.76 26.31 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.903 0.382 . . . . 0.0 110.399 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 57.3 m -150.18 123.89 9.19 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.621 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 51.8 t0 51.54 55.16 9.82 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.123 0.487 . . . . 0.0 110.999 -179.237 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.621 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 60.01 5.55 0.78 Allowed 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.074 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.621 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 2.7 m -134.6 145.21 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 O-C-N 121.682 -0.637 . . . . 0.0 112.072 178.68 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.9 m -81.37 126.41 31.57 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.101 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.488 ' CE1' HG22 ' A' ' 26' ' ' VAL . 30.0 m-85 -112.43 142.6 44.77 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 177.568 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.599 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.7 tt -104.22 88.79 3.07 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.533 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 . . . . . 0 C--N 1.326 -0.443 0 CA-C-N 114.959 -1.019 . . . . 0.0 111.356 -178.839 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.809 0 CA-C-O 120.001 -0.333 . . . . 0.0 112.98 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.662 HG22 ' HB3' ' A' ' 29' ' ' LEU . 4.9 t -100.57 119.81 57.7 Favored Pre-proline 0 C--O 1.221 -0.424 0 CA-C-N 117.758 0.779 . . . . 0.0 111.742 -179.158 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -50.22 131.43 31.23 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 123.098 2.532 . . . . 0.0 113.002 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.677 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 8.8 m -90.61 22.71 3.36 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.825 -178.84 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.23 35.69 88.72 Favored Glycine 0 C--N 1.331 0.291 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.105 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.589 ' OE2' HG12 ' A' ' 14' ' ' ILE . 44.7 tt0 -146.1 153.24 40.47 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -179.533 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -135.02 150.19 50.27 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.225 0.536 . . . . 0.0 111.436 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -100.44 51.89 0.88 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.073 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.3 t -63.61 -40.08 87.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.424 -179.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 m-85 -142.58 -42.25 0.32 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.772 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 37.2 pt -103.26 152.68 38.71 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.785 -179.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo -68.87 154.42 71.04 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.726 2.284 . . . . 0.0 111.62 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 20.6 m -64.26 122.37 16.5 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.554 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . 0.589 HG12 ' OE2' ' A' ' 6' ' ' GLU . 33.4 pt -74.12 -28.14 23.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.14 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.1 p -78.73 2.4 19.82 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.507 179.017 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -56.51 -33.77 62.82 Favored Glycine 0 C--N 1.333 0.394 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.625 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 25.6 t -61.63 -27.31 41.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.394 0.616 . . . . 0.0 110.767 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.424 ' O ' HG21 ' A' ' 18' ' ' ILE . 37.4 mm -78.15 -18.71 13.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.521 179.586 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 125.97 -7.97 7.67 Favored Glycine 0 N--CA 1.447 -0.57 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.778 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.495 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 60.4 m -63.68 124.89 22.59 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.377 0.608 . . . . 0.0 110.916 -179.774 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 8.8 m -112.21 147.09 36.93 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.371 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.8 t -75.0 123.53 25.32 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.868 0.366 . . . . 0.0 110.15 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.2 m -145.66 121.85 10.83 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 53.67 44.29 29.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.871 0.843 . . . . 0.0 110.754 -179.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.502 ' HG2' ' O ' ' A' ' 25' ' ' LYS . 11.4 ttpp 65.49 10.77 6.88 Favored 'General case' 0 CA--C 1.544 0.723 0 CA-C-N 114.338 -1.301 . . . . 0.0 112.098 179.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 49.9 t -127.4 138.42 54.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 O-C-N 121.838 -0.539 . . . . 0.0 110.447 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.8 m -82.02 122.5 27.89 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.771 0.319 . . . . 0.0 111.071 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.435 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 25.2 m-85 -116.75 139.99 49.94 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-O 121.165 0.507 . . . . 0.0 110.862 179.514 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.677 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 55.3 tp -91.59 83.89 5.42 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 177.73 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.6 m120 . . . . . 0 C--N 1.327 -0.391 0 CA-C-N 114.704 -1.135 . . . . 0.0 111.299 -178.497 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.795 0 CA-C-O 120.2 -0.222 . . . . 0.0 113.064 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.422 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 20.4 m -101.21 112.71 65.41 Favored Pre-proline 0 C--O 1.22 -0.489 0 CA-C-N 117.392 0.596 . . . . 0.0 111.041 -179.396 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.545 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 8.5 Cg_endo -49.35 130.32 24.76 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 123.031 2.487 . . . . 0.0 112.626 -179.719 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.646 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 32.4 m -83.26 11.16 6.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.285 -179.167 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 66.1 28.62 73.82 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 121.08 -0.581 . . . . 0.0 112.269 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.609 ' HG3' ' HB2' ' A' ' 27' ' ' CYS . 17.2 pt-20 -134.45 155.08 50.96 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.998 0.428 . . . . 0.0 109.86 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.8 p -124.19 154.28 40.34 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.613 0.72 . . . . 0.0 112.302 -178.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -127.25 46.1 2.59 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 114.385 -1.279 . . . . 0.0 109.791 179.654 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.3 t -70.6 -48.4 58.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.899 -178.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.2 m-85 -101.18 -47.92 4.57 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.379 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.5 pt -126.95 154.92 76.37 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.397 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -65.48 154.6 72.97 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.46 2.106 . . . . 0.0 111.885 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.461 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 71.1 m -66.58 128.08 34.85 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.803 -179.314 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . 0.416 HD12 HG23 ' A' ' 14' ' ' ILE . 11.5 tt -71.73 126.84 32.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.219 179.481 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.54 ' O ' HG12 ' A' ' 18' ' ' ILE . 21.6 m 67.07 14.58 9.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.648 -0.705 . . . . 0.0 111.844 -179.465 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -56.15 -16.23 13.22 Favored Glycine 0 C--N 1.339 0.706 0 C-N-CA 121.229 -0.51 . . . . 0.0 112.666 179.059 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 16.6 t -56.23 -17.84 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 C-N-CA 122.95 0.5 . . . . 0.0 111.272 179.172 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.54 HG12 ' O ' ' A' ' 15' ' ' SER . 47.2 mm -57.9 -29.16 35.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.613 0.72 . . . . 0.0 111.044 178.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 155.99 -22.85 0.53 Allowed Glycine 0 C--N 1.312 -0.782 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 179.787 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.463 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 60.1 m -67.35 120.49 13.95 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.644 0.735 . . . . 0.0 110.723 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.478 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 17.9 m -110.62 139.97 45.39 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.713 -179.597 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 49.1 t -67.51 109.66 3.32 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.015 0.436 . . . . 0.0 110.08 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.0 m -120.26 103.54 9.32 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.043 -179.563 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.445 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 21.7 t70 47.65 62.05 2.64 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.767 -179.572 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.445 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.6 OUTLIER 70.96 -0.5 3.02 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 115.117 -0.947 . . . . 0.0 113.356 178.71 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.461 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 50.1 t -131.89 128.26 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 118.557 0.617 . . . . 0.0 110.54 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.609 ' HB2' ' HG3' ' A' ' 6' ' ' GLU . 54.5 m -81.32 128.4 33.79 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.467 0.651 . . . . 0.0 112.457 -179.532 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.545 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 4.2 m-85 -114.46 144.21 43.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.307 -0.861 . . . . 0.0 109.941 179.258 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.646 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.1 tp -92.4 81.67 4.9 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.505 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 115.057 -0.974 . . . . 0.0 111.516 -179.188 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.725 0 CA-C-O 120.115 -0.269 . . . . 0.0 113.085 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 21.9 m -97.72 112.48 61.6 Favored Pre-proline 0 C--O 1.222 -0.384 0 CA-C-N 117.484 0.642 . . . . 0.0 111.355 -179.245 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.5 Cg_exo -50.4 131.85 33.22 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.843 2.362 . . . . 0.0 112.486 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.599 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 35.5 m -85.15 18.5 2.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.472 -179.201 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.03 33.1 77.74 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.482 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -153.0 151.56 30.41 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -132.87 146.36 51.74 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.669 0.747 . . . . 0.0 112.097 -179.284 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.465 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 2.1 p -101.37 45.39 0.97 Allowed 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.389 179.549 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.3 t -70.9 -35.65 60.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.042 -179.491 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -128.93 -50.8 1.22 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.504 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.465 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 2.4 pp -104.95 151.08 39.37 Favored Pre-proline 0 C--N 1.324 -0.529 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.738 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -71.15 150.07 59.13 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.194 1.93 . . . . 0.0 111.609 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . 0.403 ' C ' ' H ' ' A' ' 15' ' ' SER . 98.5 m -69.37 -39.68 77.9 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.923 -179.272 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ILE . . . . . 0.437 ' C ' ' H ' ' A' ' 16' ' ' GLY . 76.1 mt 71.48 -44.91 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 122.764 0.426 . . . . 0.0 111.346 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.403 ' H ' ' C ' ' A' ' 13' ' ' CYS . 8.5 p -71.02 10.46 0.54 Allowed 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 122.88 0.472 . . . . 0.0 111.753 179.274 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.438 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -57.66 -25.7 56.06 Favored Glycine 0 C--O 1.227 -0.292 0 CA-C-N 116.143 -0.48 . . . . 0.0 113.086 179.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 29.8 m -61.73 -20.91 24.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.994 0.426 . . . . 0.0 111.889 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.401 HG23 ' O ' ' A' ' 18' ' ' ILE . 16.9 mt -78.63 -14.13 13.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.599 0.714 . . . . 0.0 110.47 179.647 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.87 -14.75 6.3 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.294 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.476 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 60.0 m -63.05 125.84 25.34 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.26 0.552 . . . . 0.0 110.775 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 17.9 m -129.35 140.56 51.34 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.08 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.0 m -62.62 111.18 1.97 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.384 0.611 . . . . 0.0 111.345 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.8 m -124.43 107.09 10.73 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.585 179.474 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.419 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 45.1 t0 54.4 50.37 16.37 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.817 0.818 . . . . 0.0 110.248 -178.326 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.645 ' HZ2' ' HB2' ' A' ' 25' ' ' LYS . 0.1 OUTLIER 72.04 -7.71 1.26 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.698 -1.137 . . . . 0.0 113.105 179.692 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 41.3 t -115.25 132.03 65.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 O-C-N 122.06 -0.4 . . . . 0.0 110.464 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.476 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 39.5 m -78.65 120.37 23.23 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.512 0.672 . . . . 0.0 112.67 -179.11 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.5 m-85 -110.35 143.71 40.18 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.171 -0.922 . . . . 0.0 109.372 178.429 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.599 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.9 tt -97.98 84.85 3.38 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 178.855 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.1 m-80 . . . . . 0 C--N 1.326 -0.454 0 CA-C-N 114.898 -1.047 . . . . 0.0 111.196 -179.053 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.874 0 CA-C-O 120.089 -0.284 . . . . 0.0 112.811 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.518 ' HG1' ' HB3' ' A' ' 29' ' ' LEU . 17.0 p -98.83 113.25 64.29 Favored Pre-proline 0 C--O 1.224 -0.257 0 CA-C-N 117.507 0.653 . . . . 0.0 111.682 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.4 Cg_exo -49.51 128.96 22.01 Favored 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.932 2.422 . . . . 0.0 112.6 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 12.7 m -88.5 16.49 6.45 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.593 -178.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 58.72 32.57 69.94 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.892 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.586 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 32.8 tt0 -136.24 145.82 46.04 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -179.362 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.54 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -137.48 151.99 49.06 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.031 0.443 . . . . 0.0 111.874 -178.686 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 29.7 p -109.54 39.54 2.07 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.33 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.54 HG23 ' HB2' ' A' ' 7' ' ' SER . 16.5 t -72.04 -41.58 68.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.173 -179.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 19.5 m-85 -115.1 -47.95 2.84 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.647 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.573 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 34.7 pt -122.16 153.31 61.32 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.064 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -66.27 154.39 74.37 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.296 1.997 . . . . 0.0 111.768 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.586 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 72.3 m -68.04 128.24 35.8 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.287 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 61.8 mt -90.08 -44.35 14.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-O 121.359 0.599 . . . . 0.0 109.409 178.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.566 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.2 m -72.52 -23.66 61.04 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.139 179.267 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 1.011 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -52.62 -19.34 6.34 Favored Glycine 0 CA--C 1.519 0.31 0 CA-C-N 115.322 -0.853 . . . . 0.0 114.185 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 36.0 m -60.45 -18.96 17.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.871 0.336 . . . . 0.0 111.885 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.566 HG12 ' O ' ' A' ' 15' ' ' SER . 33.2 pt -79.79 -1.71 4.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.804 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 130.94 -19.4 4.95 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.403 -0.903 . . . . 0.0 112.14 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 1.011 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 56.2 m -58.58 121.92 12.16 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.301 0.572 . . . . 0.0 111.131 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 15.4 m -105.84 132.86 51.44 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.099 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.603 ' HA ' ' HA ' ' A' ' 27' ' ' CYS . 1.7 t -75.03 108.99 8.13 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.511 0.672 . . . . 0.0 111.176 -178.674 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.7 m -109.42 118.3 36.29 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.013 -0.994 . . . . 0.0 108.462 178.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.519 ' CG ' ' HZ3' ' A' ' 25' ' ' LYS . 30.9 t70 52.11 52.44 14.35 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 122.065 0.936 . . . . 0.0 110.93 -178.523 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.519 ' HZ3' ' CG ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 69.76 3.53 4.32 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.779 -1.1 . . . . 0.0 113.533 178.797 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 33.0 t -127.29 124.13 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 118.622 0.646 . . . . 0.0 110.505 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.603 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 7.3 m -75.53 124.87 27.92 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.658 0.742 . . . . 0.0 112.836 -179.193 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.448 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.4 m-85 -114.72 144.88 42.75 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.579 179.163 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.7 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 46.1 tp -92.9 81.32 4.63 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 178.519 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.9 m-80 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.449 -179.308 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.805 0 CA-C-O 120.028 -0.318 . . . . 0.0 113.271 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.583 HG21 ' HB3' ' A' ' 29' ' ' LEU . 4.9 t -106.92 118.45 54.1 Favored Pre-proline 0 C--O 1.223 -0.31 0 CA-C-N 117.755 0.778 . . . . 0.0 111.488 -179.178 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.548 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 9.5 Cg_endo -51.39 135.56 46.97 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 123.124 2.55 . . . . 0.0 112.373 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.684 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 6.7 m -93.7 7.65 43.96 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.345 -179.269 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 79.51 -25.97 2.75 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.576 -178.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.714 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 33.2 tt0 -74.06 131.2 41.11 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.5 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -112.56 154.0 26.64 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.49 0.662 . . . . 0.0 111.887 -178.744 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.7 p -122.24 44.75 2.52 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.872 -1.058 . . . . 0.0 109.688 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.655 HG21 ' HB3' ' A' ' 25' ' ' LYS . 12.9 t -72.43 -44.46 62.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.699 -178.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -112.19 -49.61 2.96 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.022 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 34.4 pt -118.76 155.59 52.45 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.391 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_exo -67.17 153.01 78.77 Favored 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 122.432 2.088 . . . . 0.0 111.753 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.714 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 62.0 m -70.82 130.97 43.07 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.54 -0.755 . . . . 0.0 111.462 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 27.7 pt -88.72 -38.04 10.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.889 0.376 . . . . 0.0 110.529 179.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.552 ' O ' HG12 ' A' ' 18' ' ' ILE . 2.8 m -74.77 -18.33 60.5 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.196 0.522 . . . . 0.0 109.895 179.245 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.939 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.08 -18.23 6.06 Favored Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.158 -0.928 . . . . 0.0 113.923 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.4 m -59.47 -19.81 17.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.925 0.393 . . . . 0.0 111.686 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.552 HG12 ' O ' ' A' ' 15' ' ' SER . 33.4 pt -79.04 -4.03 6.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.771 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 133.41 -21.61 4.04 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.994 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.939 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 50.1 m -60.52 122.28 14.25 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.342 0.592 . . . . 0.0 110.699 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.473 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.9 m -108.47 141.92 39.62 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.449 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.1 t -64.93 113.06 3.59 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.975 0.416 . . . . 0.0 110.262 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.1 m -122.57 100.27 6.84 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.086 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.441 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 23.0 t70 47.73 63.69 1.91 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.448 -0.796 . . . . 0.0 111.79 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.655 ' HB3' HG21 ' A' ' 9' ' ' VAL . 0.8 OUTLIER 72.43 -4.28 2.09 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 115.027 -0.988 . . . . 0.0 113.136 178.844 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 44.3 t -130.81 127.31 61.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 118.671 0.669 . . . . 0.0 110.718 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.473 ' HA ' ' O ' ' A' ' 21' ' ' SER . 30.6 m -80.71 127.75 32.85 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.539 0.685 . . . . 0.0 112.267 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.548 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.5 m-85 -112.27 144.72 41.2 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.255 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.684 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.8 tp -93.43 83.91 4.63 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 114.871 -1.059 . . . . 0.0 112.004 -179.61 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.792 0 CA-C-O 120.212 -0.215 . . . . 0.0 112.854 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.6 m -96.12 109.9 49.35 Favored Pre-proline 0 C--O 1.223 -0.335 0 CA-C-N 117.342 0.571 . . . . 0.0 111.077 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 71.1 Cg_exo -48.67 132.45 25.67 Favored 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 122.927 2.418 . . . . 0.0 112.663 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.533 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.3 m -92.34 3.58 55.12 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 121.164 0.507 . . . . 0.0 109.852 -179.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.82 -27.37 3.0 Favored Glycine 0 N--CA 1.448 -0.536 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 -178.253 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.464 ' H ' ' C ' ' A' ' 4' ' ' CYS . 21.9 tt0 -76.96 134.18 38.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 179.508 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -126.01 146.39 49.91 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.537 0.684 . . . . 0.0 112.18 -178.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.527 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 5.3 p -109.87 48.1 0.91 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.772 -1.103 . . . . 0.0 110.422 179.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.6 HG23 ' HB3' ' A' ' 25' ' ' LYS . 19.9 t -68.15 -38.21 79.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.699 -179.737 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -115.02 -50.27 2.77 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.661 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.527 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 32.9 pt -121.44 150.81 55.37 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.965 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -62.87 153.64 71.68 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.418 2.078 . . . . 0.0 112.258 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 61.1 m -74.66 131.06 40.59 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.396 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 12.7 tt -79.94 -34.95 15.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.791 178.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.701 ' O ' HG12 ' A' ' 18' ' ' ILE . 16.2 m -77.66 -0.09 25.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.888 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.729 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -56.7 -23.86 45.77 Favored Glycine 0 CA--C 1.519 0.336 0 C-N-CA 121.392 -0.432 . . . . 0.0 112.855 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.4 t -60.08 -26.42 36.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.962 0.41 . . . . 0.0 111.835 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.701 HG12 ' O ' ' A' ' 15' ' ' SER . 18.6 pt -80.9 5.21 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.592 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 120.51 -18.29 9.4 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.157 -1.021 . . . . 0.0 112.921 179.247 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.729 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 46.3 m -63.27 124.86 22.3 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.235 0.541 . . . . 0.0 110.624 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.468 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 12.2 m -119.57 144.46 47.07 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.156 -179.725 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 23.7 m -63.22 112.58 2.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.41 0.624 . . . . 0.0 111.833 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.2 m -120.02 95.67 4.85 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.139 -0.937 . . . . 0.0 108.588 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 48.1 t0 49.84 59.57 4.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.507 -0.769 . . . . 0.0 111.384 -178.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.6 ' HB3' HG23 ' A' ' 9' ' ' VAL . 26.6 mtmm 75.99 -9.79 1.39 Allowed 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.287 -0.869 . . . . 0.0 113.067 178.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.2 t -120.29 127.29 75.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.409 0.549 . . . . 0.0 110.517 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.542 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 69.7 m -80.64 122.74 27.46 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.561 0.696 . . . . 0.0 112.729 -179.089 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-30 -109.9 142.62 40.98 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.367 178.705 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.533 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.7 tt -89.88 84.52 6.23 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.511 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m120 . . . . . 0 C--N 1.324 -0.521 0 CA-C-N 114.591 -1.186 . . . . 0.0 110.996 -178.654 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.753 0 CA-C-O 120.206 -0.219 . . . . 0.0 112.751 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.2 m -99.28 113.4 64.75 Favored Pre-proline 0 C--O 1.221 -0.418 0 CA-C-N 117.4 0.6 . . . . 0.0 111.214 -179.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.439 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 78.9 Cg_exo -47.46 133.34 20.48 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.986 2.457 . . . . 0.0 112.845 -179.767 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.592 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 12.7 m -90.91 7.81 38.25 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.094 0.473 . . . . 0.0 110.019 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.27 -27.05 2.84 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 120.921 -0.656 . . . . 0.0 111.713 -178.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.427 ' H ' ' C ' ' A' ' 4' ' ' CYS . 61.3 tt0 -80.31 133.56 35.97 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.109 0.48 . . . . 0.0 109.719 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.477 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 0.5 OUTLIER -114.03 146.63 39.92 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.611 0.72 . . . . 0.0 112.044 -179.084 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.7 p -105.76 47.09 0.89 Allowed 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.706 -1.133 . . . . 0.0 110.208 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.531 ' HA ' ' HG3' ' A' ' 25' ' ' LYS . 21.2 t -73.77 -42.08 54.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.591 -179.048 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.6 m-85 -111.1 -48.31 3.12 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.304 -179.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.7 pt -129.9 161.41 59.83 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.264 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -66.85 152.11 81.06 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.278 1.986 . . . . 0.0 111.651 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.4 m -74.61 133.94 42.13 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.752 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 15.3 tt -74.41 -34.35 36.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.117 179.003 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.718 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.2 m -73.95 -0.82 17.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.829 179.534 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.635 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.61 -27.13 58.3 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.744 179.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.3 m -62.72 -20.88 26.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.718 HG12 ' O ' ' A' ' 15' ' ' SER . 13.6 pt -87.98 0.69 6.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.821 -0.351 . . . . 0.0 111.456 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 124.89 -18.74 7.04 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.249 -0.977 . . . . 0.0 112.638 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.635 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 61.9 m -60.88 122.88 15.99 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.398 0.618 . . . . 0.0 110.691 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.44 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.7 m -113.62 140.78 47.91 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.065 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 48.1 t -66.2 119.34 11.31 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.847 0.356 . . . . 0.0 110.162 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 22.9 m -133.96 107.68 7.95 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.17 -179.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.484 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 44.5 t0 49.06 57.86 6.0 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.507 -0.769 . . . . 0.0 111.921 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.531 ' HG3' ' HA ' ' A' ' 9' ' ' VAL . 0.0 OUTLIER 73.8 -4.45 2.25 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 113.416 0.895 . . . . 0.0 113.416 178.405 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.477 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 60.5 t -130.58 131.72 64.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 118.415 0.552 . . . . 0.0 110.749 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.44 ' HA ' ' O ' ' A' ' 21' ' ' SER . 87.5 m -81.28 129.21 34.51 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.297 0.57 . . . . 0.0 112.139 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.439 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.0 m-85 -112.74 142.83 44.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.46 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.592 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.8 tp -89.87 82.27 6.23 Favored 'General case' 0 C--N 1.31 -1.148 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.157 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.8 m120 . . . . . 0 N--CA 1.466 0.331 0 CA-C-N 114.804 -1.089 . . . . 0.0 111.286 -178.372 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.792 0 CA-C-O 120.146 -0.252 . . . . 0.0 113.004 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.452 ' HG1' ' HB3' ' A' ' 29' ' ' LEU . 17.0 p -99.19 115.35 65.79 Favored Pre-proline 0 C--O 1.223 -0.298 0 CA-C-N 117.499 0.65 . . . . 0.0 111.622 -179.179 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.417 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 68.9 Cg_exo -51.47 127.89 23.95 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.811 2.341 . . . . 0.0 112.59 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.656 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.4 m -84.09 12.78 5.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.652 -179.003 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.91 29.31 73.78 Favored Glycine 0 C--N 1.332 0.332 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -178.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.524 ' OE2' HG21 ' A' ' 14' ' ' ILE . 38.0 tt0 -129.63 149.56 51.34 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 114.504 -0.848 . . . . 0.0 109.03 -178.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.47 146.29 44.11 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.361 0.601 . . . . 0.0 111.752 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.534 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 8.6 p -117.89 50.62 1.12 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.488 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.9 t -68.02 -32.75 57.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.63 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -128.27 -50.67 1.3 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.24 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.534 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 31.5 pt -104.66 143.09 25.99 Favored Pre-proline 0 C--N 1.324 -0.511 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.093 179.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 21.2 Cg_exo -63.45 158.52 44.9 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.64 2.227 . . . . 0.0 112.44 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.494 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 10.9 m -60.72 119.78 8.8 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.904 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . 0.524 HG21 ' OE2' ' A' ' 6' ' ' GLU . 8.6 tp -78.98 -35.34 17.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 178.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.577 ' O ' HG21 ' A' ' 18' ' ' ILE . 25.3 t -82.94 3.49 29.75 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.693 178.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.56 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -56.18 -21.65 33.21 Favored Glycine 0 C--N 1.33 0.222 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.283 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.9 t -59.94 -28.4 40.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.981 0.42 . . . . 0.0 111.538 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.577 HG21 ' O ' ' A' ' 15' ' ' SER . 18.2 tt -78.93 -9.29 12.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 121.224 0.535 . . . . 0.0 111.442 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.67 -18.56 5.67 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.798 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.56 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 61.1 m -55.01 124.55 17.14 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.218 0.533 . . . . 0.0 110.628 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 20.4 m -122.79 150.01 43.38 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.879 -178.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.3 m -64.51 115.32 5.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.339 0.59 . . . . 0.0 111.717 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.6 m -125.44 96.79 4.94 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 179.002 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.457 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 47.8 t0 53.28 54.09 10.77 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.685 -178.169 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.614 ' HB2' ' HZ3' ' A' ' 25' ' ' LYS . 6.9 mtmp? 74.22 -9.82 1.22 Allowed 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 114.977 -1.011 . . . . 0.0 112.752 179.528 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 t -111.41 130.09 65.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.4 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 23.3 m -78.38 119.74 22.14 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.221 0.534 . . . . 0.0 111.366 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.499 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 2.8 m-85 -110.99 144.53 39.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.391 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.656 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 57.2 tp -96.99 83.12 3.32 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 178.37 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.495 -179.07 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.87 0 CA-C-O 120.155 -0.247 . . . . 0.0 112.909 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.522 ' HG1' ' HB3' ' A' ' 29' ' ' LEU . 16.8 p -100.58 113.32 65.53 Favored Pre-proline 0 C--O 1.223 -0.301 0 CA-C-N 117.399 0.599 . . . . 0.0 111.636 -179.15 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.472 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.5 Cg_exo -49.22 132.12 27.84 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.895 2.397 . . . . 0.0 112.584 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.653 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.4 m -91.53 5.23 50.34 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 121.011 0.434 . . . . 0.0 110.249 -179.329 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.45 -24.76 3.5 Favored Glycine 0 N--CA 1.451 -0.353 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -178.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.657 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 19.7 tt0 -72.3 133.11 44.83 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.441 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.5 p -115.32 164.44 14.24 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 121.413 0.625 . . . . 0.0 111.979 -178.66 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.6 p -139.43 43.77 2.0 Allowed 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.716 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 12.3 t -70.62 -44.62 76.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.054 -179.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -128.47 -45.11 1.35 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.818 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.496 HG21 ' HD2' ' A' ' 12' ' ' PRO . 66.4 mt -103.86 134.39 19.75 Favored Pre-proline 0 C--N 1.321 -0.638 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.027 179.38 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.496 ' HD2' HG21 ' A' ' 11' ' ' ILE . 14.9 Cg_exo -64.6 152.55 81.38 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.133 1.889 . . . . 0.0 111.775 -179.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.657 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 58.2 m -62.73 -47.29 84.22 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.669 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 78.6 mt 73.41 -55.53 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 122.893 0.477 . . . . 0.0 111.1 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.3 m -67.91 -16.23 63.98 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.3 0.571 . . . . 0.0 110.01 179.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.685 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.17 -16.36 4.47 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.061 -0.972 . . . . 0.0 113.675 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 31.2 m -58.31 -17.67 9.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.107 0.48 . . . . 0.0 111.224 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.4 tp -71.55 -15.99 18.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.145 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 144.96 -23.87 1.94 Allowed Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.685 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 55.5 m -65.67 121.13 14.26 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.445 0.64 . . . . 0.0 110.948 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.487 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.9 m -105.87 139.16 40.86 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.522 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 46.5 t -66.03 102.9 0.86 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.246 0.546 . . . . 0.0 110.423 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.2 m -112.46 106.98 15.59 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.072 -179.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 46.9 t0 47.21 59.55 3.99 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.887 -179.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 22.2 mtmm 70.68 6.27 5.76 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.246 -0.888 . . . . 0.0 113.317 178.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.441 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 45.2 t -137.83 125.93 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 118.236 0.471 . . . . 0.0 110.168 179.442 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.582 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 11.7 m -77.94 122.92 26.15 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.509 0.671 . . . . 0.0 112.292 -179.56 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.505 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 2.3 m-85 -108.69 144.36 36.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.9 179.296 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.653 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.8 tp -91.8 80.99 5.22 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.3 m-80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.554 -179.183 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.848 0 CA-C-O 120.278 -0.179 . . . . 0.0 112.741 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 23.5 m -98.42 112.89 63.39 Favored Pre-proline 0 C--O 1.22 -0.478 0 CA-C-N 117.327 0.564 . . . . 0.0 111.215 -179.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.428 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.4 Cg_exo -47.82 132.95 22.16 Favored 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 122.997 2.465 . . . . 0.0 112.863 -179.795 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.607 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 9.0 m -91.58 6.73 44.57 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.094 0.473 . . . . 0.0 110.024 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.2 -27.42 2.76 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.507 -178.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.497 ' OE2' ' HB3' ' A' ' 13' ' ' CYS . 16.3 tt0 -77.48 126.88 31.6 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.496 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 0.6 OUTLIER -109.12 151.87 25.85 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.627 0.727 . . . . 0.0 112.062 -178.577 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -114.78 51.06 0.92 Allowed 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.887 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.461 ' HA ' ' HB2' ' A' ' 25' ' ' LYS . 14.5 t -68.87 -44.9 81.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.769 -178.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -109.72 -46.86 3.44 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.218 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 30.7 pt -129.37 157.68 75.48 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.172 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -64.76 152.37 82.3 Favored 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 122.247 1.965 . . . . 0.0 111.616 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.497 ' HB3' ' OE2' ' A' ' 6' ' ' GLU . 27.1 m -71.41 132.73 45.23 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.573 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . 0.438 HG22 ' N ' ' A' ' 15' ' ' SER . 12.5 tt -74.7 -36.48 40.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.839 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.658 ' O ' HG12 ' A' ' 18' ' ' ILE . 15.3 m -75.81 -3.66 36.31 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.644 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.754 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.47 -22.66 46.12 Favored Glycine 0 C--N 1.331 0.282 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.822 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 13.7 p -61.06 -22.69 27.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.858 0.361 . . . . 0.0 111.831 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.658 HG12 ' O ' ' A' ' 15' ' ' SER . 18.5 pt -80.09 -1.03 4.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 111.839 0.311 . . . . 0.0 111.839 -179.837 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.69 -21.53 5.62 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.275 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.754 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 58.3 m -61.54 121.9 13.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.401 0.62 . . . . 0.0 110.809 -179.787 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.435 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -108.83 138.88 44.47 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.258 -179.724 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.7 t -69.63 124.02 22.86 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.849 0.357 . . . . 0.0 110.516 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 48.8 m -148.45 120.07 8.02 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.76 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 6.5 t70 50.99 57.67 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.372 0.606 . . . . 0.0 110.146 -178.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.76 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 54.15 14.68 0.77 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.028 1.331 . . . . 0.0 113.703 -179.709 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.496 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 57.6 t -137.07 131.32 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 O-C-N 122.052 -0.405 . . . . 0.0 110.247 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.466 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 73.1 m -82.54 128.02 33.9 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 121.723 -0.611 . . . . 0.0 112.044 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.428 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-85 -111.45 142.47 43.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.372 179.653 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.607 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.5 tp -89.59 82.22 6.39 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.345 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.7 m120 . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 114.726 -1.124 . . . . 0.0 111.128 -178.473 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.768 0 CA-C-O 120.008 -0.329 . . . . 0.0 113.306 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.5 t -104.73 118.7 55.75 Favored Pre-proline 0 C--O 1.224 -0.284 0 CA-C-N 117.766 0.783 . . . . 0.0 111.661 -179.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 65.8 Cg_exo -50.77 136.73 42.8 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 123.028 2.485 . . . . 0.0 112.535 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.606 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 10.0 m -93.65 5.42 51.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.072 0.463 . . . . 0.0 110.05 -179.566 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.82 -26.39 3.22 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.789 -178.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.413 ' H ' ' C ' ' A' ' 4' ' ' CYS . 50.9 tt0 -79.01 132.92 36.82 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.519 ' HB2' HG22 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -110.55 147.57 33.91 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.602 0.715 . . . . 0.0 112.055 -178.975 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.0 p -110.88 49.12 0.88 Allowed 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.847 -1.07 . . . . 0.0 110.143 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.531 ' HA ' ' HG3' ' A' ' 25' ' ' LYS . 20.7 t -72.08 -42.53 67.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.658 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -110.37 -48.06 3.21 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.932 -0.577 . . . . 0.0 111.357 -179.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.41 HG23 HD12 ' A' ' 11' ' ' ILE . 31.8 pt -130.0 161.81 57.58 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.304 -179.348 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo -66.2 152.33 81.4 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 122.321 2.014 . . . . 0.0 111.632 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 46.1 m -72.83 137.27 45.62 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.751 -179.069 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 46.4 mm -73.1 -38.57 55.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.223 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.598 ' O ' HG21 ' A' ' 18' ' ' ILE . 2.1 m -73.45 2.42 7.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.188 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.624 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.83 -25.64 56.44 Favored Glycine 0 N--CA 1.453 -0.201 0 C-N-CA 121.252 -0.499 . . . . 0.0 112.791 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.7 m -62.62 -20.96 26.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.598 HG21 ' O ' ' A' ' 15' ' ' SER . 8.7 tp -83.99 -6.35 10.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.25 0.548 . . . . 0.0 111.053 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.55 -18.51 5.72 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.514 -0.851 . . . . 0.0 111.816 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.624 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 60.3 m -59.23 122.04 12.85 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.395 0.617 . . . . 0.0 110.892 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.439 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.7 m -113.86 142.66 45.83 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.096 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.6 t -63.61 114.78 4.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.973 0.416 . . . . 0.0 110.184 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.7 m -121.51 94.48 4.34 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.038 -0.528 . . . . 0.0 109.924 -179.68 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.604 ' C ' ' HE3' ' A' ' 25' ' ' LYS . 38.7 t70 46.37 65.26 1.23 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.131 -0.941 . . . . 0.0 112.07 -179.172 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.604 ' HE3' ' C ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 78.09 -9.85 1.44 Allowed 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 178.028 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.423 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 42.2 t -130.4 128.21 63.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-N 118.496 0.589 . . . . 0.0 110.647 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.439 ' HA ' ' O ' ' A' ' 21' ' ' SER . 85.7 m -80.72 128.55 33.76 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.366 0.603 . . . . 0.0 112.475 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-85 -112.94 144.23 42.87 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.636 179.138 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.606 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.5 tt -95.92 85.69 4.14 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.7 m-80 . . . . . 0 C--N 1.327 -0.402 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.927 -179.333 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.876 0 CA-C-O 120.195 -0.225 . . . . 0.0 112.608 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 21.6 m -96.27 112.23 59.12 Favored Pre-proline 0 C--O 1.221 -0.432 0 CA-C-N 117.369 0.585 . . . . 0.0 111.395 -179.296 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.408 ' HG3' ' CE2' ' A' ' 28' ' ' TYR . 71.5 Cg_exo -49.14 127.29 17.11 Favored 'Trans proline' 0 C--N 1.346 0.44 0 C-N-CA 122.862 2.375 . . . . 0.0 112.787 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.685 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 20.3 m -86.04 14.14 6.67 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.795 -178.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.59 26.46 68.4 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.925 -0.655 . . . . 0.0 111.973 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.715 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 40.6 tt0 -132.35 131.08 41.54 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.528 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 0.6 OUTLIER -112.0 150.02 31.18 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.586 0.708 . . . . 0.0 112.236 -178.433 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.3 p -112.21 42.64 1.74 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.75 -1.114 . . . . 0.0 109.774 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 1.059 ' HA ' ' HD2' ' A' ' 25' ' ' LYS . 20.8 t -69.07 -63.71 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.847 -178.573 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.0 m-85 -91.53 -49.43 6.32 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.177 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.554 ' H ' HD11 ' A' ' 11' ' ' ILE . 0.2 OUTLIER -121.78 159.29 51.7 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.532 -179.347 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -68.25 153.99 73.23 Favored 'Trans proline' 0 N--CA 1.459 -0.538 0 C-N-CA 122.471 2.114 . . . . 0.0 111.637 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.715 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 58.6 m -69.65 132.64 46.49 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.481 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . 0.407 HG23 ' N ' ' A' ' 15' ' ' SER . 7.6 tp -89.99 -39.45 12.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.008 0.432 . . . . 0.0 109.908 178.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.537 ' O ' HG12 ' A' ' 18' ' ' ILE . 2.5 m -74.12 -24.07 59.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.815 179.074 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.974 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.11 -17.69 5.59 Favored Glycine 0 C--N 1.331 0.298 0 CA-C-N 115.144 -0.934 . . . . 0.0 114.108 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.7 p -58.8 -20.89 17.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.148 0.499 . . . . 0.0 111.356 179.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.537 HG12 ' O ' ' A' ' 15' ' ' SER . 35.5 pt -75.73 -5.21 6.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.03 -0.532 . . . . 0.0 112.32 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 135.43 -18.68 3.89 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.43 -0.89 . . . . 0.0 112.171 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.974 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 33.4 m -60.68 124.2 19.69 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.315 0.579 . . . . 0.0 110.764 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.438 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 6.5 m -104.57 139.69 39.08 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.518 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.6 t -71.37 119.51 15.62 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.12 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 38.4 m -144.45 121.79 11.62 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.7 t0 54.95 46.55 24.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 122.251 1.024 . . . . 0.0 109.98 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 1.059 ' HD2' ' HA ' ' A' ' 9' ' ' VAL . 66.4 mmtt 62.2 14.93 7.07 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 113.905 -1.498 . . . . 0.0 113.487 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.528 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 60.5 t -136.09 132.47 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.786 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.469 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 34.6 m -82.27 125.69 31.26 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.523 0.677 . . . . 0.0 112.341 -179.648 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.455 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 2.4 m-85 -111.3 142.86 42.97 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.163 179.588 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.685 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 45.3 tp -89.32 81.4 6.66 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 107.999 -1.112 . . . . 0.0 107.999 178.156 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m120 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 114.745 -1.116 . . . . 0.0 111.069 -178.316 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.649 0 CA-C-O 120.199 -0.223 . . . . 0.0 113.199 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.2 m -98.17 113.71 64.27 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 117.392 0.596 . . . . 0.0 111.315 -179.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.445 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 73.0 Cg_exo -49.19 133.08 29.37 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.861 2.374 . . . . 0.0 112.756 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.552 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 33.3 m -83.15 20.52 1.24 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.35 -179.209 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 61.59 30.21 74.03 Favored Glycine 0 C--O 1.227 -0.341 0 CA-C-N 115.972 -0.558 . . . . 0.0 113.03 179.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -162.75 151.32 14.51 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.143 0.497 . . . . 0.0 110.047 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.543 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 34.9 p -100.6 -174.52 2.66 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.157 -179.683 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.543 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 28.7 p -150.88 41.84 0.77 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.593 0.711 . . . . 0.0 109.572 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 17.4 t -69.12 -40.68 80.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.011 -179.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -104.76 -49.52 3.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.28 -179.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.661 ' H ' HD11 ' A' ' 11' ' ' ILE . 0.2 OUTLIER -112.13 142.76 27.45 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.481 -179.695 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 18.8 Cg_exo -64.7 159.45 45.2 Favored 'Trans proline' 0 C--O 1.234 0.279 0 C-N-CA 122.738 2.292 . . . . 0.0 112.064 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 63.8 m -59.72 110.81 1.23 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.374 -179.627 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . 0.409 HD11 HG21 ' A' ' 14' ' ' ILE . 47.8 mm -63.8 -45.37 97.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.196 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.593 ' HB3' HD11 ' A' ' 18' ' ' ILE . 6.2 m -80.1 29.45 0.28 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.296 179.626 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -59.07 -34.99 81.92 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 121.228 -0.51 . . . . 0.0 112.395 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.3 p -63.94 -21.23 28.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.119 0.485 . . . . 0.0 111.181 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.593 HD11 ' HB3' ' A' ' 15' ' ' SER . 8.0 mt -84.43 -11.86 11.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.52 0.676 . . . . 0.0 110.43 179.646 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 121.13 -7.99 10.59 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.78 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.51 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 84.3 m -65.81 123.63 20.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.235 0.541 . . . . 0.0 110.711 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.3 m -129.39 148.7 51.33 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.174 -179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 19.2 m -67.38 105.8 1.9 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.465 0.65 . . . . 0.0 112.008 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.4 m -114.7 100.02 7.95 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.153 -0.931 . . . . 0.0 108.658 178.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.464 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 47.2 t0 52.52 54.07 11.23 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.527 0.68 . . . . 0.0 110.981 -178.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.787 ' HZ2' ' HB2' ' A' ' 25' ' ' LYS . 6.9 mtmp? 71.23 -0.33 3.14 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 115.185 -0.916 . . . . 0.0 113.159 179.187 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.543 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 25.6 t -120.15 134.39 63.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 118.13 0.423 . . . . 0.0 110.136 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 78.8 m -76.74 117.4 18.32 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.038 0.447 . . . . 0.0 112.197 -179.056 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.445 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.7 m-85 -112.86 142.41 45.55 Favored 'General case' 0 CA--C 1.513 -0.451 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 177.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.552 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.9 tt -101.38 86.32 2.96 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.057 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 . . . . . 0 C--N 1.325 -0.498 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.161 -178.984 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.64 0 CA-C-O 120.224 -0.209 . . . . 0.0 113.189 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.434 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 22.0 m -98.05 113.07 63.38 Favored Pre-proline 0 C--O 1.221 -0.419 0 CA-C-N 117.407 0.603 . . . . 0.0 110.806 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 8.8 Cg_endo -49.75 134.08 33.84 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 123.063 2.509 . . . . 0.0 112.49 -179.801 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.521 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 36.6 m -81.54 21.15 0.82 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.16 -179.209 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.88 28.65 72.21 Favored Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.754 -0.657 . . . . 0.0 113.235 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -161.21 152.93 19.37 Favored 'General case' 0 C--O 1.238 0.484 0 CA-C-O 121.414 0.626 . . . . 0.0 110.635 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.57 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 21.0 p -104.44 179.51 4.25 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.14 -0.937 . . . . 0.0 111.29 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.544 ' HB2' ' HA ' ' A' ' 12' ' ' PRO . 18.3 p -151.43 50.57 0.82 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.82 179.164 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.683 HG22 ' HB3' ' A' ' 25' ' ' LYS . 17.6 t -67.45 -42.39 87.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.96 -179.489 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -94.8 -48.72 5.91 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.312 -0.858 . . . . 0.0 111.694 -179.307 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.456 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 23.9 pt -135.18 142.64 42.56 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.73 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.544 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 9.6 Cg_exo -68.68 153.12 73.92 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.985 2.456 . . . . 0.0 112.493 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 97.8 m -67.27 120.77 14.36 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.931 179.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . 0.423 ' C ' ' H ' ' A' ' 16' ' ' GLY . 48.3 mm -61.61 -41.43 90.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.743 -179.751 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.651 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.0 m -76.65 22.07 0.19 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.655 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.592 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -58.83 -21.15 50.83 Favored Glycine 0 C--N 1.33 0.227 0 C-N-CA 121.467 -0.397 . . . . 0.0 112.806 179.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.5 p -60.75 -22.06 25.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.85 0.357 . . . . 0.0 111.718 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.651 HG12 ' O ' ' A' ' 15' ' ' SER . 22.4 pt -80.09 -0.59 4.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 C-N-CA 120.955 -0.298 . . . . 0.0 111.575 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.63 -20.0 7.41 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.2 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.592 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 78.3 m -63.24 124.14 20.45 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.401 0.62 . . . . 0.0 111.248 -179.767 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 17.7 m -129.14 142.03 51.0 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.376 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 23.3 m -71.99 115.77 11.6 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.486 0.66 . . . . 0.0 111.974 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.508 ' HB ' ' CD1' ' A' ' 28' ' ' TYR . 15.7 m -124.4 108.51 12.24 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.515 178.742 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 43.7 t0 47.68 57.15 6.23 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.905 -178.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.683 ' HB3' HG22 ' A' ' 9' ' ' VAL . 20.3 mtmm 68.57 8.65 6.83 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.52 0.933 . . . . 0.0 113.52 178.372 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.57 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 48.6 t -130.04 134.45 62.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 118.611 0.641 . . . . 0.0 110.23 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 97.9 m -81.02 119.42 23.51 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.214 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.529 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 37.7 m-85 -114.88 142.77 46.13 Favored 'General case' 0 CA--C 1.516 -0.342 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.521 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.8 tt -101.94 87.22 3.05 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.087 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.0 m-80 . . . . . 0 C--N 1.326 -0.442 0 CA-C-N 114.897 -1.047 . . . . 0.0 111.352 -178.955 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.684 0 CA-C-O 120.234 -0.203 . . . . 0.0 113.142 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.446 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 22.6 m -101.69 114.71 65.56 Favored Pre-proline 0 C--O 1.22 -0.45 0 CA-C-N 117.451 0.625 . . . . 0.0 111.127 -179.352 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.55 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 7.0 Cg_endo -48.75 131.86 25.2 Favored 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 123.111 2.541 . . . . 0.0 112.484 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.683 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 31.0 m -83.6 15.86 2.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.526 -179.058 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 61.45 32.2 80.22 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.004 -0.617 . . . . 0.0 112.034 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.497 ' HG3' ' SG ' ' A' ' 13' ' ' CYS . 3.8 tp10 -143.71 140.29 29.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.074 0.464 . . . . 0.0 110.012 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.589 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 11.6 p -101.3 170.19 8.4 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.455 -0.793 . . . . 0.0 112.257 -178.763 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.0 p -150.32 49.25 0.9 Allowed 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.423 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 12.1 t -68.11 -37.84 78.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.349 -178.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -125.17 -50.0 1.69 Allowed 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.401 179.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 50.0 mm -107.08 131.48 21.66 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.902 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo -69.29 151.38 71.76 Favored 'Trans proline' 0 N--CA 1.457 -0.642 0 C-N-CA 122.336 2.024 . . . . 0.0 111.66 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.497 ' SG ' ' HG3' ' A' ' 6' ' ' GLU . 9.7 m -69.19 119.4 13.41 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.148 -179.341 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 14.0 tt -64.88 -30.72 51.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.349 0.595 . . . . 0.0 110.496 179.61 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.664 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.4 p -74.76 1.99 11.15 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.529 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.636 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.33 -20.87 38.36 Favored Glycine 0 CA--C 1.518 0.26 0 CA-C-N 116.485 -0.325 . . . . 0.0 113.16 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.8 p -60.46 -23.62 28.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.96 0.41 . . . . 0.0 111.712 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.664 HG12 ' O ' ' A' ' 15' ' ' SER . 23.0 pt -81.06 0.14 3.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.453 -0.339 . . . . 0.0 111.749 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.64 -22.04 7.01 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.216 179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.636 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 83.2 m -59.84 122.6 14.63 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.531 0.681 . . . . 0.0 110.894 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.1 m -114.9 138.23 51.05 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.795 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 47.4 t -69.34 123.89 22.41 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.5 m -137.55 113.69 9.97 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.821 0.343 . . . . 0.0 110.184 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 35.4 t70 46.45 58.32 4.68 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.469 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.448 ' HE2' ' HB2' ' A' ' 25' ' ' LYS . 26.0 mtmm 72.26 4.82 5.13 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 113.783 1.031 . . . . 0.0 113.783 177.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.589 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 4.3 p -143.02 133.2 22.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 118.768 0.713 . . . . 0.0 111.343 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 93.9 m -80.78 132.16 35.48 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -178.605 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 3.1 m-85 -117.26 146.4 43.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.952 178.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.683 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 55.9 tp -99.35 84.67 3.03 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 . . . . . 0 C--N 1.327 -0.382 0 CA-C-N 115.186 -0.915 . . . . 0.0 111.602 -179.409 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.754 0 CA-C-O 120.276 -0.18 . . . . 0.0 112.728 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.412 ' HG1' ' HB3' ' A' ' 29' ' ' LEU . 14.6 p -100.74 116.6 63.98 Favored Pre-proline 0 C--O 1.222 -0.376 0 CA-C-N 117.328 0.564 . . . . 0.0 111.289 -179.361 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.446 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 82.1 Cg_exo -45.45 132.62 12.53 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 123.128 2.552 . . . . 0.0 113.084 -179.609 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.51 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 55.9 m -82.78 19.29 1.36 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.507 -179.237 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.73 30.36 76.69 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.239 -0.505 . . . . 0.0 112.741 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.3 tp10 -156.57 153.13 28.17 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.529 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 47.3 p -102.23 -176.71 3.19 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.506 0.67 . . . . 0.0 111.831 -179.317 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.1 p -151.04 41.85 0.75 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.243 179.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 13.3 t -69.93 -42.32 79.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.528 -179.016 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -115.0 -47.63 2.86 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.934 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.454 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 32.6 pt -104.59 142.9 25.6 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.82 -179.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 14.6 Cg_exo -67.15 158.69 55.66 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.715 2.277 . . . . 0.0 111.718 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 59.7 m -59.48 106.84 0.5 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.162 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . 0.794 ' H ' HD11 ' A' ' 14' ' ' ILE . 0.2 OUTLIER -62.69 -39.29 84.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.118 0.485 . . . . 0.0 110.529 179.848 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.699 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.0 m -85.57 21.7 1.75 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.571 179.237 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.416 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -59.33 -27.2 62.74 Favored Glycine 0 C--N 1.329 0.183 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.415 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.9 p -62.59 -23.63 33.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 120.856 0.36 . . . . 0.0 111.83 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.699 HG12 ' O ' ' A' ' 15' ' ' SER . 16.0 pt -90.53 3.45 6.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 C-N-CA 120.531 -0.468 . . . . 0.0 111.421 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 115.93 -12.87 17.33 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.3 -0.953 . . . . 0.0 113.25 179.181 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.416 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 71.2 m -62.58 123.38 18.21 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.467 0.651 . . . . 0.0 110.962 -179.759 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 9.1 m -117.1 142.33 47.14 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.89 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.5 t -71.91 111.36 7.1 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.069 0.462 . . . . 0.0 109.951 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 m -119.09 103.93 10.0 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.096 -179.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.448 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 19.6 t70 47.23 61.87 2.68 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.817 -179.544 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.448 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.5 OUTLIER 67.86 4.78 4.14 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 115.013 -0.994 . . . . 0.0 113.241 178.834 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.529 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 51.4 t -131.01 130.98 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 118.418 0.554 . . . . 0.0 110.577 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 84.7 m -77.73 125.42 29.32 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.446 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 4.7 m-85 -117.2 143.11 46.22 Favored 'General case' 0 CA--C 1.517 -0.317 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.234 178.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.51 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.7 tp -96.41 83.18 3.49 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.367 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 m120 . . . . . 0 N--CA 1.465 0.309 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.584 -178.586 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.74 0 CA-C-O 120.287 -0.174 . . . . 0.0 112.709 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 19.8 m -94.38 109.63 43.94 Favored Pre-proline 0 C--O 1.22 -0.453 0 CA-C-N 117.157 0.479 . . . . 0.0 111.518 -179.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.499 ' HG3' ' CE2' ' A' ' 28' ' ' TYR . 33.1 Cg_exo -58.16 134.04 59.29 Favored 'Trans proline' 0 CA--C 1.529 0.249 0 C-N-CA 122.532 2.155 . . . . 0.0 112.913 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 6.5 m -79.57 16.74 1.01 Allowed 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.272 179.294 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.9 29.91 75.65 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.101 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -153.59 156.2 37.54 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.315 0.578 . . . . 0.0 110.152 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.541 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 40.2 p -103.14 -174.73 2.62 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.544 -179.185 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 9.2 p -151.12 39.64 0.69 Allowed 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.227 179.312 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.904 HG23 ' HB3' ' A' ' 25' ' ' LYS . 10.9 t -69.99 -36.22 67.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.251 -0.886 . . . . 0.0 111.189 -179.25 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -122.7 -45.93 2.15 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.362 -179.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 35.0 pt -103.62 147.5 34.33 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.179 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo -68.64 156.21 66.28 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.715 2.277 . . . . 0.0 111.615 179.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 77.7 m -60.64 107.79 0.74 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.783 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 11.3 tt -64.96 -38.83 83.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.15 0.5 . . . . 0.0 109.976 179.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.684 ' HB3' HD13 ' A' ' 18' ' ' ILE . 6.0 m -81.62 20.72 0.88 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.024 179.325 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.543 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -60.85 -31.11 74.75 Favored Glycine 0 C--N 1.332 0.329 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.095 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 21.9 t -63.06 -23.95 34.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.324 0.583 . . . . 0.0 110.703 179.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.684 HD13 ' HB3' ' A' ' 15' ' ' SER . 6.5 mt -81.63 -12.33 12.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.413 179.666 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 118.96 -8.54 12.58 Favored Glycine 0 N--CA 1.446 -0.698 0 CA-C-N 115.715 -0.675 . . . . 0.0 112.182 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.543 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 1.8 m -70.21 127.64 33.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.726 0.774 . . . . 0.0 111.722 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 20.1 m -116.63 149.83 39.09 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.649 -1.159 . . . . 0.0 109.715 179.502 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.2 t -69.51 111.7 5.53 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.974 0.416 . . . . 0.0 110.292 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.51 ' HB ' ' CD1' ' A' ' 28' ' ' TYR . 5.9 m -119.59 103.07 9.1 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.005 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 36.2 t70 47.53 58.77 4.63 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.271 -179.502 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.904 ' HB3' HG23 ' A' ' 9' ' ' VAL . 28.4 mtmm 72.07 2.83 4.46 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 178.451 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.541 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 42.7 t -130.43 133.1 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 118.563 0.62 . . . . 0.0 110.385 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 83.9 m -80.95 120.41 24.72 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 112.724 0.639 . . . . 0.0 112.724 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.51 ' CD1' ' HB ' ' A' ' 23' ' ' THR . 57.3 m-85 -121.47 139.89 52.89 Favored 'General case' 0 CA--C 1.518 -0.288 0 CA-C-O 121.142 0.496 . . . . 0.0 110.462 178.143 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.509 ' HB2' ' SG ' ' A' ' 20' ' ' CYS . 2.7 tt -94.11 77.89 4.05 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 178.249 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.1 m-80 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.01 -178.804 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.849 0 CA-C-O 120.211 -0.216 . . . . 0.0 112.792 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.6 m -95.83 110.7 52.92 Favored Pre-proline 0 C--O 1.222 -0.363 0 CA-C-N 117.306 0.553 . . . . 0.0 111.087 -179.414 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.41 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.1 Cg_exo -49.71 130.38 26.31 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.846 2.364 . . . . 0.0 112.627 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.601 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 4.8 m -92.16 6.69 45.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.312 -179.315 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.05 -27.23 2.73 Favored Glycine 0 N--CA 1.452 -0.286 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -178.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.679 ' OE2' ' HB3' ' A' ' 13' ' ' CYS . 19.7 tt0 -69.8 131.03 43.88 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.556 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.489 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.3 p -115.75 162.79 16.78 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.471 0.653 . . . . 0.0 112.465 -178.137 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.446 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.8 p -136.01 45.45 2.38 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.576 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.628 HG22 ' HB3' ' A' ' 25' ' ' LYS . 8.1 t -70.15 -43.21 79.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.38 -178.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -127.56 -46.98 1.43 Allowed 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.282 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 35.0 pt -104.11 149.49 37.31 Favored Pre-proline 0 C--N 1.322 -0.618 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.915 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_exo -67.82 152.51 77.31 Favored 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 122.354 2.036 . . . . 0.0 111.581 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.679 ' HB3' ' OE2' ' A' ' 6' ' ' GLU . 74.3 m -64.09 -46.42 84.36 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.257 -179.394 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . 0.405 ' HB ' ' O ' ' A' ' 13' ' ' CYS . 77.2 mt 74.19 -57.07 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 C-N-CA 123.012 0.525 . . . . 0.0 111.521 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.447 ' O ' HG12 ' A' ' 18' ' ' ILE . 0.9 OUTLIER -68.46 -18.2 64.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.261 0.553 . . . . 0.0 110.084 179.351 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.728 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -52.27 -15.21 2.56 Favored Glycine 0 C--N 1.332 0.324 0 CA-C-N 115.107 -0.951 . . . . 0.0 113.887 -179.742 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 31.6 m -58.1 -18.25 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 117.07 0.435 . . . . 0.0 111.18 178.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.447 HG12 ' O ' ' A' ' 15' ' ' SER . 39.2 pt -73.95 -9.96 13.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.821 179.631 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.07 -23.25 2.59 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.681 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.728 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 38.9 m -67.76 121.86 16.87 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.514 0.673 . . . . 0.0 111.047 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.483 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -108.57 140.42 41.94 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.187 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.2 t -65.38 112.63 3.61 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.147 0.499 . . . . 0.0 110.245 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.4 m -127.61 109.4 11.65 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.016 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 21.4 t0 48.26 59.48 4.26 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.774 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.628 ' HB3' HG22 ' A' ' 9' ' ' VAL . 1.7 mptt 69.86 3.0 4.1 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.158 -0.928 . . . . 0.0 113.357 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.489 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 62.4 t -136.28 130.42 47.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 118.516 0.598 . . . . 0.0 110.815 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.58 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 5.6 m -80.2 123.32 27.82 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.502 0.668 . . . . 0.0 112.096 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.473 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 1.9 m-85 -108.42 142.34 38.92 Favored 'General case' 0 CA--C 1.519 -0.238 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.845 179.279 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.601 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.5 tt -89.78 83.48 6.21 Favored 'General case' 0 C--N 1.309 -1.165 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 178.289 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m120 . . . . . 0 C--N 1.326 -0.427 0 CA-C-N 114.649 -1.159 . . . . 0.0 111.12 -178.574 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.858 0 CA-C-O 120.231 -0.205 . . . . 0.0 112.708 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.9 m -96.27 111.5 56.83 Favored Pre-proline 0 C--O 1.221 -0.441 0 CA-C-N 117.325 0.562 . . . . 0.0 111.2 -179.419 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 89.4 Cg_exo -47.5 127.25 13.37 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.897 2.398 . . . . 0.0 113.109 -179.562 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.592 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 22.9 m -84.72 -7.62 59.15 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.425 -179.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.14 -15.99 56.8 Favored Glycine 0 N--CA 1.448 -0.506 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.04 151.52 41.68 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.248 -0.476 . . . . 0.0 110.16 179.401 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.413 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 1.6 p -128.9 150.2 50.46 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 121.84 0.828 . . . . 0.0 112.394 -179.669 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.462 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.7 p -127.18 44.37 2.93 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 114.556 -1.202 . . . . 0.0 109.698 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.9 t -74.78 -46.41 41.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.485 -179.105 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -101.75 -48.66 4.22 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.089 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.462 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 32.5 pt -132.91 164.96 40.2 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.605 -179.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -63.89 153.91 72.96 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.063 1.842 . . . . 0.0 111.684 179.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 86.8 m -61.82 139.12 58.38 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.323 -179.173 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 50.2 mm -67.22 122.81 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 115.307 -0.861 . . . . 0.0 109.657 178.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.669 ' O ' HG13 ' A' ' 18' ' ' ILE . 35.8 p 51.91 31.17 8.06 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 115.495 -0.775 . . . . 0.0 112.655 -179.48 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -55.79 -14.24 7.26 Favored Glycine 0 C--N 1.338 0.683 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.805 178.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.7 p -56.63 -17.0 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 C-N-CA 123.147 0.579 . . . . 0.0 111.37 179.039 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.669 HG13 ' O ' ' A' ' 15' ' ' SER . 55.5 mt -55.65 -30.98 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.907 0.861 . . . . 0.0 110.633 178.632 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 150.94 -18.28 0.95 Allowed Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 114.501 -1.227 . . . . 0.0 110.099 -179.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.608 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 59.2 m -68.27 120.03 13.76 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.506 0.67 . . . . 0.0 110.734 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.523 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -107.25 139.82 41.1 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.097 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.7 t -66.67 118.4 10.18 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.862 0.363 . . . . 0.0 110.148 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 16.2 m -132.21 106.13 7.76 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.049 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.556 ' CG ' ' HZ2' ' A' ' 25' ' ' LYS . 30.2 t70 48.98 58.21 5.61 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.625 0.726 . . . . 0.0 112.091 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.556 ' HZ2' ' CG ' ' A' ' 24' ' ' ASP . 6.1 mtmp? 75.09 -5.7 2.11 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 178.408 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.413 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 1.9 m -133.2 132.0 58.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.507 0.594 . . . . 0.0 111.402 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.608 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 61.1 m -81.07 129.45 34.56 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -178.654 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.431 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.3 m-85 -110.01 143.72 39.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.761 178.64 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.592 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.4 tp -89.78 81.59 6.36 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 178.398 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.7 m120 . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.969 -178.28 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.656 0 CA-C-O 120.165 -0.241 . . . . 0.0 113.309 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.0 p -100.54 119.08 59.69 Favored Pre-proline 0 C--O 1.222 -0.382 0 CA-C-N 117.5 0.65 . . . . 0.0 111.576 -179.135 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_exo -48.41 134.31 25.91 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 123.121 2.548 . . . . 0.0 112.813 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.599 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 37.1 m -82.53 19.43 1.27 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.513 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 63.75 28.8 73.16 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.235 -0.507 . . . . 0.0 112.877 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.7 tp10 -155.81 153.45 29.81 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-O 120.946 0.403 . . . . 0.0 110.064 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.621 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 44.8 p -100.14 -177.64 3.59 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.542 -0.754 . . . . 0.0 112.235 -178.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.7 p -151.54 45.45 0.79 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.113 179.229 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 10.6 t -65.9 -39.49 84.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.357 -0.838 . . . . 0.0 111.573 -178.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -128.32 -47.6 1.32 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.503 179.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.486 HD12 ' HD2' ' A' ' 12' ' ' PRO . 5.8 tp -106.92 123.62 37.93 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.416 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.486 ' HD2' HD12 ' A' ' 11' ' ' ILE . 5.6 Cg_exo -73.05 153.42 52.12 Favored 'Trans proline' 0 N--CA 1.456 -0.685 0 C-N-CA 122.407 2.071 . . . . 0.0 111.49 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 86.1 m -67.29 117.04 8.74 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.125 -179.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . 0.434 ' C ' ' H ' ' A' ' 16' ' ' GLY . 47.3 mm -62.3 -40.09 86.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.593 -179.796 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.642 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.3 m -76.01 20.19 0.2 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.5 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.712 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -58.28 -21.07 46.44 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 121.508 -0.377 . . . . 0.0 112.898 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.9 m -61.42 -19.72 21.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 112.161 0.43 . . . . 0.0 112.161 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.642 HG12 ' O ' ' A' ' 15' ' ' SER . 23.1 pt -83.25 1.82 3.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.741 0.305 . . . . 0.0 111.31 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.05 -17.03 8.69 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.581 -0.818 . . . . 0.0 112.212 179.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.712 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 70.8 m -65.66 124.02 21.27 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.506 0.67 . . . . 0.0 111.373 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.5 m -128.04 142.47 51.21 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.239 -0.891 . . . . 0.0 109.262 179.485 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 46.4 t -73.27 124.76 26.31 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.903 0.382 . . . . 0.0 110.399 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 57.3 m -150.18 123.89 9.19 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.621 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 51.8 t0 51.54 55.16 9.82 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.123 0.487 . . . . 0.0 110.999 -179.237 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.621 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 60.01 5.55 0.78 Allowed 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.074 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.621 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 2.7 m -134.6 145.21 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 O-C-N 121.682 -0.637 . . . . 0.0 112.072 178.68 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.9 m -81.37 126.41 31.57 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.101 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.488 ' CE1' HG22 ' A' ' 26' ' ' VAL . 30.0 m-85 -112.43 142.6 44.77 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 177.568 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.599 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.7 tt -104.22 88.79 3.07 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.533 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 . . . . . 0 C--N 1.326 -0.443 0 CA-C-N 114.959 -1.019 . . . . 0.0 111.356 -178.839 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.809 0 CA-C-O 120.001 -0.333 . . . . 0.0 112.98 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.662 HG22 ' HB3' ' A' ' 29' ' ' LEU . 4.9 t -100.57 119.81 57.7 Favored Pre-proline 0 C--O 1.221 -0.424 0 CA-C-N 117.758 0.779 . . . . 0.0 111.742 -179.158 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -50.22 131.43 31.23 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 123.098 2.532 . . . . 0.0 113.002 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.677 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 8.8 m -90.61 22.71 3.36 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.825 -178.84 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.23 35.69 88.72 Favored Glycine 0 C--N 1.331 0.291 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.105 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.589 ' OE2' HG12 ' A' ' 14' ' ' ILE . 44.7 tt0 -146.1 153.24 40.47 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -179.533 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -135.02 150.19 50.27 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.225 0.536 . . . . 0.0 111.436 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -100.44 51.89 0.88 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.073 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.3 t -63.61 -40.08 87.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.424 -179.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 m-85 -142.58 -42.25 0.32 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.772 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 37.2 pt -103.26 152.68 38.71 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.785 -179.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo -68.87 154.42 71.04 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.726 2.284 . . . . 0.0 111.62 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 20.6 m -64.26 122.37 16.5 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.554 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . 0.589 HG12 ' OE2' ' A' ' 6' ' ' GLU . 33.4 pt -74.12 -28.14 23.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.14 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.1 p -78.73 2.4 19.82 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.507 179.017 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -56.51 -33.77 62.82 Favored Glycine 0 C--N 1.333 0.394 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.625 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 25.6 t -61.63 -27.31 41.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.394 0.616 . . . . 0.0 110.767 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.424 ' O ' HG21 ' A' ' 18' ' ' ILE . 37.4 mm -78.15 -18.71 13.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.521 179.586 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 125.97 -7.97 7.67 Favored Glycine 0 N--CA 1.447 -0.57 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.778 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.495 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 60.4 m -63.68 124.89 22.59 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.377 0.608 . . . . 0.0 110.916 -179.774 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 8.8 m -112.21 147.09 36.93 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.371 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.8 t -75.0 123.53 25.32 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.868 0.366 . . . . 0.0 110.15 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.2 m -145.66 121.85 10.83 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 53.67 44.29 29.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.871 0.843 . . . . 0.0 110.754 -179.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.502 ' HG2' ' O ' ' A' ' 25' ' ' LYS . 11.4 ttpp 65.49 10.77 6.88 Favored 'General case' 0 CA--C 1.544 0.723 0 CA-C-N 114.338 -1.301 . . . . 0.0 112.098 179.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 49.9 t -127.4 138.42 54.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 O-C-N 121.838 -0.539 . . . . 0.0 110.447 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.8 m -82.02 122.5 27.89 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.771 0.319 . . . . 0.0 111.071 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.435 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 25.2 m-85 -116.75 139.99 49.94 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-O 121.165 0.507 . . . . 0.0 110.862 179.514 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.677 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 55.3 tp -91.59 83.89 5.42 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 177.73 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.6 m120 . . . . . 0 C--N 1.327 -0.391 0 CA-C-N 114.704 -1.135 . . . . 0.0 111.299 -178.497 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.795 0 CA-C-O 120.2 -0.222 . . . . 0.0 113.064 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.422 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 20.4 m -101.21 112.71 65.41 Favored Pre-proline 0 C--O 1.22 -0.489 0 CA-C-N 117.392 0.596 . . . . 0.0 111.041 -179.396 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.545 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 8.5 Cg_endo -49.35 130.32 24.76 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 123.031 2.487 . . . . 0.0 112.626 -179.719 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.646 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 32.4 m -83.26 11.16 6.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.285 -179.167 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 66.1 28.62 73.82 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 121.08 -0.581 . . . . 0.0 112.269 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.609 ' HG3' ' HB2' ' A' ' 27' ' ' CYS . 17.2 pt-20 -134.45 155.08 50.96 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.998 0.428 . . . . 0.0 109.86 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.8 p -124.19 154.28 40.34 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.613 0.72 . . . . 0.0 112.302 -178.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -127.25 46.1 2.59 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 114.385 -1.279 . . . . 0.0 109.791 179.654 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.3 t -70.6 -48.4 58.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.899 -178.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.2 m-85 -101.18 -47.92 4.57 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.379 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.5 pt -126.95 154.92 76.37 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.397 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -65.48 154.6 72.97 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.46 2.106 . . . . 0.0 111.885 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.461 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 71.1 m -66.58 128.08 34.85 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.803 -179.314 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . 0.416 HD12 HG23 ' A' ' 14' ' ' ILE . 11.5 tt -71.73 126.84 32.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.219 179.481 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.54 ' O ' HG12 ' A' ' 18' ' ' ILE . 21.6 m 67.07 14.58 9.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.648 -0.705 . . . . 0.0 111.844 -179.465 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -56.15 -16.23 13.22 Favored Glycine 0 C--N 1.339 0.706 0 C-N-CA 121.229 -0.51 . . . . 0.0 112.666 179.059 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 16.6 t -56.23 -17.84 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 C-N-CA 122.95 0.5 . . . . 0.0 111.272 179.172 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.54 HG12 ' O ' ' A' ' 15' ' ' SER . 47.2 mm -57.9 -29.16 35.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.613 0.72 . . . . 0.0 111.044 178.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 155.99 -22.85 0.53 Allowed Glycine 0 C--N 1.312 -0.782 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 179.787 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.463 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 60.1 m -67.35 120.49 13.95 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.644 0.735 . . . . 0.0 110.723 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.478 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 17.9 m -110.62 139.97 45.39 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.713 -179.597 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 49.1 t -67.51 109.66 3.32 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.015 0.436 . . . . 0.0 110.08 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.0 m -120.26 103.54 9.32 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.043 -179.563 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.445 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 21.7 t70 47.65 62.05 2.64 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.767 -179.572 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.445 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.6 OUTLIER 70.96 -0.5 3.02 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 115.117 -0.947 . . . . 0.0 113.356 178.71 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.461 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 50.1 t -131.89 128.26 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 118.557 0.617 . . . . 0.0 110.54 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.609 ' HB2' ' HG3' ' A' ' 6' ' ' GLU . 54.5 m -81.32 128.4 33.79 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.467 0.651 . . . . 0.0 112.457 -179.532 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.545 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 4.2 m-85 -114.46 144.21 43.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.307 -0.861 . . . . 0.0 109.941 179.258 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.646 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.1 tp -92.4 81.67 4.9 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.505 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 115.057 -0.974 . . . . 0.0 111.516 -179.188 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.725 0 CA-C-O 120.115 -0.269 . . . . 0.0 113.085 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 21.9 m -97.72 112.48 61.6 Favored Pre-proline 0 C--O 1.222 -0.384 0 CA-C-N 117.484 0.642 . . . . 0.0 111.355 -179.245 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.5 Cg_exo -50.4 131.85 33.22 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.843 2.362 . . . . 0.0 112.486 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.599 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 35.5 m -85.15 18.5 2.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.472 -179.201 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.03 33.1 77.74 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.482 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -153.0 151.56 30.41 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -132.87 146.36 51.74 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.669 0.747 . . . . 0.0 112.097 -179.284 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.465 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 2.1 p -101.37 45.39 0.97 Allowed 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.389 179.549 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 16.3 t -70.9 -35.65 60.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.042 -179.491 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -128.93 -50.8 1.22 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.504 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.465 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 2.4 pp -104.95 151.08 39.37 Favored Pre-proline 0 C--N 1.324 -0.529 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.738 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -71.15 150.07 59.13 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.194 1.93 . . . . 0.0 111.609 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.403 ' C ' ' H ' ' A' ' 15' ' ' SER . 98.5 m -69.37 -39.68 77.9 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.923 -179.272 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . 0.437 ' C ' ' H ' ' A' ' 16' ' ' GLY . 76.1 mt 71.48 -44.91 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 122.764 0.426 . . . . 0.0 111.346 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.403 ' H ' ' C ' ' A' ' 13' ' ' CYS . 8.5 p -71.02 10.46 0.54 Allowed 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 122.88 0.472 . . . . 0.0 111.753 179.274 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.438 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -57.66 -25.7 56.06 Favored Glycine 0 C--O 1.227 -0.292 0 CA-C-N 116.143 -0.48 . . . . 0.0 113.086 179.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 29.8 m -61.73 -20.91 24.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.994 0.426 . . . . 0.0 111.889 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.401 HG23 ' O ' ' A' ' 18' ' ' ILE . 16.9 mt -78.63 -14.13 13.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.599 0.714 . . . . 0.0 110.47 179.647 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.87 -14.75 6.3 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.294 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.476 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 60.0 m -63.05 125.84 25.34 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.26 0.552 . . . . 0.0 110.775 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 17.9 m -129.35 140.56 51.34 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.08 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.0 m -62.62 111.18 1.97 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.384 0.611 . . . . 0.0 111.345 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.8 m -124.43 107.09 10.73 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.585 179.474 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.419 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 45.1 t0 54.4 50.37 16.37 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.817 0.818 . . . . 0.0 110.248 -178.326 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.645 ' HZ2' ' HB2' ' A' ' 25' ' ' LYS . 0.1 OUTLIER 72.04 -7.71 1.26 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.698 -1.137 . . . . 0.0 113.105 179.692 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 41.3 t -115.25 132.03 65.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 O-C-N 122.06 -0.4 . . . . 0.0 110.464 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.476 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 39.5 m -78.65 120.37 23.23 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.512 0.672 . . . . 0.0 112.67 -179.11 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.5 m-85 -110.35 143.71 40.18 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.171 -0.922 . . . . 0.0 109.372 178.429 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.599 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.9 tt -97.98 84.85 3.38 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 178.855 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.1 m-80 . . . . . 0 C--N 1.326 -0.454 0 CA-C-N 114.898 -1.047 . . . . 0.0 111.196 -179.053 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.874 0 CA-C-O 120.089 -0.284 . . . . 0.0 112.811 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 17.0 p -98.83 113.25 64.29 Favored Pre-proline 0 C--O 1.224 -0.257 0 CA-C-N 117.507 0.653 . . . . 0.0 111.682 -179.051 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.496 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.4 Cg_exo -49.51 128.96 22.01 Favored 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.932 2.422 . . . . 0.0 112.6 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.71 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 12.7 m -88.5 16.49 6.45 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.593 -178.823 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 58.72 32.57 69.94 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.892 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.584 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 32.8 tt0 -136.24 145.82 46.04 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -179.362 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.667 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -137.48 151.99 49.06 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.031 0.443 . . . . 0.0 111.874 -178.686 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.588 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 29.7 p -109.54 39.54 2.07 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.33 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.69 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.5 t -72.04 -41.58 68.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.173 -179.505 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 19.5 m-85 -115.1 -47.95 2.84 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.647 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.588 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 34.7 pt -122.16 153.31 61.32 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.064 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -66.27 154.39 74.37 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.296 1.997 . . . . 0.0 111.768 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.584 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 72.3 m -68.04 128.24 35.8 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.287 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 61.8 mt -90.08 -44.35 14.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-O 121.359 0.599 . . . . 0.0 109.409 178.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.57 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.2 m -72.52 -23.66 61.04 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.139 179.267 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 1.01 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -52.62 -19.34 6.34 Favored Glycine 0 CA--C 1.519 0.31 0 CA-C-N 115.322 -0.853 . . . . 0.0 114.185 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 36.0 m -60.45 -18.96 17.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.871 0.336 . . . . 0.0 111.885 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.57 HG12 ' O ' ' A' ' 15' ' ' SER . 33.2 pt -79.79 -1.71 4.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.804 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 130.94 -19.4 4.95 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.403 -0.903 . . . . 0.0 112.14 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 1.01 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 56.2 m -58.58 121.92 12.16 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.301 0.572 . . . . 0.0 111.131 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 15.4 m -105.84 132.86 51.44 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.099 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.609 ' HA ' ' HA ' ' A' ' 27' ' ' CYS . 1.7 t -75.03 108.99 8.13 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.511 0.672 . . . . 0.0 111.176 -178.674 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.7 m -109.42 118.3 36.29 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.013 -0.994 . . . . 0.0 108.462 178.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 30.9 t70 52.11 52.44 14.35 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 122.065 0.936 . . . . 0.0 110.93 -178.523 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.69 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.0 OUTLIER 69.76 3.53 4.32 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.779 -1.1 . . . . 0.0 113.533 178.797 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 33.0 t -127.29 124.13 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 118.622 0.646 . . . . 0.0 110.505 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.609 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 7.3 m -75.53 124.87 27.92 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.658 0.742 . . . . 0.0 112.836 -179.193 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.4 m-85 -114.72 144.88 42.75 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.579 179.163 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.71 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 46.1 tp -92.9 81.32 4.63 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 178.519 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.9 m-80 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.449 -179.308 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.805 0 CA-C-O 120.028 -0.318 . . . . 0.0 113.271 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.455 HG23 ' HB3' ' A' ' 29' ' ' LEU . 4.9 t -106.92 118.45 54.1 Favored Pre-proline 0 C--O 1.223 -0.31 0 CA-C-N 117.755 0.778 . . . . 0.0 111.488 -179.178 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.592 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 9.5 Cg_endo -51.39 135.56 46.97 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 123.124 2.55 . . . . 0.0 112.373 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.691 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 6.7 m -93.7 7.65 43.96 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.345 -179.269 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 79.51 -25.97 2.75 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.576 -178.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.725 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 33.2 tt0 -74.06 131.2 41.11 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.565 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -112.56 154.0 26.64 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.49 0.662 . . . . 0.0 111.887 -178.744 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.407 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.7 p -122.24 44.75 2.52 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.872 -1.058 . . . . 0.0 109.688 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.754 HG22 ' HB3' ' A' ' 25' ' ' LYS . 12.9 t -72.43 -44.46 62.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.699 -178.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -112.19 -49.61 2.96 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.022 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 34.4 pt -118.76 155.59 52.45 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.391 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_exo -67.17 153.01 78.77 Favored 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 122.432 2.088 . . . . 0.0 111.753 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.725 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 62.0 m -70.82 130.97 43.07 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.54 -0.755 . . . . 0.0 111.462 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 27.7 pt -88.72 -38.04 10.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.889 0.376 . . . . 0.0 110.529 179.31 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.558 ' O ' HG12 ' A' ' 18' ' ' ILE . 2.8 m -74.77 -18.33 60.5 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.196 0.522 . . . . 0.0 109.895 179.245 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.955 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.08 -18.23 6.06 Favored Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.158 -0.928 . . . . 0.0 113.923 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.4 m -59.47 -19.81 17.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.925 0.393 . . . . 0.0 111.686 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.558 HG12 ' O ' ' A' ' 15' ' ' SER . 33.4 pt -79.04 -4.03 6.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.771 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 133.41 -21.61 4.04 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.994 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.955 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 50.1 m -60.52 122.28 14.25 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.342 0.592 . . . . 0.0 110.699 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.9 m -108.47 141.92 39.62 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.449 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.1 t -64.93 113.06 3.59 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.975 0.416 . . . . 0.0 110.262 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.1 m -122.57 100.27 6.84 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.086 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.45 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 23.0 t70 47.73 63.69 1.91 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.448 -0.796 . . . . 0.0 111.79 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.754 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.8 OUTLIER 72.43 -4.28 2.09 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 115.027 -0.988 . . . . 0.0 113.136 178.844 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.423 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 44.3 t -130.81 127.31 61.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 118.671 0.669 . . . . 0.0 110.718 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.49 ' HA ' ' O ' ' A' ' 21' ' ' SER . 30.6 m -80.71 127.75 32.85 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.539 0.685 . . . . 0.0 112.267 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.592 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.5 m-85 -112.27 144.72 41.2 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.255 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.691 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.8 tp -93.43 83.91 4.63 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 114.871 -1.059 . . . . 0.0 112.004 -179.61 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.792 0 CA-C-O 120.212 -0.215 . . . . 0.0 112.854 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.6 m -96.12 109.9 49.35 Favored Pre-proline 0 C--O 1.223 -0.335 0 CA-C-N 117.342 0.571 . . . . 0.0 111.077 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.512 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 71.1 Cg_exo -48.67 132.45 25.67 Favored 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 122.927 2.418 . . . . 0.0 112.663 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.536 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.3 m -92.34 3.58 55.12 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 121.164 0.507 . . . . 0.0 109.852 -179.617 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.82 -27.37 3.0 Favored Glycine 0 N--CA 1.448 -0.536 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 -178.253 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.425 ' H ' ' C ' ' A' ' 4' ' ' CYS . 21.9 tt0 -76.96 134.18 38.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 179.508 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.524 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -126.01 146.39 49.91 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.537 0.684 . . . . 0.0 112.18 -178.683 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 5.3 p -109.87 48.1 0.91 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.772 -1.103 . . . . 0.0 110.422 179.589 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.68 HG22 ' HB3' ' A' ' 25' ' ' LYS . 19.9 t -68.15 -38.21 79.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.699 -179.737 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -115.02 -50.27 2.77 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.661 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.546 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 32.9 pt -121.44 150.81 55.37 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.965 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -62.87 153.64 71.68 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.418 2.078 . . . . 0.0 112.258 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 61.1 m -74.66 131.06 40.59 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.396 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 12.7 tt -79.94 -34.95 15.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.791 178.666 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.711 ' O ' HG12 ' A' ' 18' ' ' ILE . 16.2 m -77.66 -0.09 25.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.888 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.743 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -56.7 -23.86 45.77 Favored Glycine 0 CA--C 1.519 0.336 0 C-N-CA 121.392 -0.432 . . . . 0.0 112.855 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.4 t -60.08 -26.42 36.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.962 0.41 . . . . 0.0 111.835 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.711 HG12 ' O ' ' A' ' 15' ' ' SER . 18.6 pt -80.9 5.21 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.592 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 120.51 -18.29 9.4 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.157 -1.021 . . . . 0.0 112.921 179.247 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.743 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 46.3 m -63.27 124.86 22.3 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.235 0.541 . . . . 0.0 110.624 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.484 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 12.2 m -119.57 144.46 47.07 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.156 -179.725 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 23.7 m -63.22 112.58 2.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.41 0.624 . . . . 0.0 111.833 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.2 m -120.02 95.67 4.85 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.139 -0.937 . . . . 0.0 108.588 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 48.1 t0 49.84 59.57 4.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.507 -0.769 . . . . 0.0 111.384 -178.359 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.68 ' HB3' HG22 ' A' ' 9' ' ' VAL . 26.6 mtmm 75.99 -9.79 1.39 Allowed 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.287 -0.869 . . . . 0.0 113.067 178.879 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.2 t -120.29 127.29 75.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.409 0.549 . . . . 0.0 110.517 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.588 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 69.7 m -80.64 122.74 27.46 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.561 0.696 . . . . 0.0 112.729 -179.089 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.512 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-30 -109.9 142.62 40.98 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.367 178.705 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.536 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.7 tt -89.88 84.52 6.23 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.511 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 52.0 m-20 . . . . . 0 C--N 1.324 -0.521 0 CA-C-N 114.591 -1.186 . . . . 0.0 110.996 -178.654 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.753 0 CA-C-O 120.206 -0.219 . . . . 0.0 112.751 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.2 m -99.28 113.4 64.75 Favored Pre-proline 0 C--O 1.221 -0.418 0 CA-C-N 117.4 0.6 . . . . 0.0 111.214 -179.361 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.495 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 78.9 Cg_exo -47.46 133.34 20.48 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.986 2.457 . . . . 0.0 112.845 -179.767 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.6 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 12.7 m -90.91 7.81 38.25 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.094 0.473 . . . . 0.0 110.019 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.27 -27.05 2.84 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 120.921 -0.656 . . . . 0.0 111.713 -178.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 61.3 tt0 -80.31 133.56 35.97 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.109 0.48 . . . . 0.0 109.719 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.653 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -114.03 146.63 39.92 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.611 0.72 . . . . 0.0 112.044 -179.084 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.7 p -105.76 47.09 0.89 Allowed 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.706 -1.133 . . . . 0.0 110.208 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.653 HG23 ' HB2' ' A' ' 7' ' ' SER . 21.2 t -73.77 -42.08 54.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.591 -179.048 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.6 m-85 -111.1 -48.31 3.12 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.304 -179.566 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.7 pt -129.9 161.41 59.83 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.264 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -66.85 152.11 81.06 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.278 1.986 . . . . 0.0 111.651 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.4 m -74.61 133.94 42.13 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.752 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 15.3 tt -74.41 -34.35 36.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.117 179.003 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.73 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.2 m -73.95 -0.82 17.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.829 179.534 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.65 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.61 -27.13 58.3 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.744 179.779 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.3 m -62.72 -20.88 26.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.73 HG12 ' O ' ' A' ' 15' ' ' SER . 13.6 pt -87.98 0.69 6.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.821 -0.351 . . . . 0.0 111.456 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 124.89 -18.74 7.04 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.249 -0.977 . . . . 0.0 112.638 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.65 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 61.9 m -60.88 122.88 15.99 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.398 0.618 . . . . 0.0 110.691 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.7 m -113.62 140.78 47.91 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.065 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 48.1 t -66.2 119.34 11.31 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.847 0.356 . . . . 0.0 110.162 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 22.9 m -133.96 107.68 7.95 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.17 -179.491 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.497 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 44.5 t0 49.06 57.86 6.0 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.507 -0.769 . . . . 0.0 111.921 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.551 ' HG3' ' HA ' ' A' ' 9' ' ' VAL . 0.0 OUTLIER 73.8 -4.45 2.25 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 113.416 0.895 . . . . 0.0 113.416 178.405 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 60.5 t -130.58 131.72 64.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 118.415 0.552 . . . . 0.0 110.749 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.453 ' HA ' ' O ' ' A' ' 21' ' ' SER . 87.5 m -81.28 129.21 34.51 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.297 0.57 . . . . 0.0 112.139 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.495 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.0 m-85 -112.74 142.83 44.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.46 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.6 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.8 tp -89.87 82.27 6.23 Favored 'General case' 0 C--N 1.31 -1.148 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.157 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 . . . . . 0 N--CA 1.466 0.331 0 CA-C-N 114.804 -1.089 . . . . 0.0 111.286 -178.372 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.792 0 CA-C-O 120.146 -0.252 . . . . 0.0 113.004 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 17.0 p -99.19 115.35 65.79 Favored Pre-proline 0 C--O 1.223 -0.298 0 CA-C-N 117.499 0.65 . . . . 0.0 111.622 -179.179 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.455 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 68.9 Cg_exo -51.47 127.89 23.95 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.811 2.341 . . . . 0.0 112.59 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.662 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.4 m -84.09 12.78 5.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.652 -179.003 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.91 29.31 73.78 Favored Glycine 0 C--N 1.332 0.332 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -178.549 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.498 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 38.0 tt0 -129.63 149.56 51.34 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 114.504 -0.848 . . . . 0.0 109.03 -178.793 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.47 146.29 44.11 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.361 0.601 . . . . 0.0 111.752 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.554 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 8.6 p -117.89 50.62 1.12 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.488 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.518 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.9 t -68.02 -32.75 57.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.63 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -128.27 -50.67 1.3 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.24 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.554 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 31.5 pt -104.66 143.09 25.99 Favored Pre-proline 0 C--N 1.324 -0.511 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.093 179.402 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 21.2 Cg_exo -63.45 158.52 44.9 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.64 2.227 . . . . 0.0 112.44 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.498 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 10.9 m -60.72 119.78 8.8 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.904 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 8.6 tp -78.98 -35.34 17.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 178.763 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.677 ' O ' HG22 ' A' ' 18' ' ' ILE . 25.3 t -82.94 3.49 29.75 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.693 178.594 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.572 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -56.18 -21.65 33.21 Favored Glycine 0 C--N 1.33 0.222 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.283 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.9 t -59.94 -28.4 40.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.981 0.42 . . . . 0.0 111.538 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.677 HG22 ' O ' ' A' ' 15' ' ' SER . 18.2 tt -78.93 -9.29 12.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 121.224 0.535 . . . . 0.0 111.442 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.67 -18.56 5.67 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.798 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.572 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 61.1 m -55.01 124.55 17.14 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.218 0.533 . . . . 0.0 110.628 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 20.4 m -122.79 150.01 43.38 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.879 -178.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.3 m -64.51 115.32 5.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.339 0.59 . . . . 0.0 111.717 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.6 m -125.44 96.79 4.94 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 179.002 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.451 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 47.8 t0 53.28 54.09 10.77 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.685 -178.169 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.518 ' HB3' HG22 ' A' ' 9' ' ' VAL . 6.9 mtmp? 74.22 -9.82 1.22 Allowed 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 114.977 -1.011 . . . . 0.0 112.752 179.528 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 t -111.41 130.09 65.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.4 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 23.3 m -78.38 119.74 22.14 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.221 0.534 . . . . 0.0 111.366 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.503 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 2.8 m-85 -110.99 144.53 39.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.391 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.662 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 57.2 tp -96.99 83.12 3.32 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 178.37 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.495 -179.07 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.87 0 CA-C-O 120.155 -0.247 . . . . 0.0 112.909 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 16.8 p -100.58 113.32 65.53 Favored Pre-proline 0 C--O 1.223 -0.301 0 CA-C-N 117.399 0.599 . . . . 0.0 111.636 -179.15 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.5 Cg_exo -49.22 132.12 27.84 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.895 2.397 . . . . 0.0 112.584 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.661 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.4 m -91.53 5.23 50.34 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 121.011 0.434 . . . . 0.0 110.249 -179.329 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.45 -24.76 3.5 Favored Glycine 0 N--CA 1.451 -0.353 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -178.609 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.671 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 19.7 tt0 -72.3 133.11 44.83 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.737 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.5 p -115.32 164.44 14.24 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 121.413 0.625 . . . . 0.0 111.979 -178.66 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.471 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.6 p -139.43 43.77 2.0 Allowed 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.716 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.631 HG22 ' HB3' ' A' ' 25' ' ' LYS . 12.3 t -70.62 -44.62 76.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.054 -179.341 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -128.47 -45.11 1.35 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.818 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.471 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 66.4 mt -103.86 134.39 19.75 Favored Pre-proline 0 C--N 1.321 -0.638 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.027 179.38 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -64.6 152.55 81.38 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.133 1.889 . . . . 0.0 111.775 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.671 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 58.2 m -62.73 -47.29 84.22 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.669 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 78.6 mt 73.41 -55.53 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 122.893 0.477 . . . . 0.0 111.1 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.3 m -67.91 -16.23 63.98 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.3 0.571 . . . . 0.0 110.01 179.105 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.707 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.17 -16.36 4.47 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.061 -0.972 . . . . 0.0 113.675 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 31.2 m -58.31 -17.67 9.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.107 0.48 . . . . 0.0 111.224 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.4 tp -71.55 -15.99 18.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.145 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 144.96 -23.87 1.94 Allowed Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.707 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 55.5 m -65.67 121.13 14.26 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.445 0.64 . . . . 0.0 110.948 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.9 m -105.87 139.16 40.86 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.522 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 46.5 t -66.03 102.9 0.86 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.246 0.546 . . . . 0.0 110.423 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.2 m -112.46 106.98 15.59 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.072 -179.656 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 46.9 t0 47.21 59.55 3.99 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.887 -179.635 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.631 ' HB3' HG22 ' A' ' 9' ' ' VAL . 22.2 mtmm 70.68 6.27 5.76 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.246 -0.888 . . . . 0.0 113.317 178.473 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 45.2 t -137.83 125.93 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 118.236 0.471 . . . . 0.0 110.168 179.442 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.622 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 11.7 m -77.94 122.92 26.15 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.509 0.671 . . . . 0.0 112.292 -179.56 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.529 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.3 m-85 -108.69 144.36 36.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.9 179.296 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.661 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.8 tp -91.8 80.99 5.22 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.3 m-80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.554 -179.183 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.848 0 CA-C-O 120.278 -0.179 . . . . 0.0 112.741 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 23.5 m -98.42 112.89 63.39 Favored Pre-proline 0 C--O 1.22 -0.478 0 CA-C-N 117.327 0.564 . . . . 0.0 111.215 -179.347 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.481 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.4 Cg_exo -47.82 132.95 22.16 Favored 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 122.997 2.465 . . . . 0.0 112.863 -179.795 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.614 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 9.0 m -91.58 6.73 44.57 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.094 0.473 . . . . 0.0 110.024 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.2 -27.42 2.76 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.507 -178.619 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.505 ' OE2' ' HB3' ' A' ' 13' ' ' CYS . 16.3 tt0 -77.48 126.88 31.6 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.494 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 0.6 OUTLIER -109.12 151.87 25.85 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.627 0.727 . . . . 0.0 112.062 -178.577 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -114.78 51.06 0.92 Allowed 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.887 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.489 ' HA ' ' HB2' ' A' ' 25' ' ' LYS . 14.5 t -68.87 -44.9 81.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.769 -178.638 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -109.72 -46.86 3.44 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.218 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 30.7 pt -129.37 157.68 75.48 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.172 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -64.76 152.37 82.3 Favored 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 122.247 1.965 . . . . 0.0 111.616 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.505 ' HB3' ' OE2' ' A' ' 6' ' ' GLU . 27.1 m -71.41 132.73 45.23 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.573 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 12.5 tt -74.7 -36.48 40.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.839 178.644 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.661 ' O ' HG12 ' A' ' 18' ' ' ILE . 15.3 m -75.81 -3.66 36.31 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.644 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.774 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.47 -22.66 46.12 Favored Glycine 0 C--N 1.331 0.282 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.822 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 13.7 p -61.06 -22.69 27.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.858 0.361 . . . . 0.0 111.831 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.661 HG12 ' O ' ' A' ' 15' ' ' SER . 18.5 pt -80.09 -1.03 4.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 111.839 0.311 . . . . 0.0 111.839 -179.837 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.69 -21.53 5.62 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.275 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.774 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 58.3 m -61.54 121.9 13.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.401 0.62 . . . . 0.0 110.809 -179.787 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -108.83 138.88 44.47 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.258 -179.724 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.7 t -69.63 124.02 22.86 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.849 0.357 . . . . 0.0 110.516 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 48.8 m -148.45 120.07 8.02 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.77 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 6.5 t70 50.99 57.67 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.372 0.606 . . . . 0.0 110.146 -178.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.77 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 54.15 14.68 0.77 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.028 1.331 . . . . 0.0 113.703 -179.709 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 57.6 t -137.07 131.32 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 O-C-N 122.052 -0.405 . . . . 0.0 110.247 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.511 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 73.1 m -82.54 128.02 33.9 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 121.723 -0.611 . . . . 0.0 112.044 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-85 -111.45 142.47 43.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.372 179.653 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.614 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.5 tp -89.59 82.22 6.39 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.345 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 59.2 m-20 . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 114.726 -1.124 . . . . 0.0 111.128 -178.473 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.768 0 CA-C-O 120.008 -0.329 . . . . 0.0 113.306 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.5 t -104.73 118.7 55.75 Favored Pre-proline 0 C--O 1.224 -0.284 0 CA-C-N 117.766 0.783 . . . . 0.0 111.661 -179.024 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 65.8 Cg_exo -50.77 136.73 42.8 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 123.028 2.485 . . . . 0.0 112.535 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.609 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 10.0 m -93.65 5.42 51.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.072 0.463 . . . . 0.0 110.05 -179.566 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.82 -26.39 3.22 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.789 -178.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 50.9 tt0 -79.01 132.92 36.82 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.559 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -110.55 147.57 33.91 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.602 0.715 . . . . 0.0 112.055 -178.975 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.0 p -110.88 49.12 0.88 Allowed 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.847 -1.07 . . . . 0.0 110.143 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.559 HG23 ' HB2' ' A' ' 7' ' ' SER . 20.7 t -72.08 -42.53 67.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.658 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -110.37 -48.06 3.21 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.932 -0.577 . . . . 0.0 111.357 -179.557 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.8 pt -130.0 161.81 57.58 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.304 -179.348 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo -66.2 152.33 81.4 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 122.321 2.014 . . . . 0.0 111.632 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 46.1 m -72.83 137.27 45.62 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.751 -179.069 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 46.4 mm -73.1 -38.57 55.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.223 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.608 ' O ' HG22 ' A' ' 18' ' ' ILE . 2.1 m -73.45 2.42 7.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.188 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.64 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.83 -25.64 56.44 Favored Glycine 0 N--CA 1.453 -0.201 0 C-N-CA 121.252 -0.499 . . . . 0.0 112.791 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.7 m -62.62 -20.96 26.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.608 HG22 ' O ' ' A' ' 15' ' ' SER . 8.7 tp -83.99 -6.35 10.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.25 0.548 . . . . 0.0 111.053 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.55 -18.51 5.72 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.514 -0.851 . . . . 0.0 111.816 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.64 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 60.3 m -59.23 122.04 12.85 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.395 0.617 . . . . 0.0 110.892 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.449 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.7 m -113.86 142.66 45.83 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.096 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.6 t -63.61 114.78 4.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.973 0.416 . . . . 0.0 110.184 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.7 m -121.51 94.48 4.34 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.038 -0.528 . . . . 0.0 109.924 -179.68 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.606 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 38.7 t70 46.37 65.26 1.23 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.131 -0.941 . . . . 0.0 112.07 -179.172 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.606 ' HB2' ' O ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 78.09 -9.85 1.44 Allowed 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 178.028 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.433 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 42.2 t -130.4 128.21 63.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-N 118.496 0.589 . . . . 0.0 110.647 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.471 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 85.7 m -80.72 128.55 33.76 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.366 0.603 . . . . 0.0 112.475 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.522 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-85 -112.94 144.23 42.87 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.636 179.138 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.609 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.5 tt -95.92 85.69 4.14 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.7 m-80 . . . . . 0 C--N 1.327 -0.402 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.927 -179.333 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.876 0 CA-C-O 120.195 -0.225 . . . . 0.0 112.608 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 21.6 m -96.27 112.23 59.12 Favored Pre-proline 0 C--O 1.221 -0.432 0 CA-C-N 117.369 0.585 . . . . 0.0 111.395 -179.296 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 71.5 Cg_exo -49.14 127.29 17.11 Favored 'Trans proline' 0 C--N 1.346 0.44 0 C-N-CA 122.862 2.375 . . . . 0.0 112.787 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.692 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 20.3 m -86.04 14.14 6.67 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.795 -178.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.59 26.46 68.4 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.925 -0.655 . . . . 0.0 111.973 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.722 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 40.6 tt0 -132.35 131.08 41.54 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.664 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -112.0 150.02 31.18 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.586 0.708 . . . . 0.0 112.236 -178.433 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.3 p -112.21 42.64 1.74 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.75 -1.114 . . . . 0.0 109.774 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 1.097 ' HA ' ' HD2' ' A' ' 25' ' ' LYS . 20.8 t -69.07 -63.71 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.847 -178.573 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.0 m-85 -91.53 -49.43 6.32 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.177 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.679 ' H ' HD13 ' A' ' 11' ' ' ILE . 0.2 OUTLIER -121.78 159.29 51.7 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.532 -179.347 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -68.25 153.99 73.23 Favored 'Trans proline' 0 N--CA 1.459 -0.538 0 C-N-CA 122.471 2.114 . . . . 0.0 111.637 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.722 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 58.6 m -69.65 132.64 46.49 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.481 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 7.6 tp -89.99 -39.45 12.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.008 0.432 . . . . 0.0 109.908 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.539 ' O ' HG12 ' A' ' 18' ' ' ILE . 2.5 m -74.12 -24.07 59.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.815 179.074 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.977 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.11 -17.69 5.59 Favored Glycine 0 C--N 1.331 0.298 0 CA-C-N 115.144 -0.934 . . . . 0.0 114.108 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.7 p -58.8 -20.89 17.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.148 0.499 . . . . 0.0 111.356 179.513 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.539 HG12 ' O ' ' A' ' 15' ' ' SER . 35.5 pt -75.73 -5.21 6.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.03 -0.532 . . . . 0.0 112.32 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 135.43 -18.68 3.89 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.43 -0.89 . . . . 0.0 112.171 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.977 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 33.4 m -60.68 124.2 19.69 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.315 0.579 . . . . 0.0 110.764 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.455 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 6.5 m -104.57 139.69 39.08 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.518 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.6 t -71.37 119.51 15.62 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.12 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 38.4 m -144.45 121.79 11.62 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.7 t0 54.95 46.55 24.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 122.251 1.024 . . . . 0.0 109.98 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 1.097 ' HD2' ' HA ' ' A' ' 9' ' ' VAL . 66.4 mmtt 62.2 14.93 7.07 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 113.905 -1.498 . . . . 0.0 113.487 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 60.5 t -136.09 132.47 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.786 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.515 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 34.6 m -82.27 125.69 31.26 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.523 0.677 . . . . 0.0 112.341 -179.648 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.46 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 2.4 m-85 -111.3 142.86 42.97 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.163 179.588 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.692 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 45.3 tp -89.32 81.4 6.66 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 107.999 -1.112 . . . . 0.0 107.999 178.156 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 49.6 m-20 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 114.745 -1.116 . . . . 0.0 111.069 -178.316 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.649 0 CA-C-O 120.199 -0.223 . . . . 0.0 113.199 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.2 m -98.17 113.71 64.27 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 117.392 0.596 . . . . 0.0 111.315 -179.33 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 73.0 Cg_exo -49.19 133.08 29.37 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.861 2.374 . . . . 0.0 112.756 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.554 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 33.3 m -83.15 20.52 1.24 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.35 -179.209 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 61.59 30.21 74.03 Favored Glycine 0 C--O 1.227 -0.341 0 CA-C-N 115.972 -0.558 . . . . 0.0 113.03 179.59 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -162.75 151.32 14.51 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.143 0.497 . . . . 0.0 110.047 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.556 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 34.9 p -100.6 -174.52 2.66 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.157 -179.683 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.54 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 28.7 p -150.88 41.84 0.77 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.593 0.711 . . . . 0.0 109.572 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.816 HG22 ' HB3' ' A' ' 25' ' ' LYS . 17.4 t -69.12 -40.68 80.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.011 -179.516 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -104.76 -49.52 3.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.28 -179.652 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.736 ' H ' HD13 ' A' ' 11' ' ' ILE . 0.2 OUTLIER -112.13 142.76 27.45 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.481 -179.695 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 18.8 Cg_exo -64.7 159.45 45.2 Favored 'Trans proline' 0 C--O 1.234 0.279 0 C-N-CA 122.738 2.292 . . . . 0.0 112.064 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 63.8 m -59.72 110.81 1.23 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.374 -179.627 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 47.8 mm -63.8 -45.37 97.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.196 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.636 ' HB3' HD12 ' A' ' 18' ' ' ILE . 6.2 m -80.1 29.45 0.28 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.296 179.626 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -59.07 -34.99 81.92 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 121.228 -0.51 . . . . 0.0 112.395 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.3 p -63.94 -21.23 28.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.119 0.485 . . . . 0.0 111.181 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.636 HD12 ' HB3' ' A' ' 15' ' ' SER . 8.0 mt -84.43 -11.86 11.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.52 0.676 . . . . 0.0 110.43 179.646 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 121.13 -7.99 10.59 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.78 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.527 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 84.3 m -65.81 123.63 20.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.235 0.541 . . . . 0.0 110.711 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.3 m -129.39 148.7 51.33 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.174 -179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 19.2 m -67.38 105.8 1.9 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.465 0.65 . . . . 0.0 112.008 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.4 m -114.7 100.02 7.95 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.153 -0.931 . . . . 0.0 108.658 178.57 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.462 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 47.2 t0 52.52 54.07 11.23 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.527 0.68 . . . . 0.0 110.981 -178.685 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.816 ' HB3' HG22 ' A' ' 9' ' ' VAL . 6.9 mtmp? 71.23 -0.33 3.14 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 115.185 -0.916 . . . . 0.0 113.159 179.187 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 25.6 t -120.15 134.39 63.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 118.13 0.423 . . . . 0.0 110.136 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.54 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 78.8 m -76.74 117.4 18.32 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.038 0.447 . . . . 0.0 112.197 -179.056 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.491 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.7 m-85 -112.86 142.41 45.55 Favored 'General case' 0 CA--C 1.513 -0.451 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 177.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.554 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.9 tt -101.38 86.32 2.96 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.057 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 33.4 m120 . . . . . 0 C--N 1.325 -0.498 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.161 -178.984 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.64 0 CA-C-O 120.224 -0.209 . . . . 0.0 113.189 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.448 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 22.0 m -98.05 113.07 63.38 Favored Pre-proline 0 C--O 1.221 -0.419 0 CA-C-N 117.407 0.603 . . . . 0.0 110.806 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.567 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 8.8 Cg_endo -49.75 134.08 33.84 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 123.063 2.509 . . . . 0.0 112.49 -179.801 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.524 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 36.6 m -81.54 21.15 0.82 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.16 -179.209 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.88 28.65 72.21 Favored Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.754 -0.657 . . . . 0.0 113.235 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -161.21 152.93 19.37 Favored 'General case' 0 C--O 1.238 0.484 0 CA-C-O 121.414 0.626 . . . . 0.0 110.635 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.582 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 21.0 p -104.44 179.51 4.25 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.14 -0.937 . . . . 0.0 111.29 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.602 ' HB2' ' HA ' ' A' ' 12' ' ' PRO . 18.3 p -151.43 50.57 0.82 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.82 179.164 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.831 HG22 ' HB3' ' A' ' 25' ' ' LYS . 17.6 t -67.45 -42.39 87.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.96 -179.489 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -94.8 -48.72 5.91 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.312 -0.858 . . . . 0.0 111.694 -179.307 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.452 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 23.9 pt -135.18 142.64 42.56 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.73 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.602 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 9.6 Cg_exo -68.68 153.12 73.92 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.985 2.456 . . . . 0.0 112.493 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 97.8 m -67.27 120.77 14.36 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.931 179.853 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 48.3 mm -61.61 -41.43 90.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.743 -179.751 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.654 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.0 m -76.65 22.07 0.19 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.655 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.611 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -58.83 -21.15 50.83 Favored Glycine 0 C--N 1.33 0.227 0 C-N-CA 121.467 -0.397 . . . . 0.0 112.806 179.503 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.5 p -60.75 -22.06 25.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.85 0.357 . . . . 0.0 111.718 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.654 HG12 ' O ' ' A' ' 15' ' ' SER . 22.4 pt -80.09 -0.59 4.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 C-N-CA 120.955 -0.298 . . . . 0.0 111.575 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.63 -20.0 7.41 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.2 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.611 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 78.3 m -63.24 124.14 20.45 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.401 0.62 . . . . 0.0 111.248 -179.767 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 17.7 m -129.14 142.03 51.0 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.376 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 23.3 m -71.99 115.77 11.6 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.486 0.66 . . . . 0.0 111.974 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.511 ' HB ' ' CD1' ' A' ' 28' ' ' TYR . 15.7 m -124.4 108.51 12.24 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.515 178.742 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 43.7 t0 47.68 57.15 6.23 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.905 -178.724 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.831 ' HB3' HG22 ' A' ' 9' ' ' VAL . 20.3 mtmm 68.57 8.65 6.83 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.52 0.933 . . . . 0.0 113.52 178.372 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.582 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 48.6 t -130.04 134.45 62.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 118.611 0.641 . . . . 0.0 110.23 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 97.9 m -81.02 119.42 23.51 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.214 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 37.7 m-85 -114.88 142.77 46.13 Favored 'General case' 0 CA--C 1.516 -0.342 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.524 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.8 tt -101.94 87.22 3.05 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.087 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 32.3 m120 . . . . . 0 C--N 1.326 -0.442 0 CA-C-N 114.897 -1.047 . . . . 0.0 111.352 -178.955 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.684 0 CA-C-O 120.234 -0.203 . . . . 0.0 113.142 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.461 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 22.6 m -101.69 114.71 65.56 Favored Pre-proline 0 C--O 1.22 -0.45 0 CA-C-N 117.451 0.625 . . . . 0.0 111.127 -179.352 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.599 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 7.0 Cg_endo -48.75 131.86 25.2 Favored 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 123.111 2.541 . . . . 0.0 112.484 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.692 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 31.0 m -83.6 15.86 2.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.526 -179.058 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 61.45 32.2 80.22 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.004 -0.617 . . . . 0.0 112.034 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.514 ' HG3' ' SG ' ' A' ' 13' ' ' CYS . 3.8 tp10 -143.71 140.29 29.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.074 0.464 . . . . 0.0 110.012 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.617 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 11.6 p -101.3 170.19 8.4 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.455 -0.793 . . . . 0.0 112.257 -178.763 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.0 p -150.32 49.25 0.9 Allowed 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.423 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.733 HG22 ' HB3' ' A' ' 25' ' ' LYS . 12.1 t -68.11 -37.84 78.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.349 -178.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -125.17 -50.0 1.69 Allowed 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.401 179.737 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.41 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 50.0 mm -107.08 131.48 21.66 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.902 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 8.1 Cg_exo -69.29 151.38 71.76 Favored 'Trans proline' 0 N--CA 1.457 -0.642 0 C-N-CA 122.336 2.024 . . . . 0.0 111.66 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.514 ' SG ' ' HG3' ' A' ' 6' ' ' GLU . 9.7 m -69.19 119.4 13.41 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.148 -179.341 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 14.0 tt -64.88 -30.72 51.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.349 0.595 . . . . 0.0 110.496 179.61 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.671 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.4 p -74.76 1.99 11.15 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.529 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.661 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.33 -20.87 38.36 Favored Glycine 0 CA--C 1.518 0.26 0 CA-C-N 116.485 -0.325 . . . . 0.0 113.16 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.8 p -60.46 -23.62 28.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.96 0.41 . . . . 0.0 111.712 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.671 HG12 ' O ' ' A' ' 15' ' ' SER . 23.0 pt -81.06 0.14 3.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.453 -0.339 . . . . 0.0 111.749 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.64 -22.04 7.01 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.216 179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.661 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 83.2 m -59.84 122.6 14.63 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.531 0.681 . . . . 0.0 110.894 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.1 m -114.9 138.23 51.05 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.795 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 47.4 t -69.34 123.89 22.41 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.5 m -137.55 113.69 9.97 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.821 0.343 . . . . 0.0 110.184 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 35.4 t70 46.45 58.32 4.68 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.469 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.733 ' HB3' HG22 ' A' ' 9' ' ' VAL . 26.0 mtmm 72.26 4.82 5.13 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 113.783 1.031 . . . . 0.0 113.783 177.915 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.617 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 4.3 p -143.02 133.2 22.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 118.768 0.713 . . . . 0.0 111.343 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 93.9 m -80.78 132.16 35.48 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -178.605 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.599 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 3.1 m-85 -117.26 146.4 43.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.952 178.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.692 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 55.9 tp -99.35 84.67 3.03 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.901 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 . . . . . 0 C--N 1.327 -0.382 0 CA-C-N 115.186 -0.915 . . . . 0.0 111.602 -179.409 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.754 0 CA-C-O 120.276 -0.18 . . . . 0.0 112.728 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 p -100.74 116.6 63.98 Favored Pre-proline 0 C--O 1.222 -0.376 0 CA-C-N 117.328 0.564 . . . . 0.0 111.289 -179.361 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.501 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 82.1 Cg_exo -45.45 132.62 12.53 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 123.128 2.552 . . . . 0.0 113.084 -179.609 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.517 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 55.9 m -82.78 19.29 1.36 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.507 -179.237 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.73 30.36 76.69 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.239 -0.505 . . . . 0.0 112.741 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.3 tp10 -156.57 153.13 28.17 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.546 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 47.3 p -102.23 -176.71 3.19 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.506 0.67 . . . . 0.0 111.831 -179.317 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 7.1 p -151.04 41.85 0.75 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.243 179.27 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.826 HG22 ' HB3' ' A' ' 25' ' ' LYS . 13.3 t -69.93 -42.32 79.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.528 -179.016 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -115.0 -47.63 2.86 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.934 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.458 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 32.6 pt -104.59 142.9 25.6 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.82 -179.69 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.458 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 14.6 Cg_exo -67.15 158.69 55.66 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.715 2.277 . . . . 0.0 111.718 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 59.7 m -59.48 106.84 0.5 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.162 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.716 HD13 ' H ' ' A' ' 14' ' ' ILE . 0.2 OUTLIER -62.69 -39.29 84.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.118 0.485 . . . . 0.0 110.529 179.848 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.712 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.0 m -85.57 21.7 1.75 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.571 179.237 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -59.33 -27.2 62.74 Favored Glycine 0 C--N 1.329 0.183 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.415 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.9 p -62.59 -23.63 33.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 120.856 0.36 . . . . 0.0 111.83 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.712 HG12 ' O ' ' A' ' 15' ' ' SER . 16.0 pt -90.53 3.45 6.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 C-N-CA 120.531 -0.468 . . . . 0.0 111.421 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 115.93 -12.87 17.33 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.3 -0.953 . . . . 0.0 113.25 179.181 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.434 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 71.2 m -62.58 123.38 18.21 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.467 0.651 . . . . 0.0 110.962 -179.759 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 9.1 m -117.1 142.33 47.14 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.89 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.5 t -71.91 111.36 7.1 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.069 0.462 . . . . 0.0 109.951 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 m -119.09 103.93 10.0 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.096 -179.73 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.455 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 19.6 t70 47.23 61.87 2.68 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.817 -179.544 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.826 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.5 OUTLIER 67.86 4.78 4.14 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 115.013 -0.994 . . . . 0.0 113.241 178.834 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.546 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 51.4 t -131.01 130.98 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 118.418 0.554 . . . . 0.0 110.577 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 84.7 m -77.73 125.42 29.32 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.501 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 4.7 m-85 -117.2 143.11 46.22 Favored 'General case' 0 CA--C 1.517 -0.317 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.234 178.859 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.517 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.7 tp -96.41 83.18 3.49 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.367 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 65.4 m-20 . . . . . 0 N--CA 1.465 0.309 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.584 -178.586 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.74 0 CA-C-O 120.287 -0.174 . . . . 0.0 112.709 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 19.8 m -94.38 109.63 43.94 Favored Pre-proline 0 C--O 1.22 -0.453 0 CA-C-N 117.157 0.479 . . . . 0.0 111.518 -179.299 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.502 ' HG3' ' CE2' ' A' ' 28' ' ' TYR . 33.1 Cg_exo -58.16 134.04 59.29 Favored 'Trans proline' 0 CA--C 1.529 0.249 0 C-N-CA 122.532 2.155 . . . . 0.0 112.913 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 6.5 m -79.57 16.74 1.01 Allowed 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.272 179.294 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.9 29.91 75.65 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.101 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -153.59 156.2 37.54 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.315 0.578 . . . . 0.0 110.152 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.561 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 40.2 p -103.14 -174.73 2.62 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.544 -179.185 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 9.2 p -151.12 39.64 0.69 Allowed 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.227 179.312 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.906 HG22 ' HB3' ' A' ' 25' ' ' LYS . 10.9 t -69.99 -36.22 67.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.251 -0.886 . . . . 0.0 111.189 -179.25 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -122.7 -45.93 2.15 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.362 -179.57 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.412 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 35.0 pt -103.62 147.5 34.33 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.179 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 11.4 Cg_exo -68.64 156.21 66.28 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.715 2.277 . . . . 0.0 111.615 179.672 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 77.7 m -60.64 107.79 0.74 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.783 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 11.3 tt -64.96 -38.83 83.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.15 0.5 . . . . 0.0 109.976 179.22 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.556 ' HB3' HD12 ' A' ' 18' ' ' ILE . 6.0 m -81.62 20.72 0.88 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.024 179.325 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.562 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -60.85 -31.11 74.75 Favored Glycine 0 C--N 1.332 0.329 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.095 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 21.9 t -63.06 -23.95 34.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.324 0.583 . . . . 0.0 110.703 179.43 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.556 HD12 ' HB3' ' A' ' 15' ' ' SER . 6.5 mt -81.63 -12.33 12.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.413 179.666 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 118.96 -8.54 12.58 Favored Glycine 0 N--CA 1.446 -0.698 0 CA-C-N 115.715 -0.675 . . . . 0.0 112.182 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.562 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 1.8 m -70.21 127.64 33.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.726 0.774 . . . . 0.0 111.722 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 20.1 m -116.63 149.83 39.09 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.649 -1.159 . . . . 0.0 109.715 179.502 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.2 t -69.51 111.7 5.53 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.974 0.416 . . . . 0.0 110.292 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.511 ' HB ' ' CD1' ' A' ' 28' ' ' TYR . 5.9 m -119.59 103.07 9.1 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.005 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 36.2 t70 47.53 58.77 4.63 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.271 -179.502 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.906 ' HB3' HG22 ' A' ' 9' ' ' VAL . 28.4 mtmm 72.07 2.83 4.46 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 178.451 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 42.7 t -130.43 133.1 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 118.563 0.62 . . . . 0.0 110.385 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 83.9 m -80.95 120.41 24.72 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 112.724 0.639 . . . . 0.0 112.724 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.511 ' CD1' ' HB ' ' A' ' 23' ' ' THR . 57.3 m-85 -121.47 139.89 52.89 Favored 'General case' 0 CA--C 1.518 -0.288 0 CA-C-O 121.142 0.496 . . . . 0.0 110.462 178.143 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.505 ' HB2' ' SG ' ' A' ' 20' ' ' CYS . 2.7 tt -94.11 77.89 4.05 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 178.249 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 35.4 m120 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.01 -178.804 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.849 0 CA-C-O 120.211 -0.216 . . . . 0.0 112.792 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.6 m -95.83 110.7 52.92 Favored Pre-proline 0 C--O 1.222 -0.363 0 CA-C-N 117.306 0.553 . . . . 0.0 111.087 -179.414 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.1 Cg_exo -49.71 130.38 26.31 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.846 2.364 . . . . 0.0 112.627 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.602 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 4.8 m -92.16 6.69 45.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.312 -179.315 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.05 -27.23 2.73 Favored Glycine 0 N--CA 1.452 -0.286 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -178.197 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.693 ' OE2' ' HB3' ' A' ' 13' ' ' CYS . 19.7 tt0 -69.8 131.03 43.88 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.556 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.492 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.3 p -115.75 162.79 16.78 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.471 0.653 . . . . 0.0 112.465 -178.137 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.463 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.8 p -136.01 45.45 2.38 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.576 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.683 HG22 ' HB3' ' A' ' 25' ' ' LYS . 8.1 t -70.15 -43.21 79.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.38 -178.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -127.56 -46.98 1.43 Allowed 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.282 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 35.0 pt -104.11 149.49 37.31 Favored Pre-proline 0 C--N 1.322 -0.618 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.915 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_exo -67.82 152.51 77.31 Favored 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 122.354 2.036 . . . . 0.0 111.581 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.693 ' HB3' ' OE2' ' A' ' 6' ' ' GLU . 74.3 m -64.09 -46.42 84.36 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.257 -179.394 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.41 ' HB ' ' O ' ' A' ' 13' ' ' CYS . 77.2 mt 74.19 -57.07 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 C-N-CA 123.012 0.525 . . . . 0.0 111.521 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.446 ' O ' HG12 ' A' ' 18' ' ' ILE . 0.9 OUTLIER -68.46 -18.2 64.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.261 0.553 . . . . 0.0 110.084 179.351 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.752 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -52.27 -15.21 2.56 Favored Glycine 0 C--N 1.332 0.324 0 CA-C-N 115.107 -0.951 . . . . 0.0 113.887 -179.742 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 31.6 m -58.1 -18.25 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 117.07 0.435 . . . . 0.0 111.18 178.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 15' ' ' SER . 39.2 pt -73.95 -9.96 13.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.821 179.631 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.07 -23.25 2.59 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.681 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.752 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 38.9 m -67.76 121.86 16.87 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.514 0.673 . . . . 0.0 111.047 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.499 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -108.57 140.42 41.94 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.187 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.2 t -65.38 112.63 3.61 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.147 0.499 . . . . 0.0 110.245 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.4 m -127.61 109.4 11.65 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.016 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 21.4 t0 48.26 59.48 4.26 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.774 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.683 ' HB3' HG22 ' A' ' 9' ' ' VAL . 1.7 mptt 69.86 3.0 4.1 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.158 -0.928 . . . . 0.0 113.357 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.492 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 62.4 t -136.28 130.42 47.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 118.516 0.598 . . . . 0.0 110.815 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.621 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 5.6 m -80.2 123.32 27.82 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.502 0.668 . . . . 0.0 112.096 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.478 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 1.9 m-85 -108.42 142.34 38.92 Favored 'General case' 0 CA--C 1.519 -0.238 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.845 179.279 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.602 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.5 tt -89.78 83.48 6.21 Favored 'General case' 0 C--N 1.309 -1.165 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 178.289 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 49.3 m-20 . . . . . 0 C--N 1.326 -0.427 0 CA-C-N 114.649 -1.159 . . . . 0.0 111.12 -178.574 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.858 0 CA-C-O 120.231 -0.205 . . . . 0.0 112.708 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.9 m -96.27 111.5 56.83 Favored Pre-proline 0 C--O 1.221 -0.441 0 CA-C-N 117.325 0.562 . . . . 0.0 111.2 -179.419 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.501 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 89.4 Cg_exo -47.5 127.25 13.37 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.897 2.398 . . . . 0.0 113.109 -179.562 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.599 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 22.9 m -84.72 -7.62 59.15 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.425 -179.739 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.14 -15.99 56.8 Favored Glycine 0 N--CA 1.448 -0.506 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.04 151.52 41.68 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.248 -0.476 . . . . 0.0 110.16 179.401 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.433 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 1.6 p -128.9 150.2 50.46 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 121.84 0.828 . . . . 0.0 112.394 -179.669 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.482 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.7 p -127.18 44.37 2.93 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 114.556 -1.202 . . . . 0.0 109.698 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.805 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.9 t -74.78 -46.41 41.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.485 -179.105 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -101.75 -48.66 4.22 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.089 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.482 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 32.5 pt -132.91 164.96 40.2 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.605 -179.755 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -63.89 153.91 72.96 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.063 1.842 . . . . 0.0 111.684 179.643 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 86.8 m -61.82 139.12 58.38 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.323 -179.173 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 50.2 mm -67.22 122.81 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 115.307 -0.861 . . . . 0.0 109.657 178.897 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.678 ' O ' HG13 ' A' ' 18' ' ' ILE . 35.8 p 51.91 31.17 8.06 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 115.495 -0.775 . . . . 0.0 112.655 -179.48 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -55.79 -14.24 7.26 Favored Glycine 0 C--N 1.338 0.683 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.805 178.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.7 p -56.63 -17.0 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 C-N-CA 123.147 0.579 . . . . 0.0 111.37 179.039 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.678 HG13 ' O ' ' A' ' 15' ' ' SER . 55.5 mt -55.65 -30.98 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.907 0.861 . . . . 0.0 110.633 178.632 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 150.94 -18.28 0.95 Allowed Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 114.501 -1.227 . . . . 0.0 110.099 -179.639 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.653 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 59.2 m -68.27 120.03 13.76 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.506 0.67 . . . . 0.0 110.734 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.525 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -107.25 139.82 41.1 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.097 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.7 t -66.67 118.4 10.18 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.862 0.363 . . . . 0.0 110.148 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 16.2 m -132.21 106.13 7.76 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.049 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.465 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 30.2 t70 48.98 58.21 5.61 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.625 0.726 . . . . 0.0 112.091 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.805 ' HB3' HG22 ' A' ' 9' ' ' VAL . 6.1 mtmp? 75.09 -5.7 2.11 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 178.408 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.493 HG23 ' HE1' ' A' ' 28' ' ' TYR . 1.9 m -133.2 132.0 58.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.507 0.594 . . . . 0.0 111.402 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.653 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 61.1 m -81.07 129.45 34.56 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -178.654 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.501 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.3 m-85 -110.01 143.72 39.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.761 178.64 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.599 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.4 tp -89.78 81.59 6.36 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 178.398 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 58.3 m-20 . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.969 -178.28 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.656 0 CA-C-O 120.165 -0.241 . . . . 0.0 113.309 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.0 p -100.54 119.08 59.69 Favored Pre-proline 0 C--O 1.222 -0.382 0 CA-C-N 117.5 0.65 . . . . 0.0 111.576 -179.135 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.6 Cg_exo -48.41 134.31 25.91 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 123.121 2.548 . . . . 0.0 112.813 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.599 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 37.1 m -82.53 19.43 1.27 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.513 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 63.75 28.8 73.16 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.235 -0.507 . . . . 0.0 112.877 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.7 tp10 -155.81 153.45 29.81 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-O 120.946 0.403 . . . . 0.0 110.064 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.631 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 44.8 p -100.14 -177.64 3.59 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.542 -0.754 . . . . 0.0 112.235 -178.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.7 p -151.54 45.45 0.79 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.113 179.229 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 10.6 t -65.9 -39.49 84.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.357 -0.838 . . . . 0.0 111.573 -178.785 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -128.32 -47.6 1.32 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.503 179.74 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.463 HD12 ' HD2' ' A' ' 12' ' ' PRO . 5.8 tp -106.92 123.62 37.93 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.416 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' PRO . . . . . 0.463 ' HD2' HD12 ' A' ' 11' ' ' ILE . 5.6 Cg_exo -73.05 153.42 52.12 Favored 'Trans proline' 0 N--CA 1.456 -0.685 0 C-N-CA 122.407 2.071 . . . . 0.0 111.49 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 86.1 m -67.29 117.04 8.74 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.125 -179.798 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 47.3 mm -62.3 -40.09 86.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.593 -179.796 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.644 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.3 m -76.01 20.19 0.2 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.5 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.736 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -58.28 -21.07 46.44 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 121.508 -0.377 . . . . 0.0 112.898 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.9 m -61.42 -19.72 21.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 112.161 0.43 . . . . 0.0 112.161 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.644 HG12 ' O ' ' A' ' 15' ' ' SER . 23.1 pt -83.25 1.82 3.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.741 0.305 . . . . 0.0 111.31 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.05 -17.03 8.69 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.581 -0.818 . . . . 0.0 112.212 179.835 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.736 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 70.8 m -65.66 124.02 21.27 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.506 0.67 . . . . 0.0 111.373 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.5 m -128.04 142.47 51.21 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.239 -0.891 . . . . 0.0 109.262 179.485 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 46.4 t -73.27 124.76 26.31 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.903 0.382 . . . . 0.0 110.399 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 57.3 m -150.18 123.89 9.19 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.61 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 51.8 t0 51.54 55.16 9.82 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.123 0.487 . . . . 0.0 110.999 -179.237 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.61 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 60.01 5.55 0.78 Allowed 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.074 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.666 HG23 ' HE1' ' A' ' 28' ' ' TYR . 2.7 m -134.6 145.21 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 O-C-N 121.682 -0.637 . . . . 0.0 112.072 178.68 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.9 m -81.37 126.41 31.57 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.101 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.666 ' HE1' HG23 ' A' ' 26' ' ' VAL . 30.0 m-85 -112.43 142.6 44.77 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 177.568 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.599 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.7 tt -104.22 88.79 3.07 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.533 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 31.0 m120 . . . . . 0 C--N 1.326 -0.443 0 CA-C-N 114.959 -1.019 . . . . 0.0 111.356 -178.839 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.809 0 CA-C-O 120.001 -0.333 . . . . 0.0 112.98 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.535 HG23 ' HB3' ' A' ' 29' ' ' LEU . 4.9 t -100.57 119.81 57.7 Favored Pre-proline 0 C--O 1.221 -0.424 0 CA-C-N 117.758 0.779 . . . . 0.0 111.742 -179.158 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -50.22 131.43 31.23 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 123.098 2.532 . . . . 0.0 113.002 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.686 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 8.8 m -90.61 22.71 3.36 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.825 -178.84 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.23 35.69 88.72 Favored Glycine 0 C--N 1.331 0.291 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.105 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.599 ' OE2' HG12 ' A' ' 14' ' ' ILE . 44.7 tt0 -146.1 153.24 40.47 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -179.533 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -135.02 150.19 50.27 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.225 0.536 . . . . 0.0 111.436 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -100.44 51.89 0.88 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.073 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.406 HG12 ' CD1' ' A' ' 10' ' ' TYR . 16.3 t -63.61 -40.08 87.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.424 -179.268 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.406 ' CD1' HG12 ' A' ' 9' ' ' VAL . 40.4 m-85 -142.58 -42.25 0.32 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.772 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 37.2 pt -103.26 152.68 38.71 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.785 -179.487 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo -68.87 154.42 71.04 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.726 2.284 . . . . 0.0 111.62 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 20.6 m -64.26 122.37 16.5 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.554 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ILE . . . . . 0.599 HG12 ' OE2' ' A' ' 6' ' ' GLU . 33.4 pt -74.12 -28.14 23.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.14 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.1 p -78.73 2.4 19.82 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.507 179.017 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -56.51 -33.77 62.82 Favored Glycine 0 C--N 1.333 0.394 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.625 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 25.6 t -61.63 -27.31 41.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.394 0.616 . . . . 0.0 110.767 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.4 mm -78.15 -18.71 13.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.521 179.586 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 125.97 -7.97 7.67 Favored Glycine 0 N--CA 1.447 -0.57 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.778 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.513 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 60.4 m -63.68 124.89 22.59 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.377 0.608 . . . . 0.0 110.916 -179.774 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 8.8 m -112.21 147.09 36.93 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.371 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.8 t -75.0 123.53 25.32 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.868 0.366 . . . . 0.0 110.15 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.2 m -145.66 121.85 10.83 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 53.67 44.29 29.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.871 0.843 . . . . 0.0 110.754 -179.224 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.501 ' O ' ' HG2' ' A' ' 25' ' ' LYS . 11.4 ttpp 65.49 10.77 6.88 Favored 'General case' 0 CA--C 1.544 0.723 0 CA-C-N 114.338 -1.301 . . . . 0.0 112.098 179.395 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.402 ' HB ' ' HE1' ' A' ' 28' ' ' TYR . 49.9 t -127.4 138.42 54.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 O-C-N 121.838 -0.539 . . . . 0.0 110.447 179.713 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.8 m -82.02 122.5 27.89 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.771 0.319 . . . . 0.0 111.071 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.446 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 25.2 m-85 -116.75 139.99 49.94 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-O 121.165 0.507 . . . . 0.0 110.862 179.514 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.686 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 55.3 tp -91.59 83.89 5.42 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 177.73 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 57.5 m-20 . . . . . 0 C--N 1.327 -0.391 0 CA-C-N 114.704 -1.135 . . . . 0.0 111.299 -178.497 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.795 0 CA-C-O 120.2 -0.222 . . . . 0.0 113.064 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.434 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 20.4 m -101.21 112.71 65.41 Favored Pre-proline 0 C--O 1.22 -0.489 0 CA-C-N 117.392 0.596 . . . . 0.0 111.041 -179.396 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.596 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 8.5 Cg_endo -49.35 130.32 24.76 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 123.031 2.487 . . . . 0.0 112.626 -179.719 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.654 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 32.4 m -83.26 11.16 6.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.285 -179.167 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 66.1 28.62 73.82 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 121.08 -0.581 . . . . 0.0 112.269 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.627 ' HG3' ' HB2' ' A' ' 27' ' ' CYS . 17.2 pt-20 -134.45 155.08 50.96 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.998 0.428 . . . . 0.0 109.86 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.8 p -124.19 154.28 40.34 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.613 0.72 . . . . 0.0 112.302 -178.683 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -127.25 46.1 2.59 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 114.385 -1.279 . . . . 0.0 109.791 179.654 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.848 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.3 t -70.6 -48.4 58.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.899 -178.662 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.2 m-85 -101.18 -47.92 4.57 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.379 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.5 pt -126.95 154.92 76.37 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.397 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -65.48 154.6 72.97 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.46 2.106 . . . . 0.0 111.885 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' CYS . . . . . 0.46 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 71.1 m -66.58 128.08 34.85 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.803 -179.314 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 11.5 tt -71.73 126.84 32.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.219 179.481 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.562 ' O ' HG12 ' A' ' 18' ' ' ILE . 21.6 m 67.07 14.58 9.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.648 -0.705 . . . . 0.0 111.844 -179.465 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -56.15 -16.23 13.22 Favored Glycine 0 C--N 1.339 0.706 0 C-N-CA 121.229 -0.51 . . . . 0.0 112.666 179.059 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 16.6 t -56.23 -17.84 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 C-N-CA 122.95 0.5 . . . . 0.0 111.272 179.172 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.562 HG12 ' O ' ' A' ' 15' ' ' SER . 47.2 mm -57.9 -29.16 35.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.613 0.72 . . . . 0.0 111.044 178.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 155.99 -22.85 0.53 Allowed Glycine 0 C--N 1.312 -0.782 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 179.787 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.496 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 60.1 m -67.35 120.49 13.95 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.644 0.735 . . . . 0.0 110.723 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.487 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 17.9 m -110.62 139.97 45.39 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.713 -179.597 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 49.1 t -67.51 109.66 3.32 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.015 0.436 . . . . 0.0 110.08 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.0 m -120.26 103.54 9.32 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.043 -179.563 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.452 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 21.7 t70 47.65 62.05 2.64 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.767 -179.572 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.848 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.6 OUTLIER 70.96 -0.5 3.02 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 115.117 -0.947 . . . . 0.0 113.356 178.71 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 50.1 t -131.89 128.26 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 118.557 0.617 . . . . 0.0 110.54 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.627 ' HB2' ' HG3' ' A' ' 6' ' ' GLU . 54.5 m -81.32 128.4 33.79 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.467 0.651 . . . . 0.0 112.457 -179.532 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.596 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 4.2 m-85 -114.46 144.21 43.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.307 -0.861 . . . . 0.0 109.941 179.258 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.654 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.1 tp -92.4 81.67 4.9 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.505 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 115.057 -0.974 . . . . 0.0 111.516 -179.188 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.725 0 CA-C-O 120.115 -0.269 . . . . 0.0 113.085 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 21.9 m -97.72 112.48 61.6 Favored Pre-proline 0 C--O 1.222 -0.384 0 CA-C-N 117.484 0.642 . . . . 0.0 111.355 -179.245 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.5 Cg_exo -50.4 131.85 33.22 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.843 2.362 . . . . 0.0 112.486 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.601 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 35.5 m -85.15 18.5 2.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.472 -179.201 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.03 33.1 77.74 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.482 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -153.0 151.56 30.41 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.65 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -132.87 146.36 51.74 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.669 0.747 . . . . 0.0 112.097 -179.284 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.483 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 2.1 p -101.37 45.39 0.97 Allowed 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.389 179.549 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.65 HG23 ' HB2' ' A' ' 7' ' ' SER . 16.3 t -70.9 -35.65 60.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.042 -179.491 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -128.93 -50.8 1.22 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.504 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.483 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 2.4 pp -104.95 151.08 39.37 Favored Pre-proline 0 C--N 1.324 -0.529 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.738 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -71.15 150.07 59.13 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.194 1.93 . . . . 0.0 111.609 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 98.5 m -69.37 -39.68 77.9 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.923 -179.272 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 76.1 mt 71.48 -44.91 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 122.764 0.426 . . . . 0.0 111.346 -179.63 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.5 p -71.02 10.46 0.54 Allowed 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 122.88 0.472 . . . . 0.0 111.753 179.274 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.456 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -57.66 -25.7 56.06 Favored Glycine 0 C--O 1.227 -0.292 0 CA-C-N 116.143 -0.48 . . . . 0.0 113.086 179.606 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 29.8 m -61.73 -20.91 24.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.994 0.426 . . . . 0.0 111.889 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 16.9 mt -78.63 -14.13 13.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.599 0.714 . . . . 0.0 110.47 179.647 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.87 -14.75 6.3 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.294 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.505 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 60.0 m -63.05 125.84 25.34 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.26 0.552 . . . . 0.0 110.775 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 17.9 m -129.35 140.56 51.34 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.08 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.0 m -62.62 111.18 1.97 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.384 0.611 . . . . 0.0 111.345 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.8 m -124.43 107.09 10.73 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.585 179.474 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.416 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 45.1 t0 54.4 50.37 16.37 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.817 0.818 . . . . 0.0 110.248 -178.326 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.615 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.1 OUTLIER 72.04 -7.71 1.26 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.698 -1.137 . . . . 0.0 113.105 179.692 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 41.3 t -115.25 132.03 65.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 O-C-N 122.06 -0.4 . . . . 0.0 110.464 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.505 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 39.5 m -78.65 120.37 23.23 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.512 0.672 . . . . 0.0 112.67 -179.11 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.498 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.5 m-85 -110.35 143.71 40.18 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.171 -0.922 . . . . 0.0 109.372 178.429 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.601 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.9 tt -97.98 84.85 3.38 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 178.855 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 33.5 m120 . . . . . 0 C--N 1.326 -0.454 0 CA-C-N 114.898 -1.047 . . . . 0.0 111.196 -179.053 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.874 0 CA-C-O 120.089 -0.284 . . . . 0.0 112.811 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 17.0 p -98.83 113.25 64.29 Favored Pre-proline 0 C--O 1.224 -0.257 0 CA-C-N 117.507 0.653 . . . . 0.0 111.682 -179.051 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.496 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.4 Cg_exo -49.51 128.96 22.01 Favored 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.932 2.422 . . . . 0.0 112.6 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.71 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 12.7 m -88.5 16.49 6.45 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.593 -178.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 58.72 32.57 69.94 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.892 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.584 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 32.8 tt0 -136.24 145.82 46.04 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -179.362 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.667 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -137.48 151.99 49.06 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.031 0.443 . . . . 0.0 111.874 -178.686 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.588 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 29.7 p -109.54 39.54 2.07 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.33 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.69 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.5 t -72.04 -41.58 68.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.173 -179.505 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 19.5 m-85 -115.1 -47.95 2.84 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.647 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.588 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 34.7 pt -122.16 153.31 61.32 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.064 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -66.27 154.39 74.37 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.296 1.997 . . . . 0.0 111.768 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.584 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 72.3 m -68.04 128.24 35.8 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.287 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 61.8 mt -90.08 -44.35 14.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-O 121.359 0.599 . . . . 0.0 109.409 178.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.57 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.2 m -72.52 -23.66 61.04 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.139 179.267 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 1.01 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -52.62 -19.34 6.34 Favored Glycine 0 CA--C 1.519 0.31 0 CA-C-N 115.322 -0.853 . . . . 0.0 114.185 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 36.0 m -60.45 -18.96 17.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.871 0.336 . . . . 0.0 111.885 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.57 HG12 ' O ' ' A' ' 15' ' ' SER . 33.2 pt -79.79 -1.71 4.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.804 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 130.94 -19.4 4.95 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.403 -0.903 . . . . 0.0 112.14 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 1.01 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 56.2 m -58.58 121.92 12.16 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.301 0.572 . . . . 0.0 111.131 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 15.4 m -105.84 132.86 51.44 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.099 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.609 ' HA ' ' HA ' ' A' ' 27' ' ' CYS . 1.7 t -75.03 108.99 8.13 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.511 0.672 . . . . 0.0 111.176 -178.674 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.7 m -109.42 118.3 36.29 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.013 -0.994 . . . . 0.0 108.462 178.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 30.9 t70 52.11 52.44 14.35 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 122.065 0.936 . . . . 0.0 110.93 -178.523 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.69 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.0 OUTLIER 69.76 3.53 4.32 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.779 -1.1 . . . . 0.0 113.533 178.797 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 33.0 t -127.29 124.13 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 118.622 0.646 . . . . 0.0 110.505 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.609 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 7.3 m -75.53 124.87 27.92 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.658 0.742 . . . . 0.0 112.836 -179.193 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.4 m-85 -114.72 144.88 42.75 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.579 179.163 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.71 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 46.1 tp -92.9 81.32 4.63 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 178.519 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.9 m-80 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.449 -179.308 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.805 0 CA-C-O 120.028 -0.318 . . . . 0.0 113.271 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.455 HG23 ' HB3' ' A' ' 29' ' ' LEU . 4.9 t -106.92 118.45 54.1 Favored Pre-proline 0 C--O 1.223 -0.31 0 CA-C-N 117.755 0.778 . . . . 0.0 111.488 -179.178 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.592 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 9.5 Cg_endo -51.39 135.56 46.97 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 123.124 2.55 . . . . 0.0 112.373 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.691 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 6.7 m -93.7 7.65 43.96 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.345 -179.269 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 79.51 -25.97 2.75 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.576 -178.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.725 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 33.2 tt0 -74.06 131.2 41.11 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.565 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -112.56 154.0 26.64 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.49 0.662 . . . . 0.0 111.887 -178.744 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.407 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.7 p -122.24 44.75 2.52 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.872 -1.058 . . . . 0.0 109.688 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.754 HG22 ' HB3' ' A' ' 25' ' ' LYS . 12.9 t -72.43 -44.46 62.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.699 -178.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -112.19 -49.61 2.96 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.022 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 34.4 pt -118.76 155.59 52.45 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.391 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_exo -67.17 153.01 78.77 Favored 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 122.432 2.088 . . . . 0.0 111.753 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.725 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 62.0 m -70.82 130.97 43.07 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.54 -0.755 . . . . 0.0 111.462 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 27.7 pt -88.72 -38.04 10.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.889 0.376 . . . . 0.0 110.529 179.31 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.558 ' O ' HG12 ' A' ' 18' ' ' ILE . 2.8 m -74.77 -18.33 60.5 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.196 0.522 . . . . 0.0 109.895 179.245 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.955 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.08 -18.23 6.06 Favored Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.158 -0.928 . . . . 0.0 113.923 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.4 m -59.47 -19.81 17.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.925 0.393 . . . . 0.0 111.686 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.558 HG12 ' O ' ' A' ' 15' ' ' SER . 33.4 pt -79.04 -4.03 6.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.771 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 133.41 -21.61 4.04 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.994 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.955 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 50.1 m -60.52 122.28 14.25 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.342 0.592 . . . . 0.0 110.699 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.9 m -108.47 141.92 39.62 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.449 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.1 t -64.93 113.06 3.59 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.975 0.416 . . . . 0.0 110.262 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.1 m -122.57 100.27 6.84 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.086 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.45 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 23.0 t70 47.73 63.69 1.91 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.448 -0.796 . . . . 0.0 111.79 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.754 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.8 OUTLIER 72.43 -4.28 2.09 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 115.027 -0.988 . . . . 0.0 113.136 178.844 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.423 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 44.3 t -130.81 127.31 61.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 118.671 0.669 . . . . 0.0 110.718 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.49 ' HA ' ' O ' ' A' ' 21' ' ' SER . 30.6 m -80.71 127.75 32.85 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.539 0.685 . . . . 0.0 112.267 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.592 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.5 m-85 -112.27 144.72 41.2 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.255 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.691 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.8 tp -93.43 83.91 4.63 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 114.871 -1.059 . . . . 0.0 112.004 -179.61 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.792 0 CA-C-O 120.212 -0.215 . . . . 0.0 112.854 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.6 m -96.12 109.9 49.35 Favored Pre-proline 0 C--O 1.223 -0.335 0 CA-C-N 117.342 0.571 . . . . 0.0 111.077 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.512 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 71.1 Cg_exo -48.67 132.45 25.67 Favored 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 122.927 2.418 . . . . 0.0 112.663 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.536 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.3 m -92.34 3.58 55.12 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 121.164 0.507 . . . . 0.0 109.852 -179.617 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.82 -27.37 3.0 Favored Glycine 0 N--CA 1.448 -0.536 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 -178.253 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.425 ' H ' ' C ' ' A' ' 4' ' ' CYS . 21.9 tt0 -76.96 134.18 38.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 179.508 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.524 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -126.01 146.39 49.91 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.537 0.684 . . . . 0.0 112.18 -178.683 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 5.3 p -109.87 48.1 0.91 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.772 -1.103 . . . . 0.0 110.422 179.589 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.68 HG22 ' HB3' ' A' ' 25' ' ' LYS . 19.9 t -68.15 -38.21 79.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.699 -179.737 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -115.02 -50.27 2.77 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.661 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.546 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 32.9 pt -121.44 150.81 55.37 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.965 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -62.87 153.64 71.68 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.418 2.078 . . . . 0.0 112.258 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 61.1 m -74.66 131.06 40.59 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.396 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 12.7 tt -79.94 -34.95 15.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.791 178.666 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.711 ' O ' HG12 ' A' ' 18' ' ' ILE . 16.2 m -77.66 -0.09 25.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.888 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.743 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -56.7 -23.86 45.77 Favored Glycine 0 CA--C 1.519 0.336 0 C-N-CA 121.392 -0.432 . . . . 0.0 112.855 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.4 t -60.08 -26.42 36.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.962 0.41 . . . . 0.0 111.835 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.711 HG12 ' O ' ' A' ' 15' ' ' SER . 18.6 pt -80.9 5.21 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.592 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 120.51 -18.29 9.4 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.157 -1.021 . . . . 0.0 112.921 179.247 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.743 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 46.3 m -63.27 124.86 22.3 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.235 0.541 . . . . 0.0 110.624 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.484 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 12.2 m -119.57 144.46 47.07 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.156 -179.725 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 23.7 m -63.22 112.58 2.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.41 0.624 . . . . 0.0 111.833 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.2 m -120.02 95.67 4.85 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.139 -0.937 . . . . 0.0 108.588 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 48.1 t0 49.84 59.57 4.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.507 -0.769 . . . . 0.0 111.384 -178.359 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.68 ' HB3' HG22 ' A' ' 9' ' ' VAL . 26.6 mtmm 75.99 -9.79 1.39 Allowed 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.287 -0.869 . . . . 0.0 113.067 178.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.2 t -120.29 127.29 75.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.409 0.549 . . . . 0.0 110.517 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.588 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 69.7 m -80.64 122.74 27.46 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.561 0.696 . . . . 0.0 112.729 -179.089 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.512 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-30 -109.9 142.62 40.98 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.367 178.705 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.536 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.7 tt -89.88 84.52 6.23 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.511 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 52.0 m-20 . . . . . 0 C--N 1.324 -0.521 0 CA-C-N 114.591 -1.186 . . . . 0.0 110.996 -178.654 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.753 0 CA-C-O 120.206 -0.219 . . . . 0.0 112.751 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.2 m -99.28 113.4 64.75 Favored Pre-proline 0 C--O 1.221 -0.418 0 CA-C-N 117.4 0.6 . . . . 0.0 111.214 -179.361 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.495 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 78.9 Cg_exo -47.46 133.34 20.48 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.986 2.457 . . . . 0.0 112.845 -179.767 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.6 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 12.7 m -90.91 7.81 38.25 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.094 0.473 . . . . 0.0 110.019 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.27 -27.05 2.84 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 120.921 -0.656 . . . . 0.0 111.713 -178.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 61.3 tt0 -80.31 133.56 35.97 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.109 0.48 . . . . 0.0 109.719 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.653 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -114.03 146.63 39.92 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.611 0.72 . . . . 0.0 112.044 -179.084 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.7 p -105.76 47.09 0.89 Allowed 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.706 -1.133 . . . . 0.0 110.208 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.653 HG23 ' HB2' ' A' ' 7' ' ' SER . 21.2 t -73.77 -42.08 54.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.591 -179.048 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.6 m-85 -111.1 -48.31 3.12 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.304 -179.566 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.7 pt -129.9 161.41 59.83 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.264 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -66.85 152.11 81.06 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.278 1.986 . . . . 0.0 111.651 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.4 m -74.61 133.94 42.13 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.752 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 15.3 tt -74.41 -34.35 36.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.117 179.003 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.73 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.2 m -73.95 -0.82 17.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.829 179.534 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.65 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.61 -27.13 58.3 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.744 179.779 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.3 m -62.72 -20.88 26.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.73 HG12 ' O ' ' A' ' 15' ' ' SER . 13.6 pt -87.98 0.69 6.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.821 -0.351 . . . . 0.0 111.456 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 124.89 -18.74 7.04 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.249 -0.977 . . . . 0.0 112.638 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.65 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 61.9 m -60.88 122.88 15.99 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.398 0.618 . . . . 0.0 110.691 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.7 m -113.62 140.78 47.91 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.065 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 48.1 t -66.2 119.34 11.31 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.847 0.356 . . . . 0.0 110.162 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 22.9 m -133.96 107.68 7.95 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.17 -179.491 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.497 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 44.5 t0 49.06 57.86 6.0 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.507 -0.769 . . . . 0.0 111.921 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.551 ' HG3' ' HA ' ' A' ' 9' ' ' VAL . 0.0 OUTLIER 73.8 -4.45 2.25 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 113.416 0.895 . . . . 0.0 113.416 178.405 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 60.5 t -130.58 131.72 64.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 118.415 0.552 . . . . 0.0 110.749 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.453 ' HA ' ' O ' ' A' ' 21' ' ' SER . 87.5 m -81.28 129.21 34.51 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.297 0.57 . . . . 0.0 112.139 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.495 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.0 m-85 -112.74 142.83 44.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.46 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.6 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.8 tp -89.87 82.27 6.23 Favored 'General case' 0 C--N 1.31 -1.148 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.157 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 . . . . . 0 N--CA 1.466 0.331 0 CA-C-N 114.804 -1.089 . . . . 0.0 111.286 -178.372 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.792 0 CA-C-O 120.146 -0.252 . . . . 0.0 113.004 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 17.0 p -99.19 115.35 65.79 Favored Pre-proline 0 C--O 1.223 -0.298 0 CA-C-N 117.499 0.65 . . . . 0.0 111.622 -179.179 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.455 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 68.9 Cg_exo -51.47 127.89 23.95 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.811 2.341 . . . . 0.0 112.59 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.662 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.4 m -84.09 12.78 5.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.652 -179.003 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.91 29.31 73.78 Favored Glycine 0 C--N 1.332 0.332 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -178.549 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.498 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 38.0 tt0 -129.63 149.56 51.34 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 114.504 -0.848 . . . . 0.0 109.03 -178.793 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.47 146.29 44.11 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.361 0.601 . . . . 0.0 111.752 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.554 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 8.6 p -117.89 50.62 1.12 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.488 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.518 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.9 t -68.02 -32.75 57.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.63 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -128.27 -50.67 1.3 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.24 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.554 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 31.5 pt -104.66 143.09 25.99 Favored Pre-proline 0 C--N 1.324 -0.511 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.093 179.402 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 21.2 Cg_exo -63.45 158.52 44.9 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.64 2.227 . . . . 0.0 112.44 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.498 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 10.9 m -60.72 119.78 8.8 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.904 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 8.6 tp -78.98 -35.34 17.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 178.763 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.677 ' O ' HG22 ' A' ' 18' ' ' ILE . 25.3 t -82.94 3.49 29.75 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.693 178.594 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.572 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -56.18 -21.65 33.21 Favored Glycine 0 C--N 1.33 0.222 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.283 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.9 t -59.94 -28.4 40.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.981 0.42 . . . . 0.0 111.538 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.677 HG22 ' O ' ' A' ' 15' ' ' SER . 18.2 tt -78.93 -9.29 12.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 121.224 0.535 . . . . 0.0 111.442 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.67 -18.56 5.67 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.798 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.572 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 61.1 m -55.01 124.55 17.14 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.218 0.533 . . . . 0.0 110.628 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 20.4 m -122.79 150.01 43.38 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.879 -178.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.3 m -64.51 115.32 5.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.339 0.59 . . . . 0.0 111.717 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.6 m -125.44 96.79 4.94 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 179.002 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.451 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 47.8 t0 53.28 54.09 10.77 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.685 -178.169 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.518 ' HB3' HG22 ' A' ' 9' ' ' VAL . 6.9 mtmp? 74.22 -9.82 1.22 Allowed 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 114.977 -1.011 . . . . 0.0 112.752 179.528 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 t -111.41 130.09 65.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.4 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 23.3 m -78.38 119.74 22.14 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.221 0.534 . . . . 0.0 111.366 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.503 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 2.8 m-85 -110.99 144.53 39.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.391 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.662 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 57.2 tp -96.99 83.12 3.32 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 178.37 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.495 -179.07 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.87 0 CA-C-O 120.155 -0.247 . . . . 0.0 112.909 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 16.8 p -100.58 113.32 65.53 Favored Pre-proline 0 C--O 1.223 -0.301 0 CA-C-N 117.399 0.599 . . . . 0.0 111.636 -179.15 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.5 Cg_exo -49.22 132.12 27.84 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.895 2.397 . . . . 0.0 112.584 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.661 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.4 m -91.53 5.23 50.34 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 121.011 0.434 . . . . 0.0 110.249 -179.329 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.45 -24.76 3.5 Favored Glycine 0 N--CA 1.451 -0.353 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -178.609 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.671 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 19.7 tt0 -72.3 133.11 44.83 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.737 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.5 p -115.32 164.44 14.24 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 121.413 0.625 . . . . 0.0 111.979 -178.66 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.471 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.6 p -139.43 43.77 2.0 Allowed 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.716 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.631 HG22 ' HB3' ' A' ' 25' ' ' LYS . 12.3 t -70.62 -44.62 76.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.054 -179.341 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -128.47 -45.11 1.35 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.818 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.471 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 66.4 mt -103.86 134.39 19.75 Favored Pre-proline 0 C--N 1.321 -0.638 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.027 179.38 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -64.6 152.55 81.38 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.133 1.889 . . . . 0.0 111.775 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.671 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 58.2 m -62.73 -47.29 84.22 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.669 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 78.6 mt 73.41 -55.53 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 122.893 0.477 . . . . 0.0 111.1 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.3 m -67.91 -16.23 63.98 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.3 0.571 . . . . 0.0 110.01 179.105 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.707 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.17 -16.36 4.47 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.061 -0.972 . . . . 0.0 113.675 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 31.2 m -58.31 -17.67 9.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.107 0.48 . . . . 0.0 111.224 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.4 tp -71.55 -15.99 18.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.145 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 144.96 -23.87 1.94 Allowed Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.707 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 55.5 m -65.67 121.13 14.26 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.445 0.64 . . . . 0.0 110.948 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.9 m -105.87 139.16 40.86 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.522 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 46.5 t -66.03 102.9 0.86 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.246 0.546 . . . . 0.0 110.423 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.2 m -112.46 106.98 15.59 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.072 -179.656 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 46.9 t0 47.21 59.55 3.99 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.887 -179.635 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.631 ' HB3' HG22 ' A' ' 9' ' ' VAL . 22.2 mtmm 70.68 6.27 5.76 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.246 -0.888 . . . . 0.0 113.317 178.473 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 45.2 t -137.83 125.93 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 118.236 0.471 . . . . 0.0 110.168 179.442 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.622 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 11.7 m -77.94 122.92 26.15 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.509 0.671 . . . . 0.0 112.292 -179.56 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.529 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.3 m-85 -108.69 144.36 36.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.9 179.296 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.661 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.8 tp -91.8 80.99 5.22 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.3 m-80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.554 -179.183 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.848 0 CA-C-O 120.278 -0.179 . . . . 0.0 112.741 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 23.5 m -98.42 112.89 63.39 Favored Pre-proline 0 C--O 1.22 -0.478 0 CA-C-N 117.327 0.564 . . . . 0.0 111.215 -179.347 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.481 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.4 Cg_exo -47.82 132.95 22.16 Favored 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 122.997 2.465 . . . . 0.0 112.863 -179.795 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.614 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 9.0 m -91.58 6.73 44.57 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.094 0.473 . . . . 0.0 110.024 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.2 -27.42 2.76 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.507 -178.619 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.505 ' OE2' ' HB3' ' A' ' 13' ' ' CYS . 16.3 tt0 -77.48 126.88 31.6 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.494 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 0.6 OUTLIER -109.12 151.87 25.85 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.627 0.727 . . . . 0.0 112.062 -178.577 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -114.78 51.06 0.92 Allowed 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.887 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.489 ' HA ' ' HB2' ' A' ' 25' ' ' LYS . 14.5 t -68.87 -44.9 81.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.769 -178.638 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -109.72 -46.86 3.44 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.218 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 30.7 pt -129.37 157.68 75.48 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.172 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -64.76 152.37 82.3 Favored 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 122.247 1.965 . . . . 0.0 111.616 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.505 ' HB3' ' OE2' ' A' ' 6' ' ' GLU . 27.1 m -71.41 132.73 45.23 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.573 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 12.5 tt -74.7 -36.48 40.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.839 178.644 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.661 ' O ' HG12 ' A' ' 18' ' ' ILE . 15.3 m -75.81 -3.66 36.31 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.644 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.774 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.47 -22.66 46.12 Favored Glycine 0 C--N 1.331 0.282 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.822 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 13.7 p -61.06 -22.69 27.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.858 0.361 . . . . 0.0 111.831 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.661 HG12 ' O ' ' A' ' 15' ' ' SER . 18.5 pt -80.09 -1.03 4.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 111.839 0.311 . . . . 0.0 111.839 -179.837 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.69 -21.53 5.62 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.275 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.774 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 58.3 m -61.54 121.9 13.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.401 0.62 . . . . 0.0 110.809 -179.787 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -108.83 138.88 44.47 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.258 -179.724 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.7 t -69.63 124.02 22.86 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.849 0.357 . . . . 0.0 110.516 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 48.8 m -148.45 120.07 8.02 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.77 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 6.5 t70 50.99 57.67 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.372 0.606 . . . . 0.0 110.146 -178.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.77 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 54.15 14.68 0.77 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.028 1.331 . . . . 0.0 113.703 -179.709 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 57.6 t -137.07 131.32 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 O-C-N 122.052 -0.405 . . . . 0.0 110.247 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.511 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 73.1 m -82.54 128.02 33.9 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 121.723 -0.611 . . . . 0.0 112.044 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-85 -111.45 142.47 43.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.372 179.653 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.614 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.5 tp -89.59 82.22 6.39 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.345 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 59.2 m-20 . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 114.726 -1.124 . . . . 0.0 111.128 -178.473 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.768 0 CA-C-O 120.008 -0.329 . . . . 0.0 113.306 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.5 t -104.73 118.7 55.75 Favored Pre-proline 0 C--O 1.224 -0.284 0 CA-C-N 117.766 0.783 . . . . 0.0 111.661 -179.024 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 65.8 Cg_exo -50.77 136.73 42.8 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 123.028 2.485 . . . . 0.0 112.535 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.609 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 10.0 m -93.65 5.42 51.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.072 0.463 . . . . 0.0 110.05 -179.566 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.82 -26.39 3.22 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.789 -178.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 50.9 tt0 -79.01 132.92 36.82 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.559 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -110.55 147.57 33.91 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.602 0.715 . . . . 0.0 112.055 -178.975 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.0 p -110.88 49.12 0.88 Allowed 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.847 -1.07 . . . . 0.0 110.143 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.559 HG23 ' HB2' ' A' ' 7' ' ' SER . 20.7 t -72.08 -42.53 67.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.658 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -110.37 -48.06 3.21 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.932 -0.577 . . . . 0.0 111.357 -179.557 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.8 pt -130.0 161.81 57.58 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.304 -179.348 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo -66.2 152.33 81.4 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 122.321 2.014 . . . . 0.0 111.632 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 46.1 m -72.83 137.27 45.62 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.751 -179.069 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 46.4 mm -73.1 -38.57 55.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.223 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.608 ' O ' HG22 ' A' ' 18' ' ' ILE . 2.1 m -73.45 2.42 7.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.188 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.64 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.83 -25.64 56.44 Favored Glycine 0 N--CA 1.453 -0.201 0 C-N-CA 121.252 -0.499 . . . . 0.0 112.791 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.7 m -62.62 -20.96 26.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.608 HG22 ' O ' ' A' ' 15' ' ' SER . 8.7 tp -83.99 -6.35 10.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.25 0.548 . . . . 0.0 111.053 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.55 -18.51 5.72 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.514 -0.851 . . . . 0.0 111.816 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.64 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 60.3 m -59.23 122.04 12.85 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.395 0.617 . . . . 0.0 110.892 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.449 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.7 m -113.86 142.66 45.83 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.096 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.6 t -63.61 114.78 4.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.973 0.416 . . . . 0.0 110.184 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.7 m -121.51 94.48 4.34 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.038 -0.528 . . . . 0.0 109.924 -179.68 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.606 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 38.7 t70 46.37 65.26 1.23 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.131 -0.941 . . . . 0.0 112.07 -179.172 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.606 ' HB2' ' O ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 78.09 -9.85 1.44 Allowed 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 178.028 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.433 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 42.2 t -130.4 128.21 63.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-N 118.496 0.589 . . . . 0.0 110.647 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.471 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 85.7 m -80.72 128.55 33.76 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.366 0.603 . . . . 0.0 112.475 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.522 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-85 -112.94 144.23 42.87 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.636 179.138 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.609 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.5 tt -95.92 85.69 4.14 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.7 m-80 . . . . . 0 C--N 1.327 -0.402 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.927 -179.333 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.876 0 CA-C-O 120.195 -0.225 . . . . 0.0 112.608 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 21.6 m -96.27 112.23 59.12 Favored Pre-proline 0 C--O 1.221 -0.432 0 CA-C-N 117.369 0.585 . . . . 0.0 111.395 -179.296 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 71.5 Cg_exo -49.14 127.29 17.11 Favored 'Trans proline' 0 C--N 1.346 0.44 0 C-N-CA 122.862 2.375 . . . . 0.0 112.787 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.692 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 20.3 m -86.04 14.14 6.67 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.795 -178.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.59 26.46 68.4 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.925 -0.655 . . . . 0.0 111.973 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.722 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 40.6 tt0 -132.35 131.08 41.54 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.664 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -112.0 150.02 31.18 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.586 0.708 . . . . 0.0 112.236 -178.433 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.3 p -112.21 42.64 1.74 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.75 -1.114 . . . . 0.0 109.774 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 1.097 ' HA ' ' HD2' ' A' ' 25' ' ' LYS . 20.8 t -69.07 -63.71 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.847 -178.573 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.0 m-85 -91.53 -49.43 6.32 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.177 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.679 ' H ' HD13 ' A' ' 11' ' ' ILE . 0.2 OUTLIER -121.78 159.29 51.7 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.532 -179.347 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -68.25 153.99 73.23 Favored 'Trans proline' 0 N--CA 1.459 -0.538 0 C-N-CA 122.471 2.114 . . . . 0.0 111.637 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.722 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 58.6 m -69.65 132.64 46.49 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.481 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 7.6 tp -89.99 -39.45 12.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.008 0.432 . . . . 0.0 109.908 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.539 ' O ' HG12 ' A' ' 18' ' ' ILE . 2.5 m -74.12 -24.07 59.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.815 179.074 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.977 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.11 -17.69 5.59 Favored Glycine 0 C--N 1.331 0.298 0 CA-C-N 115.144 -0.934 . . . . 0.0 114.108 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.7 p -58.8 -20.89 17.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.148 0.499 . . . . 0.0 111.356 179.513 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.539 HG12 ' O ' ' A' ' 15' ' ' SER . 35.5 pt -75.73 -5.21 6.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.03 -0.532 . . . . 0.0 112.32 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 135.43 -18.68 3.89 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.43 -0.89 . . . . 0.0 112.171 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.977 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 33.4 m -60.68 124.2 19.69 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.315 0.579 . . . . 0.0 110.764 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.455 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 6.5 m -104.57 139.69 39.08 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.518 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.6 t -71.37 119.51 15.62 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.12 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 38.4 m -144.45 121.79 11.62 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.7 t0 54.95 46.55 24.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 122.251 1.024 . . . . 0.0 109.98 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 1.097 ' HD2' ' HA ' ' A' ' 9' ' ' VAL . 66.4 mmtt 62.2 14.93 7.07 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 113.905 -1.498 . . . . 0.0 113.487 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 60.5 t -136.09 132.47 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.786 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.515 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 34.6 m -82.27 125.69 31.26 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.523 0.677 . . . . 0.0 112.341 -179.648 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.46 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 2.4 m-85 -111.3 142.86 42.97 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.163 179.588 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.692 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 45.3 tp -89.32 81.4 6.66 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 107.999 -1.112 . . . . 0.0 107.999 178.156 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 49.6 m-20 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 114.745 -1.116 . . . . 0.0 111.069 -178.316 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.649 0 CA-C-O 120.199 -0.223 . . . . 0.0 113.199 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.2 m -98.17 113.71 64.27 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 117.392 0.596 . . . . 0.0 111.315 -179.33 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 73.0 Cg_exo -49.19 133.08 29.37 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.861 2.374 . . . . 0.0 112.756 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.554 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 33.3 m -83.15 20.52 1.24 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.35 -179.209 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 61.59 30.21 74.03 Favored Glycine 0 C--O 1.227 -0.341 0 CA-C-N 115.972 -0.558 . . . . 0.0 113.03 179.59 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -162.75 151.32 14.51 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.143 0.497 . . . . 0.0 110.047 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.556 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 34.9 p -100.6 -174.52 2.66 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.157 -179.683 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.54 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 28.7 p -150.88 41.84 0.77 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.593 0.711 . . . . 0.0 109.572 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.816 HG22 ' HB3' ' A' ' 25' ' ' LYS . 17.4 t -69.12 -40.68 80.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.011 -179.516 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -104.76 -49.52 3.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.28 -179.652 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.736 ' H ' HD13 ' A' ' 11' ' ' ILE . 0.2 OUTLIER -112.13 142.76 27.45 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.481 -179.695 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 18.8 Cg_exo -64.7 159.45 45.2 Favored 'Trans proline' 0 C--O 1.234 0.279 0 C-N-CA 122.738 2.292 . . . . 0.0 112.064 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 63.8 m -59.72 110.81 1.23 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.374 -179.627 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 47.8 mm -63.8 -45.37 97.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.196 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.636 ' HB3' HD12 ' A' ' 18' ' ' ILE . 6.2 m -80.1 29.45 0.28 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.296 179.626 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -59.07 -34.99 81.92 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 121.228 -0.51 . . . . 0.0 112.395 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.3 p -63.94 -21.23 28.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.119 0.485 . . . . 0.0 111.181 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.636 HD12 ' HB3' ' A' ' 15' ' ' SER . 8.0 mt -84.43 -11.86 11.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.52 0.676 . . . . 0.0 110.43 179.646 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 121.13 -7.99 10.59 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.78 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.527 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 84.3 m -65.81 123.63 20.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.235 0.541 . . . . 0.0 110.711 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.3 m -129.39 148.7 51.33 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.174 -179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 19.2 m -67.38 105.8 1.9 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.465 0.65 . . . . 0.0 112.008 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.4 m -114.7 100.02 7.95 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.153 -0.931 . . . . 0.0 108.658 178.57 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.462 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 47.2 t0 52.52 54.07 11.23 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.527 0.68 . . . . 0.0 110.981 -178.685 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.816 ' HB3' HG22 ' A' ' 9' ' ' VAL . 6.9 mtmp? 71.23 -0.33 3.14 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 115.185 -0.916 . . . . 0.0 113.159 179.187 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 25.6 t -120.15 134.39 63.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 118.13 0.423 . . . . 0.0 110.136 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.54 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 78.8 m -76.74 117.4 18.32 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.038 0.447 . . . . 0.0 112.197 -179.056 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.491 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.7 m-85 -112.86 142.41 45.55 Favored 'General case' 0 CA--C 1.513 -0.451 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 177.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.554 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.9 tt -101.38 86.32 2.96 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.057 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 33.4 m120 . . . . . 0 C--N 1.325 -0.498 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.161 -178.984 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.64 0 CA-C-O 120.224 -0.209 . . . . 0.0 113.189 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.448 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 22.0 m -98.05 113.07 63.38 Favored Pre-proline 0 C--O 1.221 -0.419 0 CA-C-N 117.407 0.603 . . . . 0.0 110.806 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.567 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 8.8 Cg_endo -49.75 134.08 33.84 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 123.063 2.509 . . . . 0.0 112.49 -179.801 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.524 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 36.6 m -81.54 21.15 0.82 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.16 -179.209 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.88 28.65 72.21 Favored Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.754 -0.657 . . . . 0.0 113.235 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -161.21 152.93 19.37 Favored 'General case' 0 C--O 1.238 0.484 0 CA-C-O 121.414 0.626 . . . . 0.0 110.635 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.582 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 21.0 p -104.44 179.51 4.25 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.14 -0.937 . . . . 0.0 111.29 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.602 ' HB2' ' HA ' ' A' ' 12' ' ' PRO . 18.3 p -151.43 50.57 0.82 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.82 179.164 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.831 HG22 ' HB3' ' A' ' 25' ' ' LYS . 17.6 t -67.45 -42.39 87.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.96 -179.489 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -94.8 -48.72 5.91 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.312 -0.858 . . . . 0.0 111.694 -179.307 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.452 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 23.9 pt -135.18 142.64 42.56 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.73 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.602 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 9.6 Cg_exo -68.68 153.12 73.92 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.985 2.456 . . . . 0.0 112.493 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 97.8 m -67.27 120.77 14.36 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.931 179.853 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 48.3 mm -61.61 -41.43 90.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.743 -179.751 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.654 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.0 m -76.65 22.07 0.19 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.655 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.611 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -58.83 -21.15 50.83 Favored Glycine 0 C--N 1.33 0.227 0 C-N-CA 121.467 -0.397 . . . . 0.0 112.806 179.503 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.5 p -60.75 -22.06 25.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.85 0.357 . . . . 0.0 111.718 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.654 HG12 ' O ' ' A' ' 15' ' ' SER . 22.4 pt -80.09 -0.59 4.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 C-N-CA 120.955 -0.298 . . . . 0.0 111.575 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.63 -20.0 7.41 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.2 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.611 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 78.3 m -63.24 124.14 20.45 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.401 0.62 . . . . 0.0 111.248 -179.767 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 17.7 m -129.14 142.03 51.0 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.376 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 23.3 m -71.99 115.77 11.6 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.486 0.66 . . . . 0.0 111.974 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.511 ' HB ' ' CD1' ' A' ' 28' ' ' TYR . 15.7 m -124.4 108.51 12.24 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.515 178.742 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 43.7 t0 47.68 57.15 6.23 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.905 -178.724 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.831 ' HB3' HG22 ' A' ' 9' ' ' VAL . 20.3 mtmm 68.57 8.65 6.83 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.52 0.933 . . . . 0.0 113.52 178.372 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.582 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 48.6 t -130.04 134.45 62.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 118.611 0.641 . . . . 0.0 110.23 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 97.9 m -81.02 119.42 23.51 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.214 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 37.7 m-85 -114.88 142.77 46.13 Favored 'General case' 0 CA--C 1.516 -0.342 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.524 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.8 tt -101.94 87.22 3.05 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.087 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 32.3 m120 . . . . . 0 C--N 1.326 -0.442 0 CA-C-N 114.897 -1.047 . . . . 0.0 111.352 -178.955 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.684 0 CA-C-O 120.234 -0.203 . . . . 0.0 113.142 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.461 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 22.6 m -101.69 114.71 65.56 Favored Pre-proline 0 C--O 1.22 -0.45 0 CA-C-N 117.451 0.625 . . . . 0.0 111.127 -179.352 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.599 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 7.0 Cg_endo -48.75 131.86 25.2 Favored 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 123.111 2.541 . . . . 0.0 112.484 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.692 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 31.0 m -83.6 15.86 2.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.526 -179.058 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 61.45 32.2 80.22 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.004 -0.617 . . . . 0.0 112.034 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.514 ' HG3' ' SG ' ' A' ' 13' ' ' CYS . 3.8 tp10 -143.71 140.29 29.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.074 0.464 . . . . 0.0 110.012 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.617 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 11.6 p -101.3 170.19 8.4 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.455 -0.793 . . . . 0.0 112.257 -178.763 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.0 p -150.32 49.25 0.9 Allowed 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.423 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.733 HG22 ' HB3' ' A' ' 25' ' ' LYS . 12.1 t -68.11 -37.84 78.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.349 -178.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -125.17 -50.0 1.69 Allowed 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.401 179.737 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.41 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 50.0 mm -107.08 131.48 21.66 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.902 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 8.1 Cg_exo -69.29 151.38 71.76 Favored 'Trans proline' 0 N--CA 1.457 -0.642 0 C-N-CA 122.336 2.024 . . . . 0.0 111.66 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.514 ' SG ' ' HG3' ' A' ' 6' ' ' GLU . 9.7 m -69.19 119.4 13.41 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.148 -179.341 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 14.0 tt -64.88 -30.72 51.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.349 0.595 . . . . 0.0 110.496 179.61 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.671 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.4 p -74.76 1.99 11.15 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.529 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.661 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.33 -20.87 38.36 Favored Glycine 0 CA--C 1.518 0.26 0 CA-C-N 116.485 -0.325 . . . . 0.0 113.16 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.8 p -60.46 -23.62 28.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.96 0.41 . . . . 0.0 111.712 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.671 HG12 ' O ' ' A' ' 15' ' ' SER . 23.0 pt -81.06 0.14 3.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.453 -0.339 . . . . 0.0 111.749 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.64 -22.04 7.01 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.216 179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.661 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 83.2 m -59.84 122.6 14.63 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.531 0.681 . . . . 0.0 110.894 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.1 m -114.9 138.23 51.05 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.795 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 47.4 t -69.34 123.89 22.41 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.5 m -137.55 113.69 9.97 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.821 0.343 . . . . 0.0 110.184 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 35.4 t70 46.45 58.32 4.68 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.469 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.733 ' HB3' HG22 ' A' ' 9' ' ' VAL . 26.0 mtmm 72.26 4.82 5.13 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 113.783 1.031 . . . . 0.0 113.783 177.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.617 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 4.3 p -143.02 133.2 22.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 118.768 0.713 . . . . 0.0 111.343 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 93.9 m -80.78 132.16 35.48 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -178.605 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.599 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 3.1 m-85 -117.26 146.4 43.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.952 178.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.692 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 55.9 tp -99.35 84.67 3.03 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 . . . . . 0 C--N 1.327 -0.382 0 CA-C-N 115.186 -0.915 . . . . 0.0 111.602 -179.409 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.754 0 CA-C-O 120.276 -0.18 . . . . 0.0 112.728 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 p -100.74 116.6 63.98 Favored Pre-proline 0 C--O 1.222 -0.376 0 CA-C-N 117.328 0.564 . . . . 0.0 111.289 -179.361 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.501 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 82.1 Cg_exo -45.45 132.62 12.53 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 123.128 2.552 . . . . 0.0 113.084 -179.609 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.517 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 55.9 m -82.78 19.29 1.36 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.507 -179.237 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.73 30.36 76.69 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.239 -0.505 . . . . 0.0 112.741 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.3 tp10 -156.57 153.13 28.17 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.546 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 47.3 p -102.23 -176.71 3.19 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.506 0.67 . . . . 0.0 111.831 -179.317 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 7.1 p -151.04 41.85 0.75 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.243 179.27 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.826 HG22 ' HB3' ' A' ' 25' ' ' LYS . 13.3 t -69.93 -42.32 79.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.528 -179.016 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -115.0 -47.63 2.86 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.934 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.458 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 32.6 pt -104.59 142.9 25.6 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.82 -179.69 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.458 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 14.6 Cg_exo -67.15 158.69 55.66 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.715 2.277 . . . . 0.0 111.718 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 59.7 m -59.48 106.84 0.5 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.162 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.716 HD13 ' H ' ' A' ' 14' ' ' ILE . 0.2 OUTLIER -62.69 -39.29 84.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.118 0.485 . . . . 0.0 110.529 179.848 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.712 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.0 m -85.57 21.7 1.75 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.571 179.237 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -59.33 -27.2 62.74 Favored Glycine 0 C--N 1.329 0.183 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.415 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.9 p -62.59 -23.63 33.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 120.856 0.36 . . . . 0.0 111.83 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.712 HG12 ' O ' ' A' ' 15' ' ' SER . 16.0 pt -90.53 3.45 6.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 C-N-CA 120.531 -0.468 . . . . 0.0 111.421 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 115.93 -12.87 17.33 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.3 -0.953 . . . . 0.0 113.25 179.181 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.434 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 71.2 m -62.58 123.38 18.21 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.467 0.651 . . . . 0.0 110.962 -179.759 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 9.1 m -117.1 142.33 47.14 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.89 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.5 t -71.91 111.36 7.1 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.069 0.462 . . . . 0.0 109.951 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 m -119.09 103.93 10.0 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.096 -179.73 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.455 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 19.6 t70 47.23 61.87 2.68 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.817 -179.544 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.826 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.5 OUTLIER 67.86 4.78 4.14 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 115.013 -0.994 . . . . 0.0 113.241 178.834 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.546 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 51.4 t -131.01 130.98 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 118.418 0.554 . . . . 0.0 110.577 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 84.7 m -77.73 125.42 29.32 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.501 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 4.7 m-85 -117.2 143.11 46.22 Favored 'General case' 0 CA--C 1.517 -0.317 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.234 178.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.517 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.7 tp -96.41 83.18 3.49 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.367 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 65.4 m-20 . . . . . 0 N--CA 1.465 0.309 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.584 -178.586 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.74 0 CA-C-O 120.287 -0.174 . . . . 0.0 112.709 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 19.8 m -94.38 109.63 43.94 Favored Pre-proline 0 C--O 1.22 -0.453 0 CA-C-N 117.157 0.479 . . . . 0.0 111.518 -179.299 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.502 ' HG3' ' CE2' ' A' ' 28' ' ' TYR . 33.1 Cg_exo -58.16 134.04 59.29 Favored 'Trans proline' 0 CA--C 1.529 0.249 0 C-N-CA 122.532 2.155 . . . . 0.0 112.913 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 6.5 m -79.57 16.74 1.01 Allowed 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.272 179.294 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.9 29.91 75.65 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.101 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -153.59 156.2 37.54 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.315 0.578 . . . . 0.0 110.152 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.561 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 40.2 p -103.14 -174.73 2.62 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.544 -179.185 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 9.2 p -151.12 39.64 0.69 Allowed 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.227 179.312 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.906 HG22 ' HB3' ' A' ' 25' ' ' LYS . 10.9 t -69.99 -36.22 67.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.251 -0.886 . . . . 0.0 111.189 -179.25 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -122.7 -45.93 2.15 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.362 -179.57 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.412 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 35.0 pt -103.62 147.5 34.33 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.179 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 11.4 Cg_exo -68.64 156.21 66.28 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.715 2.277 . . . . 0.0 111.615 179.672 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 77.7 m -60.64 107.79 0.74 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.783 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 11.3 tt -64.96 -38.83 83.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.15 0.5 . . . . 0.0 109.976 179.22 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.556 ' HB3' HD12 ' A' ' 18' ' ' ILE . 6.0 m -81.62 20.72 0.88 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.024 179.325 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.562 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -60.85 -31.11 74.75 Favored Glycine 0 C--N 1.332 0.329 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.095 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 21.9 t -63.06 -23.95 34.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.324 0.583 . . . . 0.0 110.703 179.43 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.556 HD12 ' HB3' ' A' ' 15' ' ' SER . 6.5 mt -81.63 -12.33 12.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.413 179.666 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 118.96 -8.54 12.58 Favored Glycine 0 N--CA 1.446 -0.698 0 CA-C-N 115.715 -0.675 . . . . 0.0 112.182 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.562 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 1.8 m -70.21 127.64 33.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.726 0.774 . . . . 0.0 111.722 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 20.1 m -116.63 149.83 39.09 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.649 -1.159 . . . . 0.0 109.715 179.502 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.2 t -69.51 111.7 5.53 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.974 0.416 . . . . 0.0 110.292 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.511 ' HB ' ' CD1' ' A' ' 28' ' ' TYR . 5.9 m -119.59 103.07 9.1 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.005 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 36.2 t70 47.53 58.77 4.63 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.271 -179.502 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.906 ' HB3' HG22 ' A' ' 9' ' ' VAL . 28.4 mtmm 72.07 2.83 4.46 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 178.451 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 42.7 t -130.43 133.1 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 118.563 0.62 . . . . 0.0 110.385 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 83.9 m -80.95 120.41 24.72 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 112.724 0.639 . . . . 0.0 112.724 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.511 ' CD1' ' HB ' ' A' ' 23' ' ' THR . 57.3 m-85 -121.47 139.89 52.89 Favored 'General case' 0 CA--C 1.518 -0.288 0 CA-C-O 121.142 0.496 . . . . 0.0 110.462 178.143 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.505 ' HB2' ' SG ' ' A' ' 20' ' ' CYS . 2.7 tt -94.11 77.89 4.05 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 178.249 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 35.4 m120 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.01 -178.804 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.849 0 CA-C-O 120.211 -0.216 . . . . 0.0 112.792 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.6 m -95.83 110.7 52.92 Favored Pre-proline 0 C--O 1.222 -0.363 0 CA-C-N 117.306 0.553 . . . . 0.0 111.087 -179.414 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.1 Cg_exo -49.71 130.38 26.31 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.846 2.364 . . . . 0.0 112.627 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.602 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 4.8 m -92.16 6.69 45.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.312 -179.315 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.05 -27.23 2.73 Favored Glycine 0 N--CA 1.452 -0.286 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -178.197 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.693 ' OE2' ' HB3' ' A' ' 13' ' ' CYS . 19.7 tt0 -69.8 131.03 43.88 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.556 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.492 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.3 p -115.75 162.79 16.78 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.471 0.653 . . . . 0.0 112.465 -178.137 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.463 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.8 p -136.01 45.45 2.38 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.576 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.683 HG22 ' HB3' ' A' ' 25' ' ' LYS . 8.1 t -70.15 -43.21 79.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.38 -178.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -127.56 -46.98 1.43 Allowed 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.282 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 35.0 pt -104.11 149.49 37.31 Favored Pre-proline 0 C--N 1.322 -0.618 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.915 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_exo -67.82 152.51 77.31 Favored 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 122.354 2.036 . . . . 0.0 111.581 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.693 ' HB3' ' OE2' ' A' ' 6' ' ' GLU . 74.3 m -64.09 -46.42 84.36 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.257 -179.394 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.41 ' HB ' ' O ' ' A' ' 13' ' ' CYS . 77.2 mt 74.19 -57.07 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 C-N-CA 123.012 0.525 . . . . 0.0 111.521 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.446 ' O ' HG12 ' A' ' 18' ' ' ILE . 0.9 OUTLIER -68.46 -18.2 64.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.261 0.553 . . . . 0.0 110.084 179.351 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.752 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -52.27 -15.21 2.56 Favored Glycine 0 C--N 1.332 0.324 0 CA-C-N 115.107 -0.951 . . . . 0.0 113.887 -179.742 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 31.6 m -58.1 -18.25 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 117.07 0.435 . . . . 0.0 111.18 178.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 15' ' ' SER . 39.2 pt -73.95 -9.96 13.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.821 179.631 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.07 -23.25 2.59 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.681 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.752 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 38.9 m -67.76 121.86 16.87 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.514 0.673 . . . . 0.0 111.047 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.499 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -108.57 140.42 41.94 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.187 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.2 t -65.38 112.63 3.61 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.147 0.499 . . . . 0.0 110.245 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.4 m -127.61 109.4 11.65 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.016 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 21.4 t0 48.26 59.48 4.26 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.774 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.683 ' HB3' HG22 ' A' ' 9' ' ' VAL . 1.7 mptt 69.86 3.0 4.1 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.158 -0.928 . . . . 0.0 113.357 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.492 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 62.4 t -136.28 130.42 47.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 118.516 0.598 . . . . 0.0 110.815 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.621 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 5.6 m -80.2 123.32 27.82 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.502 0.668 . . . . 0.0 112.096 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.478 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 1.9 m-85 -108.42 142.34 38.92 Favored 'General case' 0 CA--C 1.519 -0.238 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.845 179.279 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.602 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.5 tt -89.78 83.48 6.21 Favored 'General case' 0 C--N 1.309 -1.165 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 178.289 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 49.3 m-20 . . . . . 0 C--N 1.326 -0.427 0 CA-C-N 114.649 -1.159 . . . . 0.0 111.12 -178.574 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.858 0 CA-C-O 120.231 -0.205 . . . . 0.0 112.708 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.9 m -96.27 111.5 56.83 Favored Pre-proline 0 C--O 1.221 -0.441 0 CA-C-N 117.325 0.562 . . . . 0.0 111.2 -179.419 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.501 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 89.4 Cg_exo -47.5 127.25 13.37 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.897 2.398 . . . . 0.0 113.109 -179.562 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.599 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 22.9 m -84.72 -7.62 59.15 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.425 -179.739 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.14 -15.99 56.8 Favored Glycine 0 N--CA 1.448 -0.506 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.04 151.52 41.68 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.248 -0.476 . . . . 0.0 110.16 179.401 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.433 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 1.6 p -128.9 150.2 50.46 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 121.84 0.828 . . . . 0.0 112.394 -179.669 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.482 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.7 p -127.18 44.37 2.93 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 114.556 -1.202 . . . . 0.0 109.698 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.805 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.9 t -74.78 -46.41 41.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.485 -179.105 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -101.75 -48.66 4.22 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.089 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.482 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 32.5 pt -132.91 164.96 40.2 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.605 -179.755 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -63.89 153.91 72.96 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.063 1.842 . . . . 0.0 111.684 179.643 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 86.8 m -61.82 139.12 58.38 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.323 -179.173 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 50.2 mm -67.22 122.81 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 115.307 -0.861 . . . . 0.0 109.657 178.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.678 ' O ' HG13 ' A' ' 18' ' ' ILE . 35.8 p 51.91 31.17 8.06 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 115.495 -0.775 . . . . 0.0 112.655 -179.48 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -55.79 -14.24 7.26 Favored Glycine 0 C--N 1.338 0.683 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.805 178.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.7 p -56.63 -17.0 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 C-N-CA 123.147 0.579 . . . . 0.0 111.37 179.039 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.678 HG13 ' O ' ' A' ' 15' ' ' SER . 55.5 mt -55.65 -30.98 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.907 0.861 . . . . 0.0 110.633 178.632 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 150.94 -18.28 0.95 Allowed Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 114.501 -1.227 . . . . 0.0 110.099 -179.639 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.653 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 59.2 m -68.27 120.03 13.76 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.506 0.67 . . . . 0.0 110.734 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.525 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -107.25 139.82 41.1 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.097 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.7 t -66.67 118.4 10.18 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.862 0.363 . . . . 0.0 110.148 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 16.2 m -132.21 106.13 7.76 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.049 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.465 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 30.2 t70 48.98 58.21 5.61 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.625 0.726 . . . . 0.0 112.091 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.805 ' HB3' HG22 ' A' ' 9' ' ' VAL . 6.1 mtmp? 75.09 -5.7 2.11 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 178.408 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.493 HG23 ' HE1' ' A' ' 28' ' ' TYR . 1.9 m -133.2 132.0 58.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.507 0.594 . . . . 0.0 111.402 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.653 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 61.1 m -81.07 129.45 34.56 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -178.654 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.501 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.3 m-85 -110.01 143.72 39.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.761 178.64 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.599 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.4 tp -89.78 81.59 6.36 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 178.398 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 58.3 m-20 . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.969 -178.28 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.656 0 CA-C-O 120.165 -0.241 . . . . 0.0 113.309 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.0 p -100.54 119.08 59.69 Favored Pre-proline 0 C--O 1.222 -0.382 0 CA-C-N 117.5 0.65 . . . . 0.0 111.576 -179.135 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.6 Cg_exo -48.41 134.31 25.91 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 123.121 2.548 . . . . 0.0 112.813 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.599 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 37.1 m -82.53 19.43 1.27 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.513 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 63.75 28.8 73.16 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.235 -0.507 . . . . 0.0 112.877 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.7 tp10 -155.81 153.45 29.81 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-O 120.946 0.403 . . . . 0.0 110.064 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.631 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 44.8 p -100.14 -177.64 3.59 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.542 -0.754 . . . . 0.0 112.235 -178.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.7 p -151.54 45.45 0.79 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.113 179.229 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 10.6 t -65.9 -39.49 84.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.357 -0.838 . . . . 0.0 111.573 -178.785 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -128.32 -47.6 1.32 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.503 179.74 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.463 HD12 ' HD2' ' A' ' 12' ' ' PRO . 5.8 tp -106.92 123.62 37.93 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.416 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.463 ' HD2' HD12 ' A' ' 11' ' ' ILE . 5.6 Cg_exo -73.05 153.42 52.12 Favored 'Trans proline' 0 N--CA 1.456 -0.685 0 C-N-CA 122.407 2.071 . . . . 0.0 111.49 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 86.1 m -67.29 117.04 8.74 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.125 -179.798 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 47.3 mm -62.3 -40.09 86.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.593 -179.796 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.644 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.3 m -76.01 20.19 0.2 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.5 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.736 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -58.28 -21.07 46.44 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 121.508 -0.377 . . . . 0.0 112.898 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.9 m -61.42 -19.72 21.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 112.161 0.43 . . . . 0.0 112.161 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.644 HG12 ' O ' ' A' ' 15' ' ' SER . 23.1 pt -83.25 1.82 3.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.741 0.305 . . . . 0.0 111.31 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.05 -17.03 8.69 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.581 -0.818 . . . . 0.0 112.212 179.835 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.736 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 70.8 m -65.66 124.02 21.27 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.506 0.67 . . . . 0.0 111.373 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.5 m -128.04 142.47 51.21 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.239 -0.891 . . . . 0.0 109.262 179.485 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 46.4 t -73.27 124.76 26.31 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.903 0.382 . . . . 0.0 110.399 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 57.3 m -150.18 123.89 9.19 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.61 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 51.8 t0 51.54 55.16 9.82 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.123 0.487 . . . . 0.0 110.999 -179.237 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.61 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 60.01 5.55 0.78 Allowed 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.074 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.666 HG23 ' HE1' ' A' ' 28' ' ' TYR . 2.7 m -134.6 145.21 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 O-C-N 121.682 -0.637 . . . . 0.0 112.072 178.68 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.9 m -81.37 126.41 31.57 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.101 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.666 ' HE1' HG23 ' A' ' 26' ' ' VAL . 30.0 m-85 -112.43 142.6 44.77 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 177.568 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.599 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.7 tt -104.22 88.79 3.07 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.533 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 31.0 m120 . . . . . 0 C--N 1.326 -0.443 0 CA-C-N 114.959 -1.019 . . . . 0.0 111.356 -178.839 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.809 0 CA-C-O 120.001 -0.333 . . . . 0.0 112.98 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.535 HG23 ' HB3' ' A' ' 29' ' ' LEU . 4.9 t -100.57 119.81 57.7 Favored Pre-proline 0 C--O 1.221 -0.424 0 CA-C-N 117.758 0.779 . . . . 0.0 111.742 -179.158 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -50.22 131.43 31.23 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 123.098 2.532 . . . . 0.0 113.002 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.686 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 8.8 m -90.61 22.71 3.36 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.825 -178.84 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.23 35.69 88.72 Favored Glycine 0 C--N 1.331 0.291 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.105 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.599 ' OE2' HG12 ' A' ' 14' ' ' ILE . 44.7 tt0 -146.1 153.24 40.47 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -179.533 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -135.02 150.19 50.27 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.225 0.536 . . . . 0.0 111.436 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -100.44 51.89 0.88 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.073 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.406 HG12 ' CD1' ' A' ' 10' ' ' TYR . 16.3 t -63.61 -40.08 87.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.424 -179.268 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.406 ' CD1' HG12 ' A' ' 9' ' ' VAL . 40.4 m-85 -142.58 -42.25 0.32 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.772 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 37.2 pt -103.26 152.68 38.71 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.785 -179.487 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo -68.87 154.42 71.04 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.726 2.284 . . . . 0.0 111.62 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 20.6 m -64.26 122.37 16.5 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.554 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.599 HG12 ' OE2' ' A' ' 6' ' ' GLU . 33.4 pt -74.12 -28.14 23.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.14 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.1 p -78.73 2.4 19.82 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.507 179.017 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -56.51 -33.77 62.82 Favored Glycine 0 C--N 1.333 0.394 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.625 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 25.6 t -61.63 -27.31 41.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.394 0.616 . . . . 0.0 110.767 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.4 mm -78.15 -18.71 13.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.521 179.586 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 125.97 -7.97 7.67 Favored Glycine 0 N--CA 1.447 -0.57 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.778 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.513 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 60.4 m -63.68 124.89 22.59 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.377 0.608 . . . . 0.0 110.916 -179.774 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 8.8 m -112.21 147.09 36.93 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.371 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.8 t -75.0 123.53 25.32 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.868 0.366 . . . . 0.0 110.15 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.2 m -145.66 121.85 10.83 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 53.67 44.29 29.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.871 0.843 . . . . 0.0 110.754 -179.224 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.501 ' O ' ' HG2' ' A' ' 25' ' ' LYS . 11.4 ttpp 65.49 10.77 6.88 Favored 'General case' 0 CA--C 1.544 0.723 0 CA-C-N 114.338 -1.301 . . . . 0.0 112.098 179.395 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.402 ' HB ' ' HE1' ' A' ' 28' ' ' TYR . 49.9 t -127.4 138.42 54.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 O-C-N 121.838 -0.539 . . . . 0.0 110.447 179.713 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.8 m -82.02 122.5 27.89 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.771 0.319 . . . . 0.0 111.071 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.446 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 25.2 m-85 -116.75 139.99 49.94 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-O 121.165 0.507 . . . . 0.0 110.862 179.514 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.686 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 55.3 tp -91.59 83.89 5.42 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 177.73 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 57.5 m-20 . . . . . 0 C--N 1.327 -0.391 0 CA-C-N 114.704 -1.135 . . . . 0.0 111.299 -178.497 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.795 0 CA-C-O 120.2 -0.222 . . . . 0.0 113.064 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.434 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 20.4 m -101.21 112.71 65.41 Favored Pre-proline 0 C--O 1.22 -0.489 0 CA-C-N 117.392 0.596 . . . . 0.0 111.041 -179.396 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.596 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 8.5 Cg_endo -49.35 130.32 24.76 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 123.031 2.487 . . . . 0.0 112.626 -179.719 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.654 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 32.4 m -83.26 11.16 6.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.285 -179.167 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 66.1 28.62 73.82 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 121.08 -0.581 . . . . 0.0 112.269 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.627 ' HG3' ' HB2' ' A' ' 27' ' ' CYS . 17.2 pt-20 -134.45 155.08 50.96 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.998 0.428 . . . . 0.0 109.86 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.8 p -124.19 154.28 40.34 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.613 0.72 . . . . 0.0 112.302 -178.683 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -127.25 46.1 2.59 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 114.385 -1.279 . . . . 0.0 109.791 179.654 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.848 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.3 t -70.6 -48.4 58.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.899 -178.662 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.2 m-85 -101.18 -47.92 4.57 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.379 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.5 pt -126.95 154.92 76.37 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.397 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -65.48 154.6 72.97 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.46 2.106 . . . . 0.0 111.885 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.46 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 71.1 m -66.58 128.08 34.85 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.803 -179.314 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 11.5 tt -71.73 126.84 32.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.219 179.481 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.562 ' O ' HG12 ' A' ' 18' ' ' ILE . 21.6 m 67.07 14.58 9.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.648 -0.705 . . . . 0.0 111.844 -179.465 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -56.15 -16.23 13.22 Favored Glycine 0 C--N 1.339 0.706 0 C-N-CA 121.229 -0.51 . . . . 0.0 112.666 179.059 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 16.6 t -56.23 -17.84 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 C-N-CA 122.95 0.5 . . . . 0.0 111.272 179.172 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.562 HG12 ' O ' ' A' ' 15' ' ' SER . 47.2 mm -57.9 -29.16 35.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.613 0.72 . . . . 0.0 111.044 178.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 155.99 -22.85 0.53 Allowed Glycine 0 C--N 1.312 -0.782 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 179.787 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.496 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 60.1 m -67.35 120.49 13.95 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.644 0.735 . . . . 0.0 110.723 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.487 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 17.9 m -110.62 139.97 45.39 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.713 -179.597 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 49.1 t -67.51 109.66 3.32 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.015 0.436 . . . . 0.0 110.08 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.0 m -120.26 103.54 9.32 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.043 -179.563 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.452 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 21.7 t70 47.65 62.05 2.64 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.767 -179.572 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.848 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.6 OUTLIER 70.96 -0.5 3.02 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 115.117 -0.947 . . . . 0.0 113.356 178.71 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 50.1 t -131.89 128.26 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 118.557 0.617 . . . . 0.0 110.54 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.627 ' HB2' ' HG3' ' A' ' 6' ' ' GLU . 54.5 m -81.32 128.4 33.79 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.467 0.651 . . . . 0.0 112.457 -179.532 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.596 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 4.2 m-85 -114.46 144.21 43.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.307 -0.861 . . . . 0.0 109.941 179.258 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.654 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.1 tp -92.4 81.67 4.9 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.505 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 115.057 -0.974 . . . . 0.0 111.516 -179.188 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.725 0 CA-C-O 120.115 -0.269 . . . . 0.0 113.085 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 21.9 m -97.72 112.48 61.6 Favored Pre-proline 0 C--O 1.222 -0.384 0 CA-C-N 117.484 0.642 . . . . 0.0 111.355 -179.245 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.5 Cg_exo -50.4 131.85 33.22 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.843 2.362 . . . . 0.0 112.486 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.601 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 35.5 m -85.15 18.5 2.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.472 -179.201 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.03 33.1 77.74 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.482 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -153.0 151.56 30.41 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.65 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -132.87 146.36 51.74 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.669 0.747 . . . . 0.0 112.097 -179.284 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.483 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 2.1 p -101.37 45.39 0.97 Allowed 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.389 179.549 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.65 HG23 ' HB2' ' A' ' 7' ' ' SER . 16.3 t -70.9 -35.65 60.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.042 -179.491 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -128.93 -50.8 1.22 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.504 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.483 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 2.4 pp -104.95 151.08 39.37 Favored Pre-proline 0 C--N 1.324 -0.529 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.738 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -71.15 150.07 59.13 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.194 1.93 . . . . 0.0 111.609 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 98.5 m -69.37 -39.68 77.9 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.923 -179.272 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 76.1 mt 71.48 -44.91 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 122.764 0.426 . . . . 0.0 111.346 -179.63 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.5 p -71.02 10.46 0.54 Allowed 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 122.88 0.472 . . . . 0.0 111.753 179.274 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.456 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -57.66 -25.7 56.06 Favored Glycine 0 C--O 1.227 -0.292 0 CA-C-N 116.143 -0.48 . . . . 0.0 113.086 179.606 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 29.8 m -61.73 -20.91 24.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.994 0.426 . . . . 0.0 111.889 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 16.9 mt -78.63 -14.13 13.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.599 0.714 . . . . 0.0 110.47 179.647 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.87 -14.75 6.3 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.294 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.505 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 60.0 m -63.05 125.84 25.34 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.26 0.552 . . . . 0.0 110.775 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 17.9 m -129.35 140.56 51.34 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.08 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.0 m -62.62 111.18 1.97 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.384 0.611 . . . . 0.0 111.345 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.8 m -124.43 107.09 10.73 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.585 179.474 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.416 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 45.1 t0 54.4 50.37 16.37 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.817 0.818 . . . . 0.0 110.248 -178.326 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.615 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.1 OUTLIER 72.04 -7.71 1.26 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.698 -1.137 . . . . 0.0 113.105 179.692 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 41.3 t -115.25 132.03 65.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 O-C-N 122.06 -0.4 . . . . 0.0 110.464 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.505 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 39.5 m -78.65 120.37 23.23 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.512 0.672 . . . . 0.0 112.67 -179.11 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.498 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.5 m-85 -110.35 143.71 40.18 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.171 -0.922 . . . . 0.0 109.372 178.429 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.601 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.9 tt -97.98 84.85 3.38 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 178.855 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 33.5 m120 . . . . . 0 C--N 1.326 -0.454 0 CA-C-N 114.898 -1.047 . . . . 0.0 111.196 -179.053 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.874 0 CA-C-O 120.089 -0.284 . . . . 0.0 112.811 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 17.0 p -98.83 113.25 64.29 Favored Pre-proline 0 C--O 1.224 -0.257 0 CA-C-N 117.507 0.653 . . . . 0.0 111.682 -179.051 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.496 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.4 Cg_exo -49.51 128.96 22.01 Favored 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.932 2.422 . . . . 0.0 112.6 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.71 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 12.7 m -88.5 16.49 6.45 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.593 -178.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 58.72 32.57 69.94 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.892 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.584 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 32.8 tt0 -136.24 145.82 46.04 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -179.362 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.667 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -137.48 151.99 49.06 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.031 0.443 . . . . 0.0 111.874 -178.686 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.588 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 29.7 p -109.54 39.54 2.07 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.33 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.69 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.5 t -72.04 -41.58 68.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.173 -179.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 19.5 m-85 -115.1 -47.95 2.84 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.647 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.588 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 34.7 pt -122.16 153.31 61.32 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.064 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -66.27 154.39 74.37 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.296 1.997 . . . . 0.0 111.768 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.584 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 72.3 m -68.04 128.24 35.8 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.287 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 61.8 mt -90.08 -44.35 14.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-O 121.359 0.599 . . . . 0.0 109.409 178.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.57 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.2 m -72.52 -23.66 61.04 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.139 179.267 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 1.01 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -52.62 -19.34 6.34 Favored Glycine 0 CA--C 1.519 0.31 0 CA-C-N 115.322 -0.853 . . . . 0.0 114.185 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 36.0 m -60.45 -18.96 17.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.871 0.336 . . . . 0.0 111.885 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.57 HG12 ' O ' ' A' ' 15' ' ' SER . 33.2 pt -79.79 -1.71 4.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.804 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 130.94 -19.4 4.95 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.403 -0.903 . . . . 0.0 112.14 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 1.01 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 56.2 m -58.58 121.92 12.16 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.301 0.572 . . . . 0.0 111.131 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 15.4 m -105.84 132.86 51.44 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.099 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.609 ' HA ' ' HA ' ' A' ' 27' ' ' CYS . 1.7 t -75.03 108.99 8.13 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.511 0.672 . . . . 0.0 111.176 -178.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.7 m -109.42 118.3 36.29 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.013 -0.994 . . . . 0.0 108.462 178.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 30.9 t70 52.11 52.44 14.35 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 122.065 0.936 . . . . 0.0 110.93 -178.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.69 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.0 OUTLIER 69.76 3.53 4.32 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.779 -1.1 . . . . 0.0 113.533 178.797 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 33.0 t -127.29 124.13 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 118.622 0.646 . . . . 0.0 110.505 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.609 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 7.3 m -75.53 124.87 27.92 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.658 0.742 . . . . 0.0 112.836 -179.193 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.4 m-85 -114.72 144.88 42.75 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.579 179.163 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.71 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 46.1 tp -92.9 81.32 4.63 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 178.519 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.9 m-80 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.449 -179.308 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.805 0 CA-C-O 120.028 -0.318 . . . . 0.0 113.271 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.455 HG23 ' HB3' ' A' ' 29' ' ' LEU . 4.9 t -106.92 118.45 54.1 Favored Pre-proline 0 C--O 1.223 -0.31 0 CA-C-N 117.755 0.778 . . . . 0.0 111.488 -179.178 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.592 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 9.5 Cg_endo -51.39 135.56 46.97 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 123.124 2.55 . . . . 0.0 112.373 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.691 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 6.7 m -93.7 7.65 43.96 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.345 -179.269 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 79.51 -25.97 2.75 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.576 -178.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.725 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 33.2 tt0 -74.06 131.2 41.11 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.565 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -112.56 154.0 26.64 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.49 0.662 . . . . 0.0 111.887 -178.744 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.407 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.7 p -122.24 44.75 2.52 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.872 -1.058 . . . . 0.0 109.688 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.754 HG22 ' HB3' ' A' ' 25' ' ' LYS . 12.9 t -72.43 -44.46 62.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.699 -178.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -112.19 -49.61 2.96 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.022 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 34.4 pt -118.76 155.59 52.45 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.391 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_exo -67.17 153.01 78.77 Favored 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 122.432 2.088 . . . . 0.0 111.753 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.725 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 62.0 m -70.82 130.97 43.07 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.54 -0.755 . . . . 0.0 111.462 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 27.7 pt -88.72 -38.04 10.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.889 0.376 . . . . 0.0 110.529 179.31 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.558 ' O ' HG12 ' A' ' 18' ' ' ILE . 2.8 m -74.77 -18.33 60.5 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.196 0.522 . . . . 0.0 109.895 179.245 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.955 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.08 -18.23 6.06 Favored Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.158 -0.928 . . . . 0.0 113.923 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.4 m -59.47 -19.81 17.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.925 0.393 . . . . 0.0 111.686 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.558 HG12 ' O ' ' A' ' 15' ' ' SER . 33.4 pt -79.04 -4.03 6.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.771 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 133.41 -21.61 4.04 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.994 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.955 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 50.1 m -60.52 122.28 14.25 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.342 0.592 . . . . 0.0 110.699 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.9 m -108.47 141.92 39.62 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.449 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.1 t -64.93 113.06 3.59 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.975 0.416 . . . . 0.0 110.262 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.1 m -122.57 100.27 6.84 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.086 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.45 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 23.0 t70 47.73 63.69 1.91 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.448 -0.796 . . . . 0.0 111.79 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.754 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.8 OUTLIER 72.43 -4.28 2.09 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 115.027 -0.988 . . . . 0.0 113.136 178.844 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.423 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 44.3 t -130.81 127.31 61.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 118.671 0.669 . . . . 0.0 110.718 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.49 ' HA ' ' O ' ' A' ' 21' ' ' SER . 30.6 m -80.71 127.75 32.85 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.539 0.685 . . . . 0.0 112.267 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.592 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.5 m-85 -112.27 144.72 41.2 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.255 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.691 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.8 tp -93.43 83.91 4.63 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 114.871 -1.059 . . . . 0.0 112.004 -179.61 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.792 0 CA-C-O 120.212 -0.215 . . . . 0.0 112.854 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.6 m -96.12 109.9 49.35 Favored Pre-proline 0 C--O 1.223 -0.335 0 CA-C-N 117.342 0.571 . . . . 0.0 111.077 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.512 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 71.1 Cg_exo -48.67 132.45 25.67 Favored 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 122.927 2.418 . . . . 0.0 112.663 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.536 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.3 m -92.34 3.58 55.12 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 121.164 0.507 . . . . 0.0 109.852 -179.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.82 -27.37 3.0 Favored Glycine 0 N--CA 1.448 -0.536 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 -178.253 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.425 ' H ' ' C ' ' A' ' 4' ' ' CYS . 21.9 tt0 -76.96 134.18 38.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 179.508 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.524 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -126.01 146.39 49.91 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.537 0.684 . . . . 0.0 112.18 -178.683 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 5.3 p -109.87 48.1 0.91 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.772 -1.103 . . . . 0.0 110.422 179.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.68 HG22 ' HB3' ' A' ' 25' ' ' LYS . 19.9 t -68.15 -38.21 79.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.699 -179.737 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -115.02 -50.27 2.77 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.661 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.546 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 32.9 pt -121.44 150.81 55.37 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.965 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -62.87 153.64 71.68 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.418 2.078 . . . . 0.0 112.258 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 61.1 m -74.66 131.06 40.59 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.396 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 12.7 tt -79.94 -34.95 15.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.791 178.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.711 ' O ' HG12 ' A' ' 18' ' ' ILE . 16.2 m -77.66 -0.09 25.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.888 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.743 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -56.7 -23.86 45.77 Favored Glycine 0 CA--C 1.519 0.336 0 C-N-CA 121.392 -0.432 . . . . 0.0 112.855 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.4 t -60.08 -26.42 36.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.962 0.41 . . . . 0.0 111.835 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.711 HG12 ' O ' ' A' ' 15' ' ' SER . 18.6 pt -80.9 5.21 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.592 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 120.51 -18.29 9.4 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.157 -1.021 . . . . 0.0 112.921 179.247 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.743 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 46.3 m -63.27 124.86 22.3 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.235 0.541 . . . . 0.0 110.624 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.484 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 12.2 m -119.57 144.46 47.07 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.156 -179.725 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 23.7 m -63.22 112.58 2.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.41 0.624 . . . . 0.0 111.833 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.2 m -120.02 95.67 4.85 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.139 -0.937 . . . . 0.0 108.588 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 48.1 t0 49.84 59.57 4.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.507 -0.769 . . . . 0.0 111.384 -178.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.68 ' HB3' HG22 ' A' ' 9' ' ' VAL . 26.6 mtmm 75.99 -9.79 1.39 Allowed 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.287 -0.869 . . . . 0.0 113.067 178.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.2 t -120.29 127.29 75.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.409 0.549 . . . . 0.0 110.517 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.588 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 69.7 m -80.64 122.74 27.46 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.561 0.696 . . . . 0.0 112.729 -179.089 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.512 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-30 -109.9 142.62 40.98 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.367 178.705 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.536 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.7 tt -89.88 84.52 6.23 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.511 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m120 . . . . . 0 C--N 1.324 -0.521 0 CA-C-N 114.591 -1.186 . . . . 0.0 110.996 -178.654 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.753 0 CA-C-O 120.206 -0.219 . . . . 0.0 112.751 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.2 m -99.28 113.4 64.75 Favored Pre-proline 0 C--O 1.221 -0.418 0 CA-C-N 117.4 0.6 . . . . 0.0 111.214 -179.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.495 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 78.9 Cg_exo -47.46 133.34 20.48 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.986 2.457 . . . . 0.0 112.845 -179.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.6 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 12.7 m -90.91 7.81 38.25 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.094 0.473 . . . . 0.0 110.019 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.27 -27.05 2.84 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 120.921 -0.656 . . . . 0.0 111.713 -178.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 61.3 tt0 -80.31 133.56 35.97 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.109 0.48 . . . . 0.0 109.719 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.653 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -114.03 146.63 39.92 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.611 0.72 . . . . 0.0 112.044 -179.084 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.7 p -105.76 47.09 0.89 Allowed 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.706 -1.133 . . . . 0.0 110.208 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.653 HG23 ' HB2' ' A' ' 7' ' ' SER . 21.2 t -73.77 -42.08 54.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.591 -179.048 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.6 m-85 -111.1 -48.31 3.12 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.304 -179.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.7 pt -129.9 161.41 59.83 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.264 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -66.85 152.11 81.06 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.278 1.986 . . . . 0.0 111.651 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.4 m -74.61 133.94 42.13 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.752 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 15.3 tt -74.41 -34.35 36.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.117 179.003 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.73 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.2 m -73.95 -0.82 17.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.829 179.534 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.65 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.61 -27.13 58.3 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.744 179.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.3 m -62.72 -20.88 26.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.73 HG12 ' O ' ' A' ' 15' ' ' SER . 13.6 pt -87.98 0.69 6.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.821 -0.351 . . . . 0.0 111.456 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 124.89 -18.74 7.04 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.249 -0.977 . . . . 0.0 112.638 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.65 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 61.9 m -60.88 122.88 15.99 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.398 0.618 . . . . 0.0 110.691 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.7 m -113.62 140.78 47.91 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.065 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 48.1 t -66.2 119.34 11.31 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.847 0.356 . . . . 0.0 110.162 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 22.9 m -133.96 107.68 7.95 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.17 -179.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.497 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 44.5 t0 49.06 57.86 6.0 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.507 -0.769 . . . . 0.0 111.921 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.551 ' HG3' ' HA ' ' A' ' 9' ' ' VAL . 0.0 OUTLIER 73.8 -4.45 2.25 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 113.416 0.895 . . . . 0.0 113.416 178.405 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 60.5 t -130.58 131.72 64.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 118.415 0.552 . . . . 0.0 110.749 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.453 ' HA ' ' O ' ' A' ' 21' ' ' SER . 87.5 m -81.28 129.21 34.51 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.297 0.57 . . . . 0.0 112.139 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.495 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.0 m-85 -112.74 142.83 44.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.46 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.6 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.8 tp -89.87 82.27 6.23 Favored 'General case' 0 C--N 1.31 -1.148 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.157 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.8 m120 . . . . . 0 N--CA 1.466 0.331 0 CA-C-N 114.804 -1.089 . . . . 0.0 111.286 -178.372 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.792 0 CA-C-O 120.146 -0.252 . . . . 0.0 113.004 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 17.0 p -99.19 115.35 65.79 Favored Pre-proline 0 C--O 1.223 -0.298 0 CA-C-N 117.499 0.65 . . . . 0.0 111.622 -179.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.455 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 68.9 Cg_exo -51.47 127.89 23.95 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.811 2.341 . . . . 0.0 112.59 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.662 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.4 m -84.09 12.78 5.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.652 -179.003 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.91 29.31 73.78 Favored Glycine 0 C--N 1.332 0.332 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -178.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.498 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 38.0 tt0 -129.63 149.56 51.34 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 114.504 -0.848 . . . . 0.0 109.03 -178.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.47 146.29 44.11 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.361 0.601 . . . . 0.0 111.752 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.554 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 8.6 p -117.89 50.62 1.12 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.488 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.518 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.9 t -68.02 -32.75 57.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.63 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -128.27 -50.67 1.3 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.24 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.554 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 31.5 pt -104.66 143.09 25.99 Favored Pre-proline 0 C--N 1.324 -0.511 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.093 179.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 21.2 Cg_exo -63.45 158.52 44.9 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.64 2.227 . . . . 0.0 112.44 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.498 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 10.9 m -60.72 119.78 8.8 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.904 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 8.6 tp -78.98 -35.34 17.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 178.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.677 ' O ' HG22 ' A' ' 18' ' ' ILE . 25.3 t -82.94 3.49 29.75 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.693 178.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.572 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -56.18 -21.65 33.21 Favored Glycine 0 C--N 1.33 0.222 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.283 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.9 t -59.94 -28.4 40.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.981 0.42 . . . . 0.0 111.538 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.677 HG22 ' O ' ' A' ' 15' ' ' SER . 18.2 tt -78.93 -9.29 12.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 121.224 0.535 . . . . 0.0 111.442 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.67 -18.56 5.67 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.798 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.572 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 61.1 m -55.01 124.55 17.14 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.218 0.533 . . . . 0.0 110.628 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 20.4 m -122.79 150.01 43.38 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.879 -178.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.3 m -64.51 115.32 5.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.339 0.59 . . . . 0.0 111.717 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.6 m -125.44 96.79 4.94 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 179.002 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.451 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 47.8 t0 53.28 54.09 10.77 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.685 -178.169 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.518 ' HB3' HG22 ' A' ' 9' ' ' VAL . 6.9 mtmp? 74.22 -9.82 1.22 Allowed 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 114.977 -1.011 . . . . 0.0 112.752 179.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 t -111.41 130.09 65.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.4 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 23.3 m -78.38 119.74 22.14 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.221 0.534 . . . . 0.0 111.366 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.503 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 2.8 m-85 -110.99 144.53 39.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.391 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.662 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 57.2 tp -96.99 83.12 3.32 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 178.37 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.495 -179.07 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.87 0 CA-C-O 120.155 -0.247 . . . . 0.0 112.909 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 16.8 p -100.58 113.32 65.53 Favored Pre-proline 0 C--O 1.223 -0.301 0 CA-C-N 117.399 0.599 . . . . 0.0 111.636 -179.15 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.5 Cg_exo -49.22 132.12 27.84 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.895 2.397 . . . . 0.0 112.584 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.661 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.4 m -91.53 5.23 50.34 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 121.011 0.434 . . . . 0.0 110.249 -179.329 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.45 -24.76 3.5 Favored Glycine 0 N--CA 1.451 -0.353 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -178.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.671 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 19.7 tt0 -72.3 133.11 44.83 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.5 p -115.32 164.44 14.24 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 121.413 0.625 . . . . 0.0 111.979 -178.66 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.471 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.6 p -139.43 43.77 2.0 Allowed 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.716 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.631 HG22 ' HB3' ' A' ' 25' ' ' LYS . 12.3 t -70.62 -44.62 76.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.054 -179.341 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -128.47 -45.11 1.35 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.818 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.471 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 66.4 mt -103.86 134.39 19.75 Favored Pre-proline 0 C--N 1.321 -0.638 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.027 179.38 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -64.6 152.55 81.38 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.133 1.889 . . . . 0.0 111.775 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.671 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 58.2 m -62.73 -47.29 84.22 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.669 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 78.6 mt 73.41 -55.53 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 122.893 0.477 . . . . 0.0 111.1 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.3 m -67.91 -16.23 63.98 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.3 0.571 . . . . 0.0 110.01 179.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.707 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.17 -16.36 4.47 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.061 -0.972 . . . . 0.0 113.675 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 31.2 m -58.31 -17.67 9.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.107 0.48 . . . . 0.0 111.224 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.4 tp -71.55 -15.99 18.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.145 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 144.96 -23.87 1.94 Allowed Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.707 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 55.5 m -65.67 121.13 14.26 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.445 0.64 . . . . 0.0 110.948 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.9 m -105.87 139.16 40.86 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.522 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 46.5 t -66.03 102.9 0.86 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.246 0.546 . . . . 0.0 110.423 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.2 m -112.46 106.98 15.59 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.072 -179.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 46.9 t0 47.21 59.55 3.99 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.887 -179.635 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.631 ' HB3' HG22 ' A' ' 9' ' ' VAL . 22.2 mtmm 70.68 6.27 5.76 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.246 -0.888 . . . . 0.0 113.317 178.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 45.2 t -137.83 125.93 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 118.236 0.471 . . . . 0.0 110.168 179.442 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.622 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 11.7 m -77.94 122.92 26.15 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.509 0.671 . . . . 0.0 112.292 -179.56 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.529 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.3 m-85 -108.69 144.36 36.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.9 179.296 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.661 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.8 tp -91.8 80.99 5.22 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.3 m-80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.554 -179.183 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.848 0 CA-C-O 120.278 -0.179 . . . . 0.0 112.741 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 23.5 m -98.42 112.89 63.39 Favored Pre-proline 0 C--O 1.22 -0.478 0 CA-C-N 117.327 0.564 . . . . 0.0 111.215 -179.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.481 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.4 Cg_exo -47.82 132.95 22.16 Favored 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 122.997 2.465 . . . . 0.0 112.863 -179.795 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.614 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 9.0 m -91.58 6.73 44.57 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.094 0.473 . . . . 0.0 110.024 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.2 -27.42 2.76 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.507 -178.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.505 ' OE2' ' HB3' ' A' ' 13' ' ' CYS . 16.3 tt0 -77.48 126.88 31.6 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.494 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 0.6 OUTLIER -109.12 151.87 25.85 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.627 0.727 . . . . 0.0 112.062 -178.577 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -114.78 51.06 0.92 Allowed 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.887 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.489 ' HA ' ' HB2' ' A' ' 25' ' ' LYS . 14.5 t -68.87 -44.9 81.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.769 -178.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -109.72 -46.86 3.44 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.218 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 30.7 pt -129.37 157.68 75.48 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.172 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -64.76 152.37 82.3 Favored 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 122.247 1.965 . . . . 0.0 111.616 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.505 ' HB3' ' OE2' ' A' ' 6' ' ' GLU . 27.1 m -71.41 132.73 45.23 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.573 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 12.5 tt -74.7 -36.48 40.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.839 178.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.661 ' O ' HG12 ' A' ' 18' ' ' ILE . 15.3 m -75.81 -3.66 36.31 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.644 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.774 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.47 -22.66 46.12 Favored Glycine 0 C--N 1.331 0.282 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.822 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 13.7 p -61.06 -22.69 27.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.858 0.361 . . . . 0.0 111.831 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.661 HG12 ' O ' ' A' ' 15' ' ' SER . 18.5 pt -80.09 -1.03 4.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 111.839 0.311 . . . . 0.0 111.839 -179.837 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.69 -21.53 5.62 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.275 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.774 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 58.3 m -61.54 121.9 13.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.401 0.62 . . . . 0.0 110.809 -179.787 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -108.83 138.88 44.47 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.258 -179.724 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.7 t -69.63 124.02 22.86 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.849 0.357 . . . . 0.0 110.516 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 48.8 m -148.45 120.07 8.02 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.77 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 6.5 t70 50.99 57.67 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.372 0.606 . . . . 0.0 110.146 -178.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.77 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 54.15 14.68 0.77 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.028 1.331 . . . . 0.0 113.703 -179.709 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 57.6 t -137.07 131.32 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 O-C-N 122.052 -0.405 . . . . 0.0 110.247 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.511 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 73.1 m -82.54 128.02 33.9 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 121.723 -0.611 . . . . 0.0 112.044 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-85 -111.45 142.47 43.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.372 179.653 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.614 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.5 tp -89.59 82.22 6.39 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.345 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.7 m120 . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 114.726 -1.124 . . . . 0.0 111.128 -178.473 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.768 0 CA-C-O 120.008 -0.329 . . . . 0.0 113.306 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.5 t -104.73 118.7 55.75 Favored Pre-proline 0 C--O 1.224 -0.284 0 CA-C-N 117.766 0.783 . . . . 0.0 111.661 -179.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 65.8 Cg_exo -50.77 136.73 42.8 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 123.028 2.485 . . . . 0.0 112.535 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.609 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 10.0 m -93.65 5.42 51.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.072 0.463 . . . . 0.0 110.05 -179.566 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.82 -26.39 3.22 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.789 -178.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 50.9 tt0 -79.01 132.92 36.82 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.559 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -110.55 147.57 33.91 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.602 0.715 . . . . 0.0 112.055 -178.975 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.0 p -110.88 49.12 0.88 Allowed 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.847 -1.07 . . . . 0.0 110.143 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.559 HG23 ' HB2' ' A' ' 7' ' ' SER . 20.7 t -72.08 -42.53 67.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.658 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -110.37 -48.06 3.21 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.932 -0.577 . . . . 0.0 111.357 -179.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.8 pt -130.0 161.81 57.58 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.304 -179.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo -66.2 152.33 81.4 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 122.321 2.014 . . . . 0.0 111.632 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 46.1 m -72.83 137.27 45.62 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.751 -179.069 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 46.4 mm -73.1 -38.57 55.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.223 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.608 ' O ' HG22 ' A' ' 18' ' ' ILE . 2.1 m -73.45 2.42 7.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.188 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.64 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.83 -25.64 56.44 Favored Glycine 0 N--CA 1.453 -0.201 0 C-N-CA 121.252 -0.499 . . . . 0.0 112.791 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.7 m -62.62 -20.96 26.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.608 HG22 ' O ' ' A' ' 15' ' ' SER . 8.7 tp -83.99 -6.35 10.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.25 0.548 . . . . 0.0 111.053 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.55 -18.51 5.72 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.514 -0.851 . . . . 0.0 111.816 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.64 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 60.3 m -59.23 122.04 12.85 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.395 0.617 . . . . 0.0 110.892 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.449 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.7 m -113.86 142.66 45.83 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.096 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.6 t -63.61 114.78 4.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.973 0.416 . . . . 0.0 110.184 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.7 m -121.51 94.48 4.34 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.038 -0.528 . . . . 0.0 109.924 -179.68 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.606 ' C ' ' HE3' ' A' ' 25' ' ' LYS . 38.7 t70 46.37 65.26 1.23 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.131 -0.941 . . . . 0.0 112.07 -179.172 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.606 ' HE3' ' C ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 78.09 -9.85 1.44 Allowed 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 178.028 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.433 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 42.2 t -130.4 128.21 63.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-N 118.496 0.589 . . . . 0.0 110.647 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.471 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 85.7 m -80.72 128.55 33.76 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.366 0.603 . . . . 0.0 112.475 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.522 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-85 -112.94 144.23 42.87 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.636 179.138 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.609 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.5 tt -95.92 85.69 4.14 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.7 m-80 . . . . . 0 C--N 1.327 -0.402 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.927 -179.333 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.876 0 CA-C-O 120.195 -0.225 . . . . 0.0 112.608 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 21.6 m -96.27 112.23 59.12 Favored Pre-proline 0 C--O 1.221 -0.432 0 CA-C-N 117.369 0.585 . . . . 0.0 111.395 -179.296 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 71.5 Cg_exo -49.14 127.29 17.11 Favored 'Trans proline' 0 C--N 1.346 0.44 0 C-N-CA 122.862 2.375 . . . . 0.0 112.787 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.692 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 20.3 m -86.04 14.14 6.67 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.795 -178.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.59 26.46 68.4 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.925 -0.655 . . . . 0.0 111.973 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.722 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 40.6 tt0 -132.35 131.08 41.54 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.664 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -112.0 150.02 31.18 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.586 0.708 . . . . 0.0 112.236 -178.433 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.3 p -112.21 42.64 1.74 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.75 -1.114 . . . . 0.0 109.774 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 1.097 ' HA ' ' HD2' ' A' ' 25' ' ' LYS . 20.8 t -69.07 -63.71 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.847 -178.573 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.0 m-85 -91.53 -49.43 6.32 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.177 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.679 HD13 ' H ' ' A' ' 11' ' ' ILE . 0.2 OUTLIER -121.78 159.29 51.7 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.532 -179.347 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -68.25 153.99 73.23 Favored 'Trans proline' 0 N--CA 1.459 -0.538 0 C-N-CA 122.471 2.114 . . . . 0.0 111.637 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.722 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 58.6 m -69.65 132.64 46.49 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.481 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 7.6 tp -89.99 -39.45 12.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.008 0.432 . . . . 0.0 109.908 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.539 ' O ' HG12 ' A' ' 18' ' ' ILE . 2.5 m -74.12 -24.07 59.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.815 179.074 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.977 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.11 -17.69 5.59 Favored Glycine 0 C--N 1.331 0.298 0 CA-C-N 115.144 -0.934 . . . . 0.0 114.108 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.7 p -58.8 -20.89 17.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.148 0.499 . . . . 0.0 111.356 179.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.539 HG12 ' O ' ' A' ' 15' ' ' SER . 35.5 pt -75.73 -5.21 6.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.03 -0.532 . . . . 0.0 112.32 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 135.43 -18.68 3.89 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.43 -0.89 . . . . 0.0 112.171 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.977 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 33.4 m -60.68 124.2 19.69 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.315 0.579 . . . . 0.0 110.764 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.455 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 6.5 m -104.57 139.69 39.08 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.518 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.6 t -71.37 119.51 15.62 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.12 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 38.4 m -144.45 121.79 11.62 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.7 t0 54.95 46.55 24.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 122.251 1.024 . . . . 0.0 109.98 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 1.097 ' HD2' ' HA ' ' A' ' 9' ' ' VAL . 66.4 mmtt 62.2 14.93 7.07 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 113.905 -1.498 . . . . 0.0 113.487 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 60.5 t -136.09 132.47 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.515 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 34.6 m -82.27 125.69 31.26 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.523 0.677 . . . . 0.0 112.341 -179.648 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.46 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 2.4 m-85 -111.3 142.86 42.97 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.163 179.588 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.692 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 45.3 tp -89.32 81.4 6.66 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 107.999 -1.112 . . . . 0.0 107.999 178.156 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m120 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 114.745 -1.116 . . . . 0.0 111.069 -178.316 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.649 0 CA-C-O 120.199 -0.223 . . . . 0.0 113.199 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.2 m -98.17 113.71 64.27 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 117.392 0.596 . . . . 0.0 111.315 -179.33 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 73.0 Cg_exo -49.19 133.08 29.37 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.861 2.374 . . . . 0.0 112.756 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.554 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 33.3 m -83.15 20.52 1.24 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.35 -179.209 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 61.59 30.21 74.03 Favored Glycine 0 C--O 1.227 -0.341 0 CA-C-N 115.972 -0.558 . . . . 0.0 113.03 179.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -162.75 151.32 14.51 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.143 0.497 . . . . 0.0 110.047 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.556 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 34.9 p -100.6 -174.52 2.66 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.157 -179.683 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.54 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 28.7 p -150.88 41.84 0.77 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.593 0.711 . . . . 0.0 109.572 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.816 HG22 ' HB3' ' A' ' 25' ' ' LYS . 17.4 t -69.12 -40.68 80.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.011 -179.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -104.76 -49.52 3.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.28 -179.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.736 HD13 ' H ' ' A' ' 11' ' ' ILE . 0.2 OUTLIER -112.13 142.76 27.45 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.481 -179.695 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 18.8 Cg_exo -64.7 159.45 45.2 Favored 'Trans proline' 0 C--O 1.234 0.279 0 C-N-CA 122.738 2.292 . . . . 0.0 112.064 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 63.8 m -59.72 110.81 1.23 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.374 -179.627 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 47.8 mm -63.8 -45.37 97.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.196 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.636 ' HB3' HD12 ' A' ' 18' ' ' ILE . 6.2 m -80.1 29.45 0.28 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.296 179.626 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -59.07 -34.99 81.92 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 121.228 -0.51 . . . . 0.0 112.395 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.3 p -63.94 -21.23 28.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.119 0.485 . . . . 0.0 111.181 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.636 HD12 ' HB3' ' A' ' 15' ' ' SER . 8.0 mt -84.43 -11.86 11.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.52 0.676 . . . . 0.0 110.43 179.646 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 121.13 -7.99 10.59 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.78 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.527 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 84.3 m -65.81 123.63 20.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.235 0.541 . . . . 0.0 110.711 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.3 m -129.39 148.7 51.33 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.174 -179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 19.2 m -67.38 105.8 1.9 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.465 0.65 . . . . 0.0 112.008 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.4 m -114.7 100.02 7.95 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.153 -0.931 . . . . 0.0 108.658 178.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.462 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 47.2 t0 52.52 54.07 11.23 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.527 0.68 . . . . 0.0 110.981 -178.685 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.816 ' HB3' HG22 ' A' ' 9' ' ' VAL . 6.9 mtmp? 71.23 -0.33 3.14 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 115.185 -0.916 . . . . 0.0 113.159 179.187 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 25.6 t -120.15 134.39 63.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 118.13 0.423 . . . . 0.0 110.136 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.54 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 78.8 m -76.74 117.4 18.32 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.038 0.447 . . . . 0.0 112.197 -179.056 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.491 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.7 m-85 -112.86 142.41 45.55 Favored 'General case' 0 CA--C 1.513 -0.451 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 177.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.554 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.9 tt -101.38 86.32 2.96 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.057 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 . . . . . 0 C--N 1.325 -0.498 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.161 -178.984 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.64 0 CA-C-O 120.224 -0.209 . . . . 0.0 113.189 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.448 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 22.0 m -98.05 113.07 63.38 Favored Pre-proline 0 C--O 1.221 -0.419 0 CA-C-N 117.407 0.603 . . . . 0.0 110.806 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.567 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 8.8 Cg_endo -49.75 134.08 33.84 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 123.063 2.509 . . . . 0.0 112.49 -179.801 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.524 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 36.6 m -81.54 21.15 0.82 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.16 -179.209 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.88 28.65 72.21 Favored Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.754 -0.657 . . . . 0.0 113.235 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -161.21 152.93 19.37 Favored 'General case' 0 C--O 1.238 0.484 0 CA-C-O 121.414 0.626 . . . . 0.0 110.635 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.582 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 21.0 p -104.44 179.51 4.25 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.14 -0.937 . . . . 0.0 111.29 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.602 ' HB2' ' HA ' ' A' ' 12' ' ' PRO . 18.3 p -151.43 50.57 0.82 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.82 179.164 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.831 HG22 ' HB3' ' A' ' 25' ' ' LYS . 17.6 t -67.45 -42.39 87.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.96 -179.489 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -94.8 -48.72 5.91 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.312 -0.858 . . . . 0.0 111.694 -179.307 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.452 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 23.9 pt -135.18 142.64 42.56 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.73 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.602 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 9.6 Cg_exo -68.68 153.12 73.92 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.985 2.456 . . . . 0.0 112.493 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 97.8 m -67.27 120.77 14.36 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.931 179.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 48.3 mm -61.61 -41.43 90.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.743 -179.751 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.654 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.0 m -76.65 22.07 0.19 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.655 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.611 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -58.83 -21.15 50.83 Favored Glycine 0 C--N 1.33 0.227 0 C-N-CA 121.467 -0.397 . . . . 0.0 112.806 179.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.5 p -60.75 -22.06 25.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.85 0.357 . . . . 0.0 111.718 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.654 HG12 ' O ' ' A' ' 15' ' ' SER . 22.4 pt -80.09 -0.59 4.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 C-N-CA 120.955 -0.298 . . . . 0.0 111.575 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.63 -20.0 7.41 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.2 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.611 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 78.3 m -63.24 124.14 20.45 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.401 0.62 . . . . 0.0 111.248 -179.767 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 17.7 m -129.14 142.03 51.0 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.376 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 23.3 m -71.99 115.77 11.6 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.486 0.66 . . . . 0.0 111.974 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.511 ' HB ' ' CD1' ' A' ' 28' ' ' TYR . 15.7 m -124.4 108.51 12.24 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.515 178.742 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 43.7 t0 47.68 57.15 6.23 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.905 -178.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.831 ' HB3' HG22 ' A' ' 9' ' ' VAL . 20.3 mtmm 68.57 8.65 6.83 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.52 0.933 . . . . 0.0 113.52 178.372 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.582 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 48.6 t -130.04 134.45 62.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 118.611 0.641 . . . . 0.0 110.23 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 97.9 m -81.02 119.42 23.51 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.214 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 37.7 m-85 -114.88 142.77 46.13 Favored 'General case' 0 CA--C 1.516 -0.342 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.524 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.8 tt -101.94 87.22 3.05 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.087 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.0 m-80 . . . . . 0 C--N 1.326 -0.442 0 CA-C-N 114.897 -1.047 . . . . 0.0 111.352 -178.955 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.684 0 CA-C-O 120.234 -0.203 . . . . 0.0 113.142 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.461 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 22.6 m -101.69 114.71 65.56 Favored Pre-proline 0 C--O 1.22 -0.45 0 CA-C-N 117.451 0.625 . . . . 0.0 111.127 -179.352 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.599 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 7.0 Cg_endo -48.75 131.86 25.2 Favored 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 123.111 2.541 . . . . 0.0 112.484 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.692 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 31.0 m -83.6 15.86 2.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.526 -179.058 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 61.45 32.2 80.22 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.004 -0.617 . . . . 0.0 112.034 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.514 ' HG3' ' SG ' ' A' ' 13' ' ' CYS . 3.8 tp10 -143.71 140.29 29.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.074 0.464 . . . . 0.0 110.012 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.617 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 11.6 p -101.3 170.19 8.4 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.455 -0.793 . . . . 0.0 112.257 -178.763 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.0 p -150.32 49.25 0.9 Allowed 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.423 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.733 HG22 ' HB3' ' A' ' 25' ' ' LYS . 12.1 t -68.11 -37.84 78.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.349 -178.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -125.17 -50.0 1.69 Allowed 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.401 179.737 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.41 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 50.0 mm -107.08 131.48 21.66 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.902 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 8.1 Cg_exo -69.29 151.38 71.76 Favored 'Trans proline' 0 N--CA 1.457 -0.642 0 C-N-CA 122.336 2.024 . . . . 0.0 111.66 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.514 ' SG ' ' HG3' ' A' ' 6' ' ' GLU . 9.7 m -69.19 119.4 13.41 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.148 -179.341 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 14.0 tt -64.88 -30.72 51.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.349 0.595 . . . . 0.0 110.496 179.61 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.671 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.4 p -74.76 1.99 11.15 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.529 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.661 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.33 -20.87 38.36 Favored Glycine 0 CA--C 1.518 0.26 0 CA-C-N 116.485 -0.325 . . . . 0.0 113.16 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.8 p -60.46 -23.62 28.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.96 0.41 . . . . 0.0 111.712 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.671 HG12 ' O ' ' A' ' 15' ' ' SER . 23.0 pt -81.06 0.14 3.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.453 -0.339 . . . . 0.0 111.749 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.64 -22.04 7.01 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.216 179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.661 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 83.2 m -59.84 122.6 14.63 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.531 0.681 . . . . 0.0 110.894 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.1 m -114.9 138.23 51.05 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.795 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 47.4 t -69.34 123.89 22.41 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.5 m -137.55 113.69 9.97 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.821 0.343 . . . . 0.0 110.184 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 35.4 t70 46.45 58.32 4.68 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.469 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.733 ' HB3' HG22 ' A' ' 9' ' ' VAL . 26.0 mtmm 72.26 4.82 5.13 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 113.783 1.031 . . . . 0.0 113.783 177.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.617 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 4.3 p -143.02 133.2 22.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 118.768 0.713 . . . . 0.0 111.343 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 93.9 m -80.78 132.16 35.48 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -178.605 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.599 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 3.1 m-85 -117.26 146.4 43.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.952 178.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.692 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 55.9 tp -99.35 84.67 3.03 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 . . . . . 0 C--N 1.327 -0.382 0 CA-C-N 115.186 -0.915 . . . . 0.0 111.602 -179.409 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.754 0 CA-C-O 120.276 -0.18 . . . . 0.0 112.728 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 p -100.74 116.6 63.98 Favored Pre-proline 0 C--O 1.222 -0.376 0 CA-C-N 117.328 0.564 . . . . 0.0 111.289 -179.361 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.501 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 82.1 Cg_exo -45.45 132.62 12.53 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 123.128 2.552 . . . . 0.0 113.084 -179.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.517 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 55.9 m -82.78 19.29 1.36 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.507 -179.237 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.73 30.36 76.69 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.239 -0.505 . . . . 0.0 112.741 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.3 tp10 -156.57 153.13 28.17 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.546 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 47.3 p -102.23 -176.71 3.19 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.506 0.67 . . . . 0.0 111.831 -179.317 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 7.1 p -151.04 41.85 0.75 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.243 179.27 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.826 HG22 ' HB3' ' A' ' 25' ' ' LYS . 13.3 t -69.93 -42.32 79.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.528 -179.016 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -115.0 -47.63 2.86 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.934 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.458 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 32.6 pt -104.59 142.9 25.6 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.82 -179.69 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.458 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 14.6 Cg_exo -67.15 158.69 55.66 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.715 2.277 . . . . 0.0 111.718 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 59.7 m -59.48 106.84 0.5 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.162 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.716 HD13 ' H ' ' A' ' 14' ' ' ILE . 0.2 OUTLIER -62.69 -39.29 84.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.118 0.485 . . . . 0.0 110.529 179.848 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.712 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.0 m -85.57 21.7 1.75 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.571 179.237 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -59.33 -27.2 62.74 Favored Glycine 0 C--N 1.329 0.183 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.415 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.9 p -62.59 -23.63 33.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 120.856 0.36 . . . . 0.0 111.83 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.712 HG12 ' O ' ' A' ' 15' ' ' SER . 16.0 pt -90.53 3.45 6.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 C-N-CA 120.531 -0.468 . . . . 0.0 111.421 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 115.93 -12.87 17.33 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.3 -0.953 . . . . 0.0 113.25 179.181 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.434 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 71.2 m -62.58 123.38 18.21 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.467 0.651 . . . . 0.0 110.962 -179.759 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 9.1 m -117.1 142.33 47.14 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.89 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.5 t -71.91 111.36 7.1 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.069 0.462 . . . . 0.0 109.951 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 m -119.09 103.93 10.0 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.096 -179.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.455 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 19.6 t70 47.23 61.87 2.68 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.817 -179.544 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.826 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.5 OUTLIER 67.86 4.78 4.14 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 115.013 -0.994 . . . . 0.0 113.241 178.834 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.546 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 51.4 t -131.01 130.98 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 118.418 0.554 . . . . 0.0 110.577 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 84.7 m -77.73 125.42 29.32 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.501 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 4.7 m-85 -117.2 143.11 46.22 Favored 'General case' 0 CA--C 1.517 -0.317 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.234 178.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.517 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.7 tp -96.41 83.18 3.49 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.367 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 m120 . . . . . 0 N--CA 1.465 0.309 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.584 -178.586 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.74 0 CA-C-O 120.287 -0.174 . . . . 0.0 112.709 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 19.8 m -94.38 109.63 43.94 Favored Pre-proline 0 C--O 1.22 -0.453 0 CA-C-N 117.157 0.479 . . . . 0.0 111.518 -179.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.502 ' HG3' ' CE2' ' A' ' 28' ' ' TYR . 33.1 Cg_exo -58.16 134.04 59.29 Favored 'Trans proline' 0 CA--C 1.529 0.249 0 C-N-CA 122.532 2.155 . . . . 0.0 112.913 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 6.5 m -79.57 16.74 1.01 Allowed 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.272 179.294 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.9 29.91 75.65 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.101 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -153.59 156.2 37.54 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.315 0.578 . . . . 0.0 110.152 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.561 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 40.2 p -103.14 -174.73 2.62 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.544 -179.185 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 9.2 p -151.12 39.64 0.69 Allowed 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.227 179.312 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.906 HG22 ' HB3' ' A' ' 25' ' ' LYS . 10.9 t -69.99 -36.22 67.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.251 -0.886 . . . . 0.0 111.189 -179.25 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -122.7 -45.93 2.15 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.362 -179.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.412 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 35.0 pt -103.62 147.5 34.33 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.179 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 11.4 Cg_exo -68.64 156.21 66.28 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.715 2.277 . . . . 0.0 111.615 179.672 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 77.7 m -60.64 107.79 0.74 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.783 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 11.3 tt -64.96 -38.83 83.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.15 0.5 . . . . 0.0 109.976 179.22 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.556 ' HB3' HD12 ' A' ' 18' ' ' ILE . 6.0 m -81.62 20.72 0.88 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.024 179.325 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.562 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -60.85 -31.11 74.75 Favored Glycine 0 C--N 1.332 0.329 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.095 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 21.9 t -63.06 -23.95 34.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.324 0.583 . . . . 0.0 110.703 179.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.556 HD12 ' HB3' ' A' ' 15' ' ' SER . 6.5 mt -81.63 -12.33 12.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.413 179.666 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 118.96 -8.54 12.58 Favored Glycine 0 N--CA 1.446 -0.698 0 CA-C-N 115.715 -0.675 . . . . 0.0 112.182 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.562 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 1.8 m -70.21 127.64 33.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.726 0.774 . . . . 0.0 111.722 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 20.1 m -116.63 149.83 39.09 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.649 -1.159 . . . . 0.0 109.715 179.502 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.2 t -69.51 111.7 5.53 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.974 0.416 . . . . 0.0 110.292 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.511 ' HB ' ' CD1' ' A' ' 28' ' ' TYR . 5.9 m -119.59 103.07 9.1 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.005 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 36.2 t70 47.53 58.77 4.63 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.271 -179.502 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.906 ' HB3' HG22 ' A' ' 9' ' ' VAL . 28.4 mtmm 72.07 2.83 4.46 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 178.451 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 42.7 t -130.43 133.1 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 118.563 0.62 . . . . 0.0 110.385 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 83.9 m -80.95 120.41 24.72 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 112.724 0.639 . . . . 0.0 112.724 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.511 ' CD1' ' HB ' ' A' ' 23' ' ' THR . 57.3 m-85 -121.47 139.89 52.89 Favored 'General case' 0 CA--C 1.518 -0.288 0 CA-C-O 121.142 0.496 . . . . 0.0 110.462 178.143 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.505 ' HB2' ' SG ' ' A' ' 20' ' ' CYS . 2.7 tt -94.11 77.89 4.05 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 178.249 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.1 m-80 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.01 -178.804 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.849 0 CA-C-O 120.211 -0.216 . . . . 0.0 112.792 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.6 m -95.83 110.7 52.92 Favored Pre-proline 0 C--O 1.222 -0.363 0 CA-C-N 117.306 0.553 . . . . 0.0 111.087 -179.414 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.1 Cg_exo -49.71 130.38 26.31 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.846 2.364 . . . . 0.0 112.627 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.602 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 4.8 m -92.16 6.69 45.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.312 -179.315 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.05 -27.23 2.73 Favored Glycine 0 N--CA 1.452 -0.286 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -178.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.693 ' OE2' ' HB3' ' A' ' 13' ' ' CYS . 19.7 tt0 -69.8 131.03 43.88 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.556 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.492 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.3 p -115.75 162.79 16.78 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.471 0.653 . . . . 0.0 112.465 -178.137 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.463 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.8 p -136.01 45.45 2.38 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.576 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.683 HG22 ' HB3' ' A' ' 25' ' ' LYS . 8.1 t -70.15 -43.21 79.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.38 -178.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -127.56 -46.98 1.43 Allowed 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.282 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 35.0 pt -104.11 149.49 37.31 Favored Pre-proline 0 C--N 1.322 -0.618 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.915 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_exo -67.82 152.51 77.31 Favored 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 122.354 2.036 . . . . 0.0 111.581 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.693 ' HB3' ' OE2' ' A' ' 6' ' ' GLU . 74.3 m -64.09 -46.42 84.36 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.257 -179.394 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.41 ' HB ' ' O ' ' A' ' 13' ' ' CYS . 77.2 mt 74.19 -57.07 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 C-N-CA 123.012 0.525 . . . . 0.0 111.521 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.446 ' O ' HG12 ' A' ' 18' ' ' ILE . 0.9 OUTLIER -68.46 -18.2 64.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.261 0.553 . . . . 0.0 110.084 179.351 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.752 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -52.27 -15.21 2.56 Favored Glycine 0 C--N 1.332 0.324 0 CA-C-N 115.107 -0.951 . . . . 0.0 113.887 -179.742 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 31.6 m -58.1 -18.25 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 117.07 0.435 . . . . 0.0 111.18 178.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 15' ' ' SER . 39.2 pt -73.95 -9.96 13.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.821 179.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.07 -23.25 2.59 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.681 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.752 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 38.9 m -67.76 121.86 16.87 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.514 0.673 . . . . 0.0 111.047 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.499 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -108.57 140.42 41.94 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.187 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.2 t -65.38 112.63 3.61 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.147 0.499 . . . . 0.0 110.245 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.4 m -127.61 109.4 11.65 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.016 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 21.4 t0 48.26 59.48 4.26 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.774 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.683 ' HB3' HG22 ' A' ' 9' ' ' VAL . 1.7 mptt 69.86 3.0 4.1 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.158 -0.928 . . . . 0.0 113.357 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.492 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 62.4 t -136.28 130.42 47.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 118.516 0.598 . . . . 0.0 110.815 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.621 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 5.6 m -80.2 123.32 27.82 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.502 0.668 . . . . 0.0 112.096 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.478 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 1.9 m-85 -108.42 142.34 38.92 Favored 'General case' 0 CA--C 1.519 -0.238 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.845 179.279 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.602 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.5 tt -89.78 83.48 6.21 Favored 'General case' 0 C--N 1.309 -1.165 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 178.289 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m120 . . . . . 0 C--N 1.326 -0.427 0 CA-C-N 114.649 -1.159 . . . . 0.0 111.12 -178.574 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.858 0 CA-C-O 120.231 -0.205 . . . . 0.0 112.708 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.9 m -96.27 111.5 56.83 Favored Pre-proline 0 C--O 1.221 -0.441 0 CA-C-N 117.325 0.562 . . . . 0.0 111.2 -179.419 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.501 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 89.4 Cg_exo -47.5 127.25 13.37 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.897 2.398 . . . . 0.0 113.109 -179.562 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.599 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 22.9 m -84.72 -7.62 59.15 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.425 -179.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.14 -15.99 56.8 Favored Glycine 0 N--CA 1.448 -0.506 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.04 151.52 41.68 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.248 -0.476 . . . . 0.0 110.16 179.401 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.433 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 1.6 p -128.9 150.2 50.46 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 121.84 0.828 . . . . 0.0 112.394 -179.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.482 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.7 p -127.18 44.37 2.93 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 114.556 -1.202 . . . . 0.0 109.698 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.805 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.9 t -74.78 -46.41 41.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.485 -179.105 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -101.75 -48.66 4.22 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.089 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.482 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 32.5 pt -132.91 164.96 40.2 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.605 -179.755 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -63.89 153.91 72.96 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.063 1.842 . . . . 0.0 111.684 179.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 86.8 m -61.82 139.12 58.38 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.323 -179.173 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 50.2 mm -67.22 122.81 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 115.307 -0.861 . . . . 0.0 109.657 178.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.678 ' O ' HG13 ' A' ' 18' ' ' ILE . 35.8 p 51.91 31.17 8.06 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 115.495 -0.775 . . . . 0.0 112.655 -179.48 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -55.79 -14.24 7.26 Favored Glycine 0 C--N 1.338 0.683 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.805 178.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.7 p -56.63 -17.0 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 C-N-CA 123.147 0.579 . . . . 0.0 111.37 179.039 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.678 HG13 ' O ' ' A' ' 15' ' ' SER . 55.5 mt -55.65 -30.98 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.907 0.861 . . . . 0.0 110.633 178.632 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 150.94 -18.28 0.95 Allowed Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 114.501 -1.227 . . . . 0.0 110.099 -179.639 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.653 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 59.2 m -68.27 120.03 13.76 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.506 0.67 . . . . 0.0 110.734 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.525 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -107.25 139.82 41.1 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.097 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.7 t -66.67 118.4 10.18 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.862 0.363 . . . . 0.0 110.148 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 16.2 m -132.21 106.13 7.76 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.049 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.465 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 30.2 t70 48.98 58.21 5.61 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.625 0.726 . . . . 0.0 112.091 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.805 ' HB3' HG22 ' A' ' 9' ' ' VAL . 6.1 mtmp? 75.09 -5.7 2.11 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 178.408 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.493 HG23 ' HE1' ' A' ' 28' ' ' TYR . 1.9 m -133.2 132.0 58.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.507 0.594 . . . . 0.0 111.402 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.653 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 61.1 m -81.07 129.45 34.56 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -178.654 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.501 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.3 m-85 -110.01 143.72 39.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.761 178.64 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.599 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.4 tp -89.78 81.59 6.36 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 178.398 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.7 m120 . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.969 -178.28 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.656 0 CA-C-O 120.165 -0.241 . . . . 0.0 113.309 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.0 p -100.54 119.08 59.69 Favored Pre-proline 0 C--O 1.222 -0.382 0 CA-C-N 117.5 0.65 . . . . 0.0 111.576 -179.135 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.6 Cg_exo -48.41 134.31 25.91 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 123.121 2.548 . . . . 0.0 112.813 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.599 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 37.1 m -82.53 19.43 1.27 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.513 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 63.75 28.8 73.16 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.235 -0.507 . . . . 0.0 112.877 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.7 tp10 -155.81 153.45 29.81 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-O 120.946 0.403 . . . . 0.0 110.064 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.631 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 44.8 p -100.14 -177.64 3.59 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.542 -0.754 . . . . 0.0 112.235 -178.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.7 p -151.54 45.45 0.79 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.113 179.229 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 10.6 t -65.9 -39.49 84.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.357 -0.838 . . . . 0.0 111.573 -178.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -128.32 -47.6 1.32 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.503 179.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.463 HD12 ' HD2' ' A' ' 12' ' ' PRO . 5.8 tp -106.92 123.62 37.93 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.416 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . 0.463 ' HD2' HD12 ' A' ' 11' ' ' ILE . 5.6 Cg_exo -73.05 153.42 52.12 Favored 'Trans proline' 0 N--CA 1.456 -0.685 0 C-N-CA 122.407 2.071 . . . . 0.0 111.49 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 86.1 m -67.29 117.04 8.74 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.125 -179.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 47.3 mm -62.3 -40.09 86.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.593 -179.796 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.644 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.3 m -76.01 20.19 0.2 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.5 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.736 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -58.28 -21.07 46.44 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 121.508 -0.377 . . . . 0.0 112.898 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.9 m -61.42 -19.72 21.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 112.161 0.43 . . . . 0.0 112.161 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.644 HG12 ' O ' ' A' ' 15' ' ' SER . 23.1 pt -83.25 1.82 3.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.741 0.305 . . . . 0.0 111.31 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.05 -17.03 8.69 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.581 -0.818 . . . . 0.0 112.212 179.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.736 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 70.8 m -65.66 124.02 21.27 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.506 0.67 . . . . 0.0 111.373 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.5 m -128.04 142.47 51.21 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.239 -0.891 . . . . 0.0 109.262 179.485 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 46.4 t -73.27 124.76 26.31 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.903 0.382 . . . . 0.0 110.399 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 57.3 m -150.18 123.89 9.19 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.61 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 51.8 t0 51.54 55.16 9.82 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.123 0.487 . . . . 0.0 110.999 -179.237 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.61 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 60.01 5.55 0.78 Allowed 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.074 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.666 HG23 ' HE1' ' A' ' 28' ' ' TYR . 2.7 m -134.6 145.21 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 O-C-N 121.682 -0.637 . . . . 0.0 112.072 178.68 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.9 m -81.37 126.41 31.57 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.101 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.666 ' HE1' HG23 ' A' ' 26' ' ' VAL . 30.0 m-85 -112.43 142.6 44.77 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 177.568 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.599 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.7 tt -104.22 88.79 3.07 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.533 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 . . . . . 0 C--N 1.326 -0.443 0 CA-C-N 114.959 -1.019 . . . . 0.0 111.356 -178.839 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.809 0 CA-C-O 120.001 -0.333 . . . . 0.0 112.98 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.535 HG23 ' HB3' ' A' ' 29' ' ' LEU . 4.9 t -100.57 119.81 57.7 Favored Pre-proline 0 C--O 1.221 -0.424 0 CA-C-N 117.758 0.779 . . . . 0.0 111.742 -179.158 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -50.22 131.43 31.23 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 123.098 2.532 . . . . 0.0 113.002 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.686 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 8.8 m -90.61 22.71 3.36 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.825 -178.84 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.23 35.69 88.72 Favored Glycine 0 C--N 1.331 0.291 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.105 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.599 ' OE2' HG12 ' A' ' 14' ' ' ILE . 44.7 tt0 -146.1 153.24 40.47 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -179.533 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -135.02 150.19 50.27 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.225 0.536 . . . . 0.0 111.436 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -100.44 51.89 0.88 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.073 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.406 HG12 ' CD1' ' A' ' 10' ' ' TYR . 16.3 t -63.61 -40.08 87.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.424 -179.268 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.406 ' CD1' HG12 ' A' ' 9' ' ' VAL . 40.4 m-85 -142.58 -42.25 0.32 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.772 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 37.2 pt -103.26 152.68 38.71 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.785 -179.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo -68.87 154.42 71.04 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.726 2.284 . . . . 0.0 111.62 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 20.6 m -64.26 122.37 16.5 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.554 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . 0.599 HG12 ' OE2' ' A' ' 6' ' ' GLU . 33.4 pt -74.12 -28.14 23.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.14 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.1 p -78.73 2.4 19.82 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.507 179.017 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -56.51 -33.77 62.82 Favored Glycine 0 C--N 1.333 0.394 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.625 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 25.6 t -61.63 -27.31 41.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.394 0.616 . . . . 0.0 110.767 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.4 mm -78.15 -18.71 13.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.521 179.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 125.97 -7.97 7.67 Favored Glycine 0 N--CA 1.447 -0.57 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.778 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.513 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 60.4 m -63.68 124.89 22.59 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.377 0.608 . . . . 0.0 110.916 -179.774 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 8.8 m -112.21 147.09 36.93 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.371 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.8 t -75.0 123.53 25.32 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.868 0.366 . . . . 0.0 110.15 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.2 m -145.66 121.85 10.83 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 53.67 44.29 29.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.871 0.843 . . . . 0.0 110.754 -179.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.501 ' HG2' ' O ' ' A' ' 25' ' ' LYS . 11.4 ttpp 65.49 10.77 6.88 Favored 'General case' 0 CA--C 1.544 0.723 0 CA-C-N 114.338 -1.301 . . . . 0.0 112.098 179.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.402 ' HB ' ' HE1' ' A' ' 28' ' ' TYR . 49.9 t -127.4 138.42 54.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 O-C-N 121.838 -0.539 . . . . 0.0 110.447 179.713 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.8 m -82.02 122.5 27.89 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.771 0.319 . . . . 0.0 111.071 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.446 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 25.2 m-85 -116.75 139.99 49.94 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-O 121.165 0.507 . . . . 0.0 110.862 179.514 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.686 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 55.3 tp -91.59 83.89 5.42 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 177.73 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.6 m120 . . . . . 0 C--N 1.327 -0.391 0 CA-C-N 114.704 -1.135 . . . . 0.0 111.299 -178.497 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.795 0 CA-C-O 120.2 -0.222 . . . . 0.0 113.064 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.434 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 20.4 m -101.21 112.71 65.41 Favored Pre-proline 0 C--O 1.22 -0.489 0 CA-C-N 117.392 0.596 . . . . 0.0 111.041 -179.396 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.596 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 8.5 Cg_endo -49.35 130.32 24.76 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 123.031 2.487 . . . . 0.0 112.626 -179.719 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.654 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 32.4 m -83.26 11.16 6.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.285 -179.167 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 66.1 28.62 73.82 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 121.08 -0.581 . . . . 0.0 112.269 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.627 ' HG3' ' HB2' ' A' ' 27' ' ' CYS . 17.2 pt-20 -134.45 155.08 50.96 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.998 0.428 . . . . 0.0 109.86 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.8 p -124.19 154.28 40.34 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.613 0.72 . . . . 0.0 112.302 -178.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -127.25 46.1 2.59 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 114.385 -1.279 . . . . 0.0 109.791 179.654 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.848 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.3 t -70.6 -48.4 58.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.899 -178.662 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.2 m-85 -101.18 -47.92 4.57 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.379 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.5 pt -126.95 154.92 76.37 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.397 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -65.48 154.6 72.97 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.46 2.106 . . . . 0.0 111.885 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . 0.46 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 71.1 m -66.58 128.08 34.85 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.803 -179.314 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 11.5 tt -71.73 126.84 32.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.219 179.481 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.562 ' O ' HG12 ' A' ' 18' ' ' ILE . 21.6 m 67.07 14.58 9.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.648 -0.705 . . . . 0.0 111.844 -179.465 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -56.15 -16.23 13.22 Favored Glycine 0 C--N 1.339 0.706 0 C-N-CA 121.229 -0.51 . . . . 0.0 112.666 179.059 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 16.6 t -56.23 -17.84 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 C-N-CA 122.95 0.5 . . . . 0.0 111.272 179.172 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.562 HG12 ' O ' ' A' ' 15' ' ' SER . 47.2 mm -57.9 -29.16 35.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.613 0.72 . . . . 0.0 111.044 178.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 155.99 -22.85 0.53 Allowed Glycine 0 C--N 1.312 -0.782 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 179.787 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.496 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 60.1 m -67.35 120.49 13.95 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.644 0.735 . . . . 0.0 110.723 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.487 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 17.9 m -110.62 139.97 45.39 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.713 -179.597 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 49.1 t -67.51 109.66 3.32 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.015 0.436 . . . . 0.0 110.08 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.0 m -120.26 103.54 9.32 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.043 -179.563 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.452 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 21.7 t70 47.65 62.05 2.64 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.767 -179.572 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.848 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.6 OUTLIER 70.96 -0.5 3.02 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 115.117 -0.947 . . . . 0.0 113.356 178.71 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 50.1 t -131.89 128.26 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 118.557 0.617 . . . . 0.0 110.54 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.627 ' HB2' ' HG3' ' A' ' 6' ' ' GLU . 54.5 m -81.32 128.4 33.79 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.467 0.651 . . . . 0.0 112.457 -179.532 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.596 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 4.2 m-85 -114.46 144.21 43.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.307 -0.861 . . . . 0.0 109.941 179.258 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.654 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.1 tp -92.4 81.67 4.9 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.505 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 115.057 -0.974 . . . . 0.0 111.516 -179.188 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.725 0 CA-C-O 120.115 -0.269 . . . . 0.0 113.085 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 21.9 m -97.72 112.48 61.6 Favored Pre-proline 0 C--O 1.222 -0.384 0 CA-C-N 117.484 0.642 . . . . 0.0 111.355 -179.245 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.5 Cg_exo -50.4 131.85 33.22 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.843 2.362 . . . . 0.0 112.486 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.601 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 35.5 m -85.15 18.5 2.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.472 -179.201 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.03 33.1 77.74 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.482 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -153.0 151.56 30.41 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.65 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -132.87 146.36 51.74 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.669 0.747 . . . . 0.0 112.097 -179.284 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.483 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 2.1 p -101.37 45.39 0.97 Allowed 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.389 179.549 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.65 HG23 ' HB2' ' A' ' 7' ' ' SER . 16.3 t -70.9 -35.65 60.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.042 -179.491 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -128.93 -50.8 1.22 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.504 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.483 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 2.4 pp -104.95 151.08 39.37 Favored Pre-proline 0 C--N 1.324 -0.529 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.738 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -71.15 150.07 59.13 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.194 1.93 . . . . 0.0 111.609 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 98.5 m -69.37 -39.68 77.9 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.923 -179.272 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 76.1 mt 71.48 -44.91 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 122.764 0.426 . . . . 0.0 111.346 -179.63 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.5 p -71.02 10.46 0.54 Allowed 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 122.88 0.472 . . . . 0.0 111.753 179.274 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.456 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -57.66 -25.7 56.06 Favored Glycine 0 C--O 1.227 -0.292 0 CA-C-N 116.143 -0.48 . . . . 0.0 113.086 179.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 29.8 m -61.73 -20.91 24.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.994 0.426 . . . . 0.0 111.889 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 16.9 mt -78.63 -14.13 13.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.599 0.714 . . . . 0.0 110.47 179.647 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.87 -14.75 6.3 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.505 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 60.0 m -63.05 125.84 25.34 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.26 0.552 . . . . 0.0 110.775 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 17.9 m -129.35 140.56 51.34 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.08 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.0 m -62.62 111.18 1.97 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.384 0.611 . . . . 0.0 111.345 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.8 m -124.43 107.09 10.73 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.585 179.474 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.416 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 45.1 t0 54.4 50.37 16.37 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.817 0.818 . . . . 0.0 110.248 -178.326 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.615 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.1 OUTLIER 72.04 -7.71 1.26 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.698 -1.137 . . . . 0.0 113.105 179.692 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 41.3 t -115.25 132.03 65.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 O-C-N 122.06 -0.4 . . . . 0.0 110.464 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.505 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 39.5 m -78.65 120.37 23.23 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.512 0.672 . . . . 0.0 112.67 -179.11 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.498 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.5 m-85 -110.35 143.71 40.18 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.171 -0.922 . . . . 0.0 109.372 178.429 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.601 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.9 tt -97.98 84.85 3.38 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 178.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.1 m-80 . . . . . 0 C--N 1.326 -0.454 0 CA-C-N 114.898 -1.047 . . . . 0.0 111.196 -179.053 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.874 0 CA-C-O 120.089 -0.284 . . . . 0.0 112.811 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 17.0 p -98.83 113.25 64.29 Favored Pre-proline 0 C--O 1.224 -0.257 0 CA-C-N 117.507 0.653 . . . . 0.0 111.682 -179.051 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.496 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.4 Cg_exo -49.51 128.96 22.01 Favored 'Trans proline' 0 C--N 1.347 0.474 0 C-N-CA 122.932 2.422 . . . . 0.0 112.6 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.71 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 12.7 m -88.5 16.49 6.45 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.593 -178.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 58.72 32.57 69.94 Favored Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.892 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.584 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 32.8 tt0 -136.24 145.82 46.04 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -179.362 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.667 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -137.48 151.99 49.06 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.031 0.443 . . . . 0.0 111.874 -178.686 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.588 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 29.7 p -109.54 39.54 2.07 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.33 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.69 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.5 t -72.04 -41.58 68.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.173 -179.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 19.5 m-85 -115.1 -47.95 2.84 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.647 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.588 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 34.7 pt -122.16 153.31 61.32 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.064 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_exo -66.27 154.39 74.37 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.296 1.997 . . . . 0.0 111.768 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.584 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 72.3 m -68.04 128.24 35.8 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.287 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 61.8 mt -90.08 -44.35 14.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-O 121.359 0.599 . . . . 0.0 109.409 178.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.57 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.2 m -72.52 -23.66 61.04 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.139 179.267 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 1.01 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -52.62 -19.34 6.34 Favored Glycine 0 CA--C 1.519 0.31 0 CA-C-N 115.322 -0.853 . . . . 0.0 114.185 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 36.0 m -60.45 -18.96 17.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.871 0.336 . . . . 0.0 111.885 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.57 HG12 ' O ' ' A' ' 15' ' ' SER . 33.2 pt -79.79 -1.71 4.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.804 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 130.94 -19.4 4.95 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.403 -0.903 . . . . 0.0 112.14 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 1.01 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 56.2 m -58.58 121.92 12.16 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.301 0.572 . . . . 0.0 111.131 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 15.4 m -105.84 132.86 51.44 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.099 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.609 ' HA ' ' HA ' ' A' ' 27' ' ' CYS . 1.7 t -75.03 108.99 8.13 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.511 0.672 . . . . 0.0 111.176 -178.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.7 m -109.42 118.3 36.29 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.013 -0.994 . . . . 0.0 108.462 178.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 30.9 t70 52.11 52.44 14.35 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 122.065 0.936 . . . . 0.0 110.93 -178.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.69 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.0 OUTLIER 69.76 3.53 4.32 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.779 -1.1 . . . . 0.0 113.533 178.797 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 33.0 t -127.29 124.13 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 118.622 0.646 . . . . 0.0 110.505 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.609 ' HA ' ' HA ' ' A' ' 22' ' ' CYS . 7.3 m -75.53 124.87 27.92 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.658 0.742 . . . . 0.0 112.836 -179.193 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.4 m-85 -114.72 144.88 42.75 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.579 179.163 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.71 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 46.1 tp -92.9 81.32 4.63 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 178.519 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.9 m-80 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.449 -179.308 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.805 0 CA-C-O 120.028 -0.318 . . . . 0.0 113.271 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.455 HG23 ' HB3' ' A' ' 29' ' ' LEU . 4.9 t -106.92 118.45 54.1 Favored Pre-proline 0 C--O 1.223 -0.31 0 CA-C-N 117.755 0.778 . . . . 0.0 111.488 -179.178 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.592 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 9.5 Cg_endo -51.39 135.56 46.97 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 123.124 2.55 . . . . 0.0 112.373 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.691 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 6.7 m -93.7 7.65 43.96 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.345 -179.269 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 79.51 -25.97 2.75 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.576 -178.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.725 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 33.2 tt0 -74.06 131.2 41.11 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.565 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -112.56 154.0 26.64 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.49 0.662 . . . . 0.0 111.887 -178.744 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.407 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.7 p -122.24 44.75 2.52 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.872 -1.058 . . . . 0.0 109.688 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.754 HG22 ' HB3' ' A' ' 25' ' ' LYS . 12.9 t -72.43 -44.46 62.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.699 -178.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 21.5 m-85 -112.19 -49.61 2.96 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.022 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 34.4 pt -118.76 155.59 52.45 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.391 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_exo -67.17 153.01 78.77 Favored 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 122.432 2.088 . . . . 0.0 111.753 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.725 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 62.0 m -70.82 130.97 43.07 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.54 -0.755 . . . . 0.0 111.462 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 27.7 pt -88.72 -38.04 10.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.889 0.376 . . . . 0.0 110.529 179.31 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.558 ' O ' HG12 ' A' ' 18' ' ' ILE . 2.8 m -74.77 -18.33 60.5 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.196 0.522 . . . . 0.0 109.895 179.245 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.955 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.08 -18.23 6.06 Favored Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.158 -0.928 . . . . 0.0 113.923 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.4 m -59.47 -19.81 17.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.925 0.393 . . . . 0.0 111.686 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.558 HG12 ' O ' ' A' ' 15' ' ' SER . 33.4 pt -79.04 -4.03 6.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.771 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 133.41 -21.61 4.04 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.994 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.955 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 50.1 m -60.52 122.28 14.25 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.342 0.592 . . . . 0.0 110.699 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.9 m -108.47 141.92 39.62 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.449 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.1 t -64.93 113.06 3.59 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.975 0.416 . . . . 0.0 110.262 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.1 m -122.57 100.27 6.84 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.086 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.45 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 23.0 t70 47.73 63.69 1.91 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.448 -0.796 . . . . 0.0 111.79 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.754 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.8 OUTLIER 72.43 -4.28 2.09 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 115.027 -0.988 . . . . 0.0 113.136 178.844 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.423 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 44.3 t -130.81 127.31 61.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 118.671 0.669 . . . . 0.0 110.718 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.49 ' HA ' ' O ' ' A' ' 21' ' ' SER . 30.6 m -80.71 127.75 32.85 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.539 0.685 . . . . 0.0 112.267 -179.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.592 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.5 m-85 -112.27 144.72 41.2 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.255 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.691 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.8 tp -93.43 83.91 4.63 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 114.871 -1.059 . . . . 0.0 112.004 -179.61 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.792 0 CA-C-O 120.212 -0.215 . . . . 0.0 112.854 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.6 m -96.12 109.9 49.35 Favored Pre-proline 0 C--O 1.223 -0.335 0 CA-C-N 117.342 0.571 . . . . 0.0 111.077 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.512 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 71.1 Cg_exo -48.67 132.45 25.67 Favored 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 122.927 2.418 . . . . 0.0 112.663 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.536 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.3 m -92.34 3.58 55.12 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 121.164 0.507 . . . . 0.0 109.852 -179.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.82 -27.37 3.0 Favored Glycine 0 N--CA 1.448 -0.536 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 -178.253 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.425 ' H ' ' C ' ' A' ' 4' ' ' CYS . 21.9 tt0 -76.96 134.18 38.97 Favored 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 179.508 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.524 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -126.01 146.39 49.91 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.537 0.684 . . . . 0.0 112.18 -178.683 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 5.3 p -109.87 48.1 0.91 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.772 -1.103 . . . . 0.0 110.422 179.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.68 HG22 ' HB3' ' A' ' 25' ' ' LYS . 19.9 t -68.15 -38.21 79.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.699 -179.737 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -115.02 -50.27 2.77 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.661 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.546 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 32.9 pt -121.44 150.81 55.37 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.965 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -62.87 153.64 71.68 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.418 2.078 . . . . 0.0 112.258 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 61.1 m -74.66 131.06 40.59 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.396 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 12.7 tt -79.94 -34.95 15.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.791 178.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.711 ' O ' HG12 ' A' ' 18' ' ' ILE . 16.2 m -77.66 -0.09 25.36 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.888 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.743 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -56.7 -23.86 45.77 Favored Glycine 0 CA--C 1.519 0.336 0 C-N-CA 121.392 -0.432 . . . . 0.0 112.855 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.4 t -60.08 -26.42 36.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.962 0.41 . . . . 0.0 111.835 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.711 HG12 ' O ' ' A' ' 15' ' ' SER . 18.6 pt -80.9 5.21 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.592 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 120.51 -18.29 9.4 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.157 -1.021 . . . . 0.0 112.921 179.247 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.743 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 46.3 m -63.27 124.86 22.3 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.235 0.541 . . . . 0.0 110.624 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.484 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 12.2 m -119.57 144.46 47.07 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.156 -179.725 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 23.7 m -63.22 112.58 2.73 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.41 0.624 . . . . 0.0 111.833 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.2 m -120.02 95.67 4.85 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.139 -0.937 . . . . 0.0 108.588 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 48.1 t0 49.84 59.57 4.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.507 -0.769 . . . . 0.0 111.384 -178.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.68 ' HB3' HG22 ' A' ' 9' ' ' VAL . 26.6 mtmm 75.99 -9.79 1.39 Allowed 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.287 -0.869 . . . . 0.0 113.067 178.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.2 t -120.29 127.29 75.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.409 0.549 . . . . 0.0 110.517 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.588 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 69.7 m -80.64 122.74 27.46 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.561 0.696 . . . . 0.0 112.729 -179.089 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.512 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-30 -109.9 142.62 40.98 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.367 178.705 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.536 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.7 tt -89.88 84.52 6.23 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 178.511 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m120 . . . . . 0 C--N 1.324 -0.521 0 CA-C-N 114.591 -1.186 . . . . 0.0 110.996 -178.654 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.753 0 CA-C-O 120.206 -0.219 . . . . 0.0 112.751 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.2 m -99.28 113.4 64.75 Favored Pre-proline 0 C--O 1.221 -0.418 0 CA-C-N 117.4 0.6 . . . . 0.0 111.214 -179.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.495 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 78.9 Cg_exo -47.46 133.34 20.48 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.986 2.457 . . . . 0.0 112.845 -179.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.6 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 12.7 m -90.91 7.81 38.25 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.094 0.473 . . . . 0.0 110.019 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.27 -27.05 2.84 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 120.921 -0.656 . . . . 0.0 111.713 -178.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 61.3 tt0 -80.31 133.56 35.97 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.109 0.48 . . . . 0.0 109.719 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.653 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -114.03 146.63 39.92 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.611 0.72 . . . . 0.0 112.044 -179.084 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.7 p -105.76 47.09 0.89 Allowed 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.706 -1.133 . . . . 0.0 110.208 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.653 HG23 ' HB2' ' A' ' 7' ' ' SER . 21.2 t -73.77 -42.08 54.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.591 -179.048 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.6 m-85 -111.1 -48.31 3.12 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.304 -179.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.7 pt -129.9 161.41 59.83 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.264 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -66.85 152.11 81.06 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.278 1.986 . . . . 0.0 111.651 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 35.4 m -74.61 133.94 42.13 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.752 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 15.3 tt -74.41 -34.35 36.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.117 179.003 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.73 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.2 m -73.95 -0.82 17.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.829 179.534 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.65 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.61 -27.13 58.3 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.744 179.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.3 m -62.72 -20.88 26.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.73 HG12 ' O ' ' A' ' 15' ' ' SER . 13.6 pt -87.98 0.69 6.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 C-N-CA 120.821 -0.351 . . . . 0.0 111.456 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 124.89 -18.74 7.04 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.249 -0.977 . . . . 0.0 112.638 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.65 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 61.9 m -60.88 122.88 15.99 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.398 0.618 . . . . 0.0 110.691 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.7 m -113.62 140.78 47.91 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.065 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 48.1 t -66.2 119.34 11.31 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.847 0.356 . . . . 0.0 110.162 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 22.9 m -133.96 107.68 7.95 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.17 -179.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.497 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 44.5 t0 49.06 57.86 6.0 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.507 -0.769 . . . . 0.0 111.921 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.551 ' HG3' ' HA ' ' A' ' 9' ' ' VAL . 0.0 OUTLIER 73.8 -4.45 2.25 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 113.416 0.895 . . . . 0.0 113.416 178.405 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 60.5 t -130.58 131.72 64.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 118.415 0.552 . . . . 0.0 110.749 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.453 ' HA ' ' O ' ' A' ' 21' ' ' SER . 87.5 m -81.28 129.21 34.51 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.297 0.57 . . . . 0.0 112.139 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.495 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.0 m-85 -112.74 142.83 44.91 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.46 179.607 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.6 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.8 tp -89.87 82.27 6.23 Favored 'General case' 0 C--N 1.31 -1.148 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.157 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.8 m120 . . . . . 0 N--CA 1.466 0.331 0 CA-C-N 114.804 -1.089 . . . . 0.0 111.286 -178.372 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.792 0 CA-C-O 120.146 -0.252 . . . . 0.0 113.004 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 17.0 p -99.19 115.35 65.79 Favored Pre-proline 0 C--O 1.223 -0.298 0 CA-C-N 117.499 0.65 . . . . 0.0 111.622 -179.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.455 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 68.9 Cg_exo -51.47 127.89 23.95 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.811 2.341 . . . . 0.0 112.59 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.662 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.4 m -84.09 12.78 5.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.652 -179.003 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.91 29.31 73.78 Favored Glycine 0 C--N 1.332 0.332 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -178.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.498 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 38.0 tt0 -129.63 149.56 51.34 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 114.504 -0.848 . . . . 0.0 109.03 -178.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.47 146.29 44.11 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.361 0.601 . . . . 0.0 111.752 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.554 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 8.6 p -117.89 50.62 1.12 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.488 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.518 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.9 t -68.02 -32.75 57.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.63 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -128.27 -50.67 1.3 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.24 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.554 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 31.5 pt -104.66 143.09 25.99 Favored Pre-proline 0 C--N 1.324 -0.511 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.093 179.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 21.2 Cg_exo -63.45 158.52 44.9 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.64 2.227 . . . . 0.0 112.44 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.498 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 10.9 m -60.72 119.78 8.8 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.904 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 8.6 tp -78.98 -35.34 17.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 178.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.677 ' O ' HG22 ' A' ' 18' ' ' ILE . 25.3 t -82.94 3.49 29.75 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.693 178.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.572 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -56.18 -21.65 33.21 Favored Glycine 0 C--N 1.33 0.222 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.283 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.9 t -59.94 -28.4 40.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.981 0.42 . . . . 0.0 111.538 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.677 HG22 ' O ' ' A' ' 15' ' ' SER . 18.2 tt -78.93 -9.29 12.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 121.224 0.535 . . . . 0.0 111.442 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.67 -18.56 5.67 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.798 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.572 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 61.1 m -55.01 124.55 17.14 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.218 0.533 . . . . 0.0 110.628 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 20.4 m -122.79 150.01 43.38 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.879 -178.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.3 m -64.51 115.32 5.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.339 0.59 . . . . 0.0 111.717 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.6 m -125.44 96.79 4.94 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 179.002 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.451 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 47.8 t0 53.28 54.09 10.77 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.685 -178.169 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.518 ' HB3' HG22 ' A' ' 9' ' ' VAL . 6.9 mtmp? 74.22 -9.82 1.22 Allowed 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 114.977 -1.011 . . . . 0.0 112.752 179.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 t -111.41 130.09 65.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 C-N-CA 120.856 -0.338 . . . . 0.0 110.4 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 23.3 m -78.38 119.74 22.14 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.221 0.534 . . . . 0.0 111.366 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.503 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 2.8 m-85 -110.99 144.53 39.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.391 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.662 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 57.2 tp -96.99 83.12 3.32 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 178.37 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.495 -179.07 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.87 0 CA-C-O 120.155 -0.247 . . . . 0.0 112.909 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 16.8 p -100.58 113.32 65.53 Favored Pre-proline 0 C--O 1.223 -0.301 0 CA-C-N 117.399 0.599 . . . . 0.0 111.636 -179.15 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.5 Cg_exo -49.22 132.12 27.84 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.895 2.397 . . . . 0.0 112.584 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.661 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 7.4 m -91.53 5.23 50.34 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 121.011 0.434 . . . . 0.0 110.249 -179.329 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.45 -24.76 3.5 Favored Glycine 0 N--CA 1.451 -0.353 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -178.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.671 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 19.7 tt0 -72.3 133.11 44.83 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.5 p -115.32 164.44 14.24 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 121.413 0.625 . . . . 0.0 111.979 -178.66 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.471 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.6 p -139.43 43.77 2.0 Allowed 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.716 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.631 HG22 ' HB3' ' A' ' 25' ' ' LYS . 12.3 t -70.62 -44.62 76.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.054 -179.341 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -128.47 -45.11 1.35 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.818 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.471 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 66.4 mt -103.86 134.39 19.75 Favored Pre-proline 0 C--N 1.321 -0.638 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.027 179.38 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -64.6 152.55 81.38 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 122.133 1.889 . . . . 0.0 111.775 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.671 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 58.2 m -62.73 -47.29 84.22 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.669 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 78.6 mt 73.41 -55.53 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 122.893 0.477 . . . . 0.0 111.1 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.3 m -67.91 -16.23 63.98 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.3 0.571 . . . . 0.0 110.01 179.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.707 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.17 -16.36 4.47 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.061 -0.972 . . . . 0.0 113.675 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 31.2 m -58.31 -17.67 9.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.107 0.48 . . . . 0.0 111.224 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.4 tp -71.55 -15.99 18.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.145 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 144.96 -23.87 1.94 Allowed Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.707 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 55.5 m -65.67 121.13 14.26 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.445 0.64 . . . . 0.0 110.948 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.9 m -105.87 139.16 40.86 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.522 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 46.5 t -66.03 102.9 0.86 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.246 0.546 . . . . 0.0 110.423 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.2 m -112.46 106.98 15.59 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.072 -179.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 46.9 t0 47.21 59.55 3.99 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.887 -179.635 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.631 ' HB3' HG22 ' A' ' 9' ' ' VAL . 22.2 mtmm 70.68 6.27 5.76 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.246 -0.888 . . . . 0.0 113.317 178.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.445 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 45.2 t -137.83 125.93 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 118.236 0.471 . . . . 0.0 110.168 179.442 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.622 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 11.7 m -77.94 122.92 26.15 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.509 0.671 . . . . 0.0 112.292 -179.56 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.529 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.3 m-85 -108.69 144.36 36.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.9 179.296 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.661 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.8 tp -91.8 80.99 5.22 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.3 m-80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.554 -179.183 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.848 0 CA-C-O 120.278 -0.179 . . . . 0.0 112.741 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 23.5 m -98.42 112.89 63.39 Favored Pre-proline 0 C--O 1.22 -0.478 0 CA-C-N 117.327 0.564 . . . . 0.0 111.215 -179.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.481 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 74.4 Cg_exo -47.82 132.95 22.16 Favored 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 122.997 2.465 . . . . 0.0 112.863 -179.795 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.614 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 9.0 m -91.58 6.73 44.57 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.094 0.473 . . . . 0.0 110.024 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.2 -27.42 2.76 Favored Glycine 0 N--CA 1.447 -0.595 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.507 -178.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.505 ' OE2' ' HB3' ' A' ' 13' ' ' CYS . 16.3 tt0 -77.48 126.88 31.6 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.494 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 0.6 OUTLIER -109.12 151.87 25.85 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.627 0.727 . . . . 0.0 112.062 -178.577 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -114.78 51.06 0.92 Allowed 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.887 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.489 ' HA ' ' HB2' ' A' ' 25' ' ' LYS . 14.5 t -68.87 -44.9 81.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.769 -178.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -109.72 -46.86 3.44 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.218 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 30.7 pt -129.37 157.68 75.48 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.172 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_exo -64.76 152.37 82.3 Favored 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 122.247 1.965 . . . . 0.0 111.616 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.505 ' HB3' ' OE2' ' A' ' 6' ' ' GLU . 27.1 m -71.41 132.73 45.23 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.573 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 12.5 tt -74.7 -36.48 40.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.839 178.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.661 ' O ' HG12 ' A' ' 18' ' ' ILE . 15.3 m -75.81 -3.66 36.31 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.644 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.774 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.47 -22.66 46.12 Favored Glycine 0 C--N 1.331 0.282 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.822 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 13.7 p -61.06 -22.69 27.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.858 0.361 . . . . 0.0 111.831 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.661 HG12 ' O ' ' A' ' 15' ' ' SER . 18.5 pt -80.09 -1.03 4.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 111.839 0.311 . . . . 0.0 111.839 -179.837 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.69 -21.53 5.62 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.337 -0.935 . . . . 0.0 112.275 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.774 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 58.3 m -61.54 121.9 13.89 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.401 0.62 . . . . 0.0 110.809 -179.787 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -108.83 138.88 44.47 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.258 -179.724 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.7 t -69.63 124.02 22.86 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.849 0.357 . . . . 0.0 110.516 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 48.8 m -148.45 120.07 8.02 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.77 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 6.5 t70 50.99 57.67 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.372 0.606 . . . . 0.0 110.146 -178.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.77 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 54.15 14.68 0.77 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.028 1.331 . . . . 0.0 113.703 -179.709 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 57.6 t -137.07 131.32 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 O-C-N 122.052 -0.405 . . . . 0.0 110.247 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.511 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 73.1 m -82.54 128.02 33.9 Favored 'General case' 0 C--N 1.324 -0.512 0 O-C-N 121.723 -0.611 . . . . 0.0 112.044 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-85 -111.45 142.47 43.67 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.372 179.653 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.614 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.5 tp -89.59 82.22 6.39 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.345 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.7 m120 . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 114.726 -1.124 . . . . 0.0 111.128 -178.473 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.768 0 CA-C-O 120.008 -0.329 . . . . 0.0 113.306 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.5 t -104.73 118.7 55.75 Favored Pre-proline 0 C--O 1.224 -0.284 0 CA-C-N 117.766 0.783 . . . . 0.0 111.661 -179.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 65.8 Cg_exo -50.77 136.73 42.8 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 123.028 2.485 . . . . 0.0 112.535 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.609 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 10.0 m -93.65 5.42 51.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.072 0.463 . . . . 0.0 110.05 -179.566 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.82 -26.39 3.22 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.789 -178.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 50.9 tt0 -79.01 132.92 36.82 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.559 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.5 OUTLIER -110.55 147.57 33.91 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 121.602 0.715 . . . . 0.0 112.055 -178.975 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.0 p -110.88 49.12 0.88 Allowed 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.847 -1.07 . . . . 0.0 110.143 179.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.559 HG23 ' HB2' ' A' ' 7' ' ' SER . 20.7 t -72.08 -42.53 67.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.658 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 15.4 m-85 -110.37 -48.06 3.21 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.932 -0.577 . . . . 0.0 111.357 -179.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.8 pt -130.0 161.81 57.58 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.304 -179.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo -66.2 152.33 81.4 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 122.321 2.014 . . . . 0.0 111.632 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 46.1 m -72.83 137.27 45.62 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.751 -179.069 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 46.4 mm -73.1 -38.57 55.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.223 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.608 ' O ' HG22 ' A' ' 18' ' ' ILE . 2.1 m -73.45 2.42 7.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.188 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.64 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.83 -25.64 56.44 Favored Glycine 0 N--CA 1.453 -0.201 0 C-N-CA 121.252 -0.499 . . . . 0.0 112.791 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.7 m -62.62 -20.96 26.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.608 HG22 ' O ' ' A' ' 15' ' ' SER . 8.7 tp -83.99 -6.35 10.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.25 0.548 . . . . 0.0 111.053 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.55 -18.51 5.72 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.514 -0.851 . . . . 0.0 111.816 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.64 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 60.3 m -59.23 122.04 12.85 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.395 0.617 . . . . 0.0 110.892 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.449 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 16.7 m -113.86 142.66 45.83 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.096 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 43.6 t -63.61 114.78 4.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.973 0.416 . . . . 0.0 110.184 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.7 m -121.51 94.48 4.34 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.038 -0.528 . . . . 0.0 109.924 -179.68 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.606 ' C ' ' HE3' ' A' ' 25' ' ' LYS . 38.7 t70 46.37 65.26 1.23 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.131 -0.941 . . . . 0.0 112.07 -179.172 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.606 ' HE3' ' C ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 78.09 -9.85 1.44 Allowed 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 178.028 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.433 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 42.2 t -130.4 128.21 63.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-N 118.496 0.589 . . . . 0.0 110.647 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.471 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 85.7 m -80.72 128.55 33.76 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.366 0.603 . . . . 0.0 112.475 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.522 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.1 m-85 -112.94 144.23 42.87 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.636 179.138 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.609 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.5 tt -95.92 85.69 4.14 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.7 m-80 . . . . . 0 C--N 1.327 -0.402 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.927 -179.333 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.876 0 CA-C-O 120.195 -0.225 . . . . 0.0 112.608 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 21.6 m -96.27 112.23 59.12 Favored Pre-proline 0 C--O 1.221 -0.432 0 CA-C-N 117.369 0.585 . . . . 0.0 111.395 -179.296 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 71.5 Cg_exo -49.14 127.29 17.11 Favored 'Trans proline' 0 C--N 1.346 0.44 0 C-N-CA 122.862 2.375 . . . . 0.0 112.787 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.692 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 20.3 m -86.04 14.14 6.67 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.795 -178.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.59 26.46 68.4 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.925 -0.655 . . . . 0.0 111.973 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.722 ' OE1' ' HB3' ' A' ' 13' ' ' CYS . 40.6 tt0 -132.35 131.08 41.54 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.664 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -112.0 150.02 31.18 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.586 0.708 . . . . 0.0 112.236 -178.433 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.3 p -112.21 42.64 1.74 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 114.75 -1.114 . . . . 0.0 109.774 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 1.097 ' HA ' ' HD2' ' A' ' 25' ' ' LYS . 20.8 t -69.07 -63.71 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.847 -178.573 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.0 m-85 -91.53 -49.43 6.32 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.177 -179.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.679 HD13 ' H ' ' A' ' 11' ' ' ILE . 0.2 OUTLIER -121.78 159.29 51.7 Favored Pre-proline 0 C--N 1.323 -0.579 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.532 -179.347 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -68.25 153.99 73.23 Favored 'Trans proline' 0 N--CA 1.459 -0.538 0 C-N-CA 122.471 2.114 . . . . 0.0 111.637 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.722 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 58.6 m -69.65 132.64 46.49 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.481 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 7.6 tp -89.99 -39.45 12.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.008 0.432 . . . . 0.0 109.908 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.539 ' O ' HG12 ' A' ' 18' ' ' ILE . 2.5 m -74.12 -24.07 59.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.815 179.074 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.977 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -53.11 -17.69 5.59 Favored Glycine 0 C--N 1.331 0.298 0 CA-C-N 115.144 -0.934 . . . . 0.0 114.108 -179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.7 p -58.8 -20.89 17.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.148 0.499 . . . . 0.0 111.356 179.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.539 HG12 ' O ' ' A' ' 15' ' ' SER . 35.5 pt -75.73 -5.21 6.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.03 -0.532 . . . . 0.0 112.32 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 135.43 -18.68 3.89 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.43 -0.89 . . . . 0.0 112.171 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.977 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 33.4 m -60.68 124.2 19.69 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.315 0.579 . . . . 0.0 110.764 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.455 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 6.5 m -104.57 139.69 39.08 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.518 -179.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.6 t -71.37 119.51 15.62 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.12 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 38.4 m -144.45 121.79 11.62 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.7 t0 54.95 46.55 24.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 122.251 1.024 . . . . 0.0 109.98 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 1.097 ' HD2' ' HA ' ' A' ' 9' ' ' VAL . 66.4 mmtt 62.2 14.93 7.07 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 113.905 -1.498 . . . . 0.0 113.487 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 60.5 t -136.09 132.47 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.515 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 34.6 m -82.27 125.69 31.26 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.523 0.677 . . . . 0.0 112.341 -179.648 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.46 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 2.4 m-85 -111.3 142.86 42.97 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.163 179.588 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.692 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 45.3 tp -89.32 81.4 6.66 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 107.999 -1.112 . . . . 0.0 107.999 178.156 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m120 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 114.745 -1.116 . . . . 0.0 111.069 -178.316 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.649 0 CA-C-O 120.199 -0.223 . . . . 0.0 113.199 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.2 m -98.17 113.71 64.27 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 117.392 0.596 . . . . 0.0 111.315 -179.33 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 73.0 Cg_exo -49.19 133.08 29.37 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.861 2.374 . . . . 0.0 112.756 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.554 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 33.3 m -83.15 20.52 1.24 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.35 -179.209 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 61.59 30.21 74.03 Favored Glycine 0 C--O 1.227 -0.341 0 CA-C-N 115.972 -0.558 . . . . 0.0 113.03 179.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -162.75 151.32 14.51 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.143 0.497 . . . . 0.0 110.047 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.556 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 34.9 p -100.6 -174.52 2.66 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.157 -179.683 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.54 ' HB3' ' SG ' ' A' ' 27' ' ' CYS . 28.7 p -150.88 41.84 0.77 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.593 0.711 . . . . 0.0 109.572 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.816 HG22 ' HB3' ' A' ' 25' ' ' LYS . 17.4 t -69.12 -40.68 80.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.011 -179.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -104.76 -49.52 3.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.28 -179.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.736 HD13 ' H ' ' A' ' 11' ' ' ILE . 0.2 OUTLIER -112.13 142.76 27.45 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.481 -179.695 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 18.8 Cg_exo -64.7 159.45 45.2 Favored 'Trans proline' 0 C--O 1.234 0.279 0 C-N-CA 122.738 2.292 . . . . 0.0 112.064 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 63.8 m -59.72 110.81 1.23 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.374 -179.627 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 47.8 mm -63.8 -45.37 97.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.196 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.636 ' HB3' HD12 ' A' ' 18' ' ' ILE . 6.2 m -80.1 29.45 0.28 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.296 179.626 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -59.07 -34.99 81.92 Favored Glycine 0 C--N 1.331 0.261 0 C-N-CA 121.228 -0.51 . . . . 0.0 112.395 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.3 p -63.94 -21.23 28.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.119 0.485 . . . . 0.0 111.181 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.636 HD12 ' HB3' ' A' ' 15' ' ' SER . 8.0 mt -84.43 -11.86 11.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.52 0.676 . . . . 0.0 110.43 179.646 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 121.13 -7.99 10.59 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.78 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.527 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 84.3 m -65.81 123.63 20.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.235 0.541 . . . . 0.0 110.711 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.3 m -129.39 148.7 51.33 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.174 -179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 19.2 m -67.38 105.8 1.9 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.465 0.65 . . . . 0.0 112.008 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 8.4 m -114.7 100.02 7.95 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.153 -0.931 . . . . 0.0 108.658 178.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.462 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 47.2 t0 52.52 54.07 11.23 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.527 0.68 . . . . 0.0 110.981 -178.685 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.816 ' HB3' HG22 ' A' ' 9' ' ' VAL . 6.9 mtmp? 71.23 -0.33 3.14 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 115.185 -0.916 . . . . 0.0 113.159 179.187 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 25.6 t -120.15 134.39 63.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 118.13 0.423 . . . . 0.0 110.136 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.54 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 78.8 m -76.74 117.4 18.32 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.038 0.447 . . . . 0.0 112.197 -179.056 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.491 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.7 m-85 -112.86 142.41 45.55 Favored 'General case' 0 CA--C 1.513 -0.451 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 177.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.554 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.9 tt -101.38 86.32 2.96 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.057 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 . . . . . 0 C--N 1.325 -0.498 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.161 -178.984 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.64 0 CA-C-O 120.224 -0.209 . . . . 0.0 113.189 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.448 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 22.0 m -98.05 113.07 63.38 Favored Pre-proline 0 C--O 1.221 -0.419 0 CA-C-N 117.407 0.603 . . . . 0.0 110.806 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.567 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 8.8 Cg_endo -49.75 134.08 33.84 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 123.063 2.509 . . . . 0.0 112.49 -179.801 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.524 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 36.6 m -81.54 21.15 0.82 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.16 -179.209 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.88 28.65 72.21 Favored Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.754 -0.657 . . . . 0.0 113.235 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -161.21 152.93 19.37 Favored 'General case' 0 C--O 1.238 0.484 0 CA-C-O 121.414 0.626 . . . . 0.0 110.635 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.582 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 21.0 p -104.44 179.51 4.25 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.14 -0.937 . . . . 0.0 111.29 -179.714 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.602 ' HB2' ' HA ' ' A' ' 12' ' ' PRO . 18.3 p -151.43 50.57 0.82 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.82 179.164 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.831 HG22 ' HB3' ' A' ' 25' ' ' LYS . 17.6 t -67.45 -42.39 87.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.96 -179.489 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -94.8 -48.72 5.91 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.312 -0.858 . . . . 0.0 111.694 -179.307 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.452 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 23.9 pt -135.18 142.64 42.56 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.73 -179.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.602 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 9.6 Cg_exo -68.68 153.12 73.92 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.985 2.456 . . . . 0.0 112.493 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 97.8 m -67.27 120.77 14.36 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.931 179.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 48.3 mm -61.61 -41.43 90.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.743 -179.751 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.654 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.0 m -76.65 22.07 0.19 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.655 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.611 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -58.83 -21.15 50.83 Favored Glycine 0 C--N 1.33 0.227 0 C-N-CA 121.467 -0.397 . . . . 0.0 112.806 179.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.5 p -60.75 -22.06 25.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.85 0.357 . . . . 0.0 111.718 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.654 HG12 ' O ' ' A' ' 15' ' ' SER . 22.4 pt -80.09 -0.59 4.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 C-N-CA 120.955 -0.298 . . . . 0.0 111.575 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.63 -20.0 7.41 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.2 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.611 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 78.3 m -63.24 124.14 20.45 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.401 0.62 . . . . 0.0 111.248 -179.767 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 17.7 m -129.14 142.03 51.0 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.376 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 23.3 m -71.99 115.77 11.6 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.486 0.66 . . . . 0.0 111.974 -179.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.511 ' HB ' ' CD1' ' A' ' 28' ' ' TYR . 15.7 m -124.4 108.51 12.24 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.515 178.742 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 43.7 t0 47.68 57.15 6.23 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.905 -178.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.831 ' HB3' HG22 ' A' ' 9' ' ' VAL . 20.3 mtmm 68.57 8.65 6.83 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.52 0.933 . . . . 0.0 113.52 178.372 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.582 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 48.6 t -130.04 134.45 62.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 118.611 0.641 . . . . 0.0 110.23 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 97.9 m -81.02 119.42 23.51 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.214 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 37.7 m-85 -114.88 142.77 46.13 Favored 'General case' 0 CA--C 1.516 -0.342 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.524 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.8 tt -101.94 87.22 3.05 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.087 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.0 m-80 . . . . . 0 C--N 1.326 -0.442 0 CA-C-N 114.897 -1.047 . . . . 0.0 111.352 -178.955 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.684 0 CA-C-O 120.234 -0.203 . . . . 0.0 113.142 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.461 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 22.6 m -101.69 114.71 65.56 Favored Pre-proline 0 C--O 1.22 -0.45 0 CA-C-N 117.451 0.625 . . . . 0.0 111.127 -179.352 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.599 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 7.0 Cg_endo -48.75 131.86 25.2 Favored 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 123.111 2.541 . . . . 0.0 112.484 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.692 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 31.0 m -83.6 15.86 2.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.526 -179.058 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 61.45 32.2 80.22 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.004 -0.617 . . . . 0.0 112.034 -179.74 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.514 ' HG3' ' SG ' ' A' ' 13' ' ' CYS . 3.8 tp10 -143.71 140.29 29.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.074 0.464 . . . . 0.0 110.012 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.617 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 11.6 p -101.3 170.19 8.4 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.455 -0.793 . . . . 0.0 112.257 -178.763 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.0 p -150.32 49.25 0.9 Allowed 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.423 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.733 HG22 ' HB3' ' A' ' 25' ' ' LYS . 12.1 t -68.11 -37.84 78.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.349 -178.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -125.17 -50.0 1.69 Allowed 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.401 179.737 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.41 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 50.0 mm -107.08 131.48 21.66 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.902 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 8.1 Cg_exo -69.29 151.38 71.76 Favored 'Trans proline' 0 N--CA 1.457 -0.642 0 C-N-CA 122.336 2.024 . . . . 0.0 111.66 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.514 ' SG ' ' HG3' ' A' ' 6' ' ' GLU . 9.7 m -69.19 119.4 13.41 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.148 -179.341 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 14.0 tt -64.88 -30.72 51.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.349 0.595 . . . . 0.0 110.496 179.61 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.671 ' O ' HG12 ' A' ' 18' ' ' ILE . 3.4 p -74.76 1.99 11.15 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.529 179.469 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.661 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -57.33 -20.87 38.36 Favored Glycine 0 CA--C 1.518 0.26 0 CA-C-N 116.485 -0.325 . . . . 0.0 113.16 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.8 p -60.46 -23.62 28.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.96 0.41 . . . . 0.0 111.712 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.671 HG12 ' O ' ' A' ' 15' ' ' SER . 23.0 pt -81.06 0.14 3.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.453 -0.339 . . . . 0.0 111.749 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.64 -22.04 7.01 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.216 179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.661 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 83.2 m -59.84 122.6 14.63 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.531 0.681 . . . . 0.0 110.894 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.1 m -114.9 138.23 51.05 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.795 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 47.4 t -69.34 123.89 22.41 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.5 m -137.55 113.69 9.97 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.821 0.343 . . . . 0.0 110.184 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 35.4 t70 46.45 58.32 4.68 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.469 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.733 ' HB3' HG22 ' A' ' 9' ' ' VAL . 26.0 mtmm 72.26 4.82 5.13 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 113.783 1.031 . . . . 0.0 113.783 177.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.617 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 4.3 p -143.02 133.2 22.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 118.768 0.713 . . . . 0.0 111.343 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 93.9 m -80.78 132.16 35.48 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -178.605 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.599 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 3.1 m-85 -117.26 146.4 43.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.952 178.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.692 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 55.9 tp -99.35 84.67 3.03 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 178.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 . . . . . 0 C--N 1.327 -0.382 0 CA-C-N 115.186 -0.915 . . . . 0.0 111.602 -179.409 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.754 0 CA-C-O 120.276 -0.18 . . . . 0.0 112.728 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 p -100.74 116.6 63.98 Favored Pre-proline 0 C--O 1.222 -0.376 0 CA-C-N 117.328 0.564 . . . . 0.0 111.289 -179.361 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.501 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 82.1 Cg_exo -45.45 132.62 12.53 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 123.128 2.552 . . . . 0.0 113.084 -179.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.517 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 55.9 m -82.78 19.29 1.36 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.507 -179.237 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.73 30.36 76.69 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.239 -0.505 . . . . 0.0 112.741 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 12.3 tp10 -156.57 153.13 28.17 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.546 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 47.3 p -102.23 -176.71 3.19 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.506 0.67 . . . . 0.0 111.831 -179.317 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 7.1 p -151.04 41.85 0.75 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.243 179.27 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.826 HG22 ' HB3' ' A' ' 25' ' ' LYS . 13.3 t -69.93 -42.32 79.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.528 -179.016 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -115.0 -47.63 2.86 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.934 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.458 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 32.6 pt -104.59 142.9 25.6 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.82 -179.69 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.458 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 14.6 Cg_exo -67.15 158.69 55.66 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.715 2.277 . . . . 0.0 111.718 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 59.7 m -59.48 106.84 0.5 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.162 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.716 HD13 ' H ' ' A' ' 14' ' ' ILE . 0.2 OUTLIER -62.69 -39.29 84.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.118 0.485 . . . . 0.0 110.529 179.848 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.712 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.0 m -85.57 21.7 1.75 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.571 179.237 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -59.33 -27.2 62.74 Favored Glycine 0 C--N 1.329 0.183 0 C-N-CA 121.13 -0.557 . . . . 0.0 112.415 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.9 p -62.59 -23.63 33.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 120.856 0.36 . . . . 0.0 111.83 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.712 HG12 ' O ' ' A' ' 15' ' ' SER . 16.0 pt -90.53 3.45 6.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 C-N-CA 120.531 -0.468 . . . . 0.0 111.421 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 115.93 -12.87 17.33 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.3 -0.953 . . . . 0.0 113.25 179.181 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.434 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 71.2 m -62.58 123.38 18.21 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.467 0.651 . . . . 0.0 110.962 -179.759 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 9.1 m -117.1 142.33 47.14 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.89 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 40.5 t -71.91 111.36 7.1 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.069 0.462 . . . . 0.0 109.951 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 m -119.09 103.93 10.0 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.096 -179.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.455 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 19.6 t70 47.23 61.87 2.68 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.817 -179.544 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.826 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.5 OUTLIER 67.86 4.78 4.14 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 115.013 -0.994 . . . . 0.0 113.241 178.834 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.546 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 51.4 t -131.01 130.98 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 118.418 0.554 . . . . 0.0 110.577 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 84.7 m -77.73 125.42 29.32 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.501 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 4.7 m-85 -117.2 143.11 46.22 Favored 'General case' 0 CA--C 1.517 -0.317 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.234 178.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.517 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.7 tp -96.41 83.18 3.49 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 178.367 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 4.0 m120 . . . . . 0 N--CA 1.465 0.309 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.584 -178.586 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.74 0 CA-C-O 120.287 -0.174 . . . . 0.0 112.709 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 19.8 m -94.38 109.63 43.94 Favored Pre-proline 0 C--O 1.22 -0.453 0 CA-C-N 117.157 0.479 . . . . 0.0 111.518 -179.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.502 ' HG3' ' CE2' ' A' ' 28' ' ' TYR . 33.1 Cg_exo -58.16 134.04 59.29 Favored 'Trans proline' 0 CA--C 1.529 0.249 0 C-N-CA 122.532 2.155 . . . . 0.0 112.913 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 6.5 m -79.57 16.74 1.01 Allowed 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.516 -0.311 . . . . 0.0 111.272 179.294 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 62.9 29.91 75.65 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.101 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -153.59 156.2 37.54 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.315 0.578 . . . . 0.0 110.152 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.561 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 40.2 p -103.14 -174.73 2.62 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.544 -179.185 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 9.2 p -151.12 39.64 0.69 Allowed 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.227 179.312 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.906 HG22 ' HB3' ' A' ' 25' ' ' LYS . 10.9 t -69.99 -36.22 67.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.251 -0.886 . . . . 0.0 111.189 -179.25 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 29.2 m-85 -122.7 -45.93 2.15 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.362 -179.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.412 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 35.0 pt -103.62 147.5 34.33 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.179 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 11' ' ' ILE . 11.4 Cg_exo -68.64 156.21 66.28 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.715 2.277 . . . . 0.0 111.615 179.672 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 77.7 m -60.64 107.79 0.74 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.783 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 11.3 tt -64.96 -38.83 83.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 121.15 0.5 . . . . 0.0 109.976 179.22 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.556 ' HB3' HD12 ' A' ' 18' ' ' ILE . 6.0 m -81.62 20.72 0.88 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.024 179.325 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.562 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -60.85 -31.11 74.75 Favored Glycine 0 C--N 1.332 0.329 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.095 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 21.9 t -63.06 -23.95 34.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.324 0.583 . . . . 0.0 110.703 179.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.556 HD12 ' HB3' ' A' ' 15' ' ' SER . 6.5 mt -81.63 -12.33 12.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.413 179.666 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 118.96 -8.54 12.58 Favored Glycine 0 N--CA 1.446 -0.698 0 CA-C-N 115.715 -0.675 . . . . 0.0 112.182 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.562 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 1.8 m -70.21 127.64 33.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.726 0.774 . . . . 0.0 111.722 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 20.1 m -116.63 149.83 39.09 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.649 -1.159 . . . . 0.0 109.715 179.502 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.2 t -69.51 111.7 5.53 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.974 0.416 . . . . 0.0 110.292 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.511 ' HB ' ' CD1' ' A' ' 28' ' ' TYR . 5.9 m -119.59 103.07 9.1 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.005 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 36.2 t70 47.53 58.77 4.63 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.271 -179.502 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.906 ' HB3' HG22 ' A' ' 9' ' ' VAL . 28.4 mtmm 72.07 2.83 4.46 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 178.451 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 42.7 t -130.43 133.1 64.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 118.563 0.62 . . . . 0.0 110.385 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 83.9 m -80.95 120.41 24.72 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 112.724 0.639 . . . . 0.0 112.724 -178.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.511 ' CD1' ' HB ' ' A' ' 23' ' ' THR . 57.3 m-85 -121.47 139.89 52.89 Favored 'General case' 0 CA--C 1.518 -0.288 0 CA-C-O 121.142 0.496 . . . . 0.0 110.462 178.143 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.505 ' HB2' ' SG ' ' A' ' 20' ' ' CYS . 2.7 tt -94.11 77.89 4.05 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 178.249 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.1 m-80 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.01 -178.804 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.849 0 CA-C-O 120.211 -0.216 . . . . 0.0 112.792 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.6 m -95.83 110.7 52.92 Favored Pre-proline 0 C--O 1.222 -0.363 0 CA-C-N 117.306 0.553 . . . . 0.0 111.087 -179.414 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.1 Cg_exo -49.71 130.38 26.31 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.846 2.364 . . . . 0.0 112.627 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.602 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 4.8 m -92.16 6.69 45.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.312 -179.315 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.05 -27.23 2.73 Favored Glycine 0 N--CA 1.452 -0.286 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -178.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.693 ' OE2' ' HB3' ' A' ' 13' ' ' CYS . 19.7 tt0 -69.8 131.03 43.88 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 179.556 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.492 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.3 p -115.75 162.79 16.78 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.471 0.653 . . . . 0.0 112.465 -178.137 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.463 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.8 p -136.01 45.45 2.38 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.576 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.683 HG22 ' HB3' ' A' ' 25' ' ' LYS . 8.1 t -70.15 -43.21 79.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.38 -178.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -127.56 -46.98 1.43 Allowed 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.282 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 35.0 pt -104.11 149.49 37.31 Favored Pre-proline 0 C--N 1.322 -0.618 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.915 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_exo -67.82 152.51 77.31 Favored 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 122.354 2.036 . . . . 0.0 111.581 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.693 ' HB3' ' OE2' ' A' ' 6' ' ' GLU . 74.3 m -64.09 -46.42 84.36 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.257 -179.394 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.41 ' HB ' ' O ' ' A' ' 13' ' ' CYS . 77.2 mt 74.19 -57.07 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 C-N-CA 123.012 0.525 . . . . 0.0 111.521 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.446 ' O ' HG12 ' A' ' 18' ' ' ILE . 0.9 OUTLIER -68.46 -18.2 64.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.261 0.553 . . . . 0.0 110.084 179.351 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.752 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -52.27 -15.21 2.56 Favored Glycine 0 C--N 1.332 0.324 0 CA-C-N 115.107 -0.951 . . . . 0.0 113.887 -179.742 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 31.6 m -58.1 -18.25 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 117.07 0.435 . . . . 0.0 111.18 178.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 15' ' ' SER . 39.2 pt -73.95 -9.96 13.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.821 179.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.07 -23.25 2.59 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.746 -0.74 . . . . 0.0 111.681 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.752 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 38.9 m -67.76 121.86 16.87 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.514 0.673 . . . . 0.0 111.047 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.499 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -108.57 140.42 41.94 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.187 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.2 t -65.38 112.63 3.61 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.147 0.499 . . . . 0.0 110.245 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.4 m -127.61 109.4 11.65 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.016 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 21.4 t0 48.26 59.48 4.26 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.774 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.683 ' HB3' HG22 ' A' ' 9' ' ' VAL . 1.7 mptt 69.86 3.0 4.1 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.158 -0.928 . . . . 0.0 113.357 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.492 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 62.4 t -136.28 130.42 47.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 118.516 0.598 . . . . 0.0 110.815 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.621 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 5.6 m -80.2 123.32 27.82 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.502 0.668 . . . . 0.0 112.096 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.478 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 1.9 m-85 -108.42 142.34 38.92 Favored 'General case' 0 CA--C 1.519 -0.238 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.845 179.279 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.602 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.5 tt -89.78 83.48 6.21 Favored 'General case' 0 C--N 1.309 -1.165 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 178.289 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.3 m120 . . . . . 0 C--N 1.326 -0.427 0 CA-C-N 114.649 -1.159 . . . . 0.0 111.12 -178.574 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.858 0 CA-C-O 120.231 -0.205 . . . . 0.0 112.708 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 20.9 m -96.27 111.5 56.83 Favored Pre-proline 0 C--O 1.221 -0.441 0 CA-C-N 117.325 0.562 . . . . 0.0 111.2 -179.419 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.501 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 89.4 Cg_exo -47.5 127.25 13.37 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.897 2.398 . . . . 0.0 113.109 -179.562 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.599 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 22.9 m -84.72 -7.62 59.15 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.425 -179.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.14 -15.99 56.8 Favored Glycine 0 N--CA 1.448 -0.506 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.04 151.52 41.68 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.248 -0.476 . . . . 0.0 110.16 179.401 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.433 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 1.6 p -128.9 150.2 50.46 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 121.84 0.828 . . . . 0.0 112.394 -179.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.482 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 1.7 p -127.18 44.37 2.93 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 114.556 -1.202 . . . . 0.0 109.698 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.805 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.9 t -74.78 -46.41 41.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.485 -179.105 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -101.75 -48.66 4.22 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.089 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.482 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 32.5 pt -132.91 164.96 40.2 Favored Pre-proline 0 C--N 1.324 -0.503 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.605 -179.755 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -63.89 153.91 72.96 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.063 1.842 . . . . 0.0 111.684 179.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 86.8 m -61.82 139.12 58.38 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.323 -179.173 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 50.2 mm -67.22 122.81 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 115.307 -0.861 . . . . 0.0 109.657 178.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.678 ' O ' HG13 ' A' ' 18' ' ' ILE . 35.8 p 51.91 31.17 8.06 Favored 'General case' 0 CA--C 1.536 0.415 0 CA-C-N 115.495 -0.775 . . . . 0.0 112.655 -179.48 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -55.79 -14.24 7.26 Favored Glycine 0 C--N 1.338 0.683 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.805 178.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.7 p -56.63 -17.0 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 C-N-CA 123.147 0.579 . . . . 0.0 111.37 179.039 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.678 HG13 ' O ' ' A' ' 15' ' ' SER . 55.5 mt -55.65 -30.98 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.907 0.861 . . . . 0.0 110.633 178.632 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 150.94 -18.28 0.95 Allowed Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 114.501 -1.227 . . . . 0.0 110.099 -179.639 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.653 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 59.2 m -68.27 120.03 13.76 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.506 0.67 . . . . 0.0 110.734 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.525 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 7.3 m -107.25 139.82 41.1 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.097 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.7 t -66.67 118.4 10.18 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.862 0.363 . . . . 0.0 110.148 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 16.2 m -132.21 106.13 7.76 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.049 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.465 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 30.2 t70 48.98 58.21 5.61 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.625 0.726 . . . . 0.0 112.091 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.805 ' HB3' HG22 ' A' ' 9' ' ' VAL . 6.1 mtmp? 75.09 -5.7 2.11 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 178.408 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.493 HG23 ' HE1' ' A' ' 28' ' ' TYR . 1.9 m -133.2 132.0 58.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 118.507 0.594 . . . . 0.0 111.402 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.653 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 61.1 m -81.07 129.45 34.56 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -178.654 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.501 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.3 m-85 -110.01 143.72 39.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.761 178.64 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.599 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.4 tp -89.78 81.59 6.36 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 178.398 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.7 m120 . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.969 -178.28 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.656 0 CA-C-O 120.165 -0.241 . . . . 0.0 113.309 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 13.0 p -100.54 119.08 59.69 Favored Pre-proline 0 C--O 1.222 -0.382 0 CA-C-N 117.5 0.65 . . . . 0.0 111.576 -179.135 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.6 Cg_exo -48.41 134.31 25.91 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 123.121 2.548 . . . . 0.0 112.813 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.599 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 37.1 m -82.53 19.43 1.27 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.513 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 63.75 28.8 73.16 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.235 -0.507 . . . . 0.0 112.877 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 11.7 tp10 -155.81 153.45 29.81 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-O 120.946 0.403 . . . . 0.0 110.064 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.631 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 44.8 p -100.14 -177.64 3.59 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.542 -0.754 . . . . 0.0 112.235 -178.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.7 p -151.54 45.45 0.79 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.113 179.229 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 10.6 t -65.9 -39.49 84.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.357 -0.838 . . . . 0.0 111.573 -178.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -128.32 -47.6 1.32 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.503 179.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.463 HD12 ' HD2' ' A' ' 12' ' ' PRO . 5.8 tp -106.92 123.62 37.93 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.416 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.463 ' HD2' HD12 ' A' ' 11' ' ' ILE . 5.6 Cg_exo -73.05 153.42 52.12 Favored 'Trans proline' 0 N--CA 1.456 -0.685 0 C-N-CA 122.407 2.071 . . . . 0.0 111.49 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 86.1 m -67.29 117.04 8.74 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.125 -179.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 47.3 mm -62.3 -40.09 86.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.593 -179.796 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.644 ' O ' HG12 ' A' ' 18' ' ' ILE . 6.3 m -76.01 20.19 0.2 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.5 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.736 ' HA2' ' HB2' ' A' ' 20' ' ' CYS . . . -58.28 -21.07 46.44 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 121.508 -0.377 . . . . 0.0 112.898 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.9 m -61.42 -19.72 21.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 112.161 0.43 . . . . 0.0 112.161 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.644 HG12 ' O ' ' A' ' 15' ' ' SER . 23.1 pt -83.25 1.82 3.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.741 0.305 . . . . 0.0 111.31 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.05 -17.03 8.69 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.581 -0.818 . . . . 0.0 112.212 179.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.736 ' HB2' ' HA2' ' A' ' 16' ' ' GLY . 70.8 m -65.66 124.02 21.27 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.506 0.67 . . . . 0.0 111.373 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 18.5 m -128.04 142.47 51.21 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.239 -0.891 . . . . 0.0 109.262 179.485 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 46.4 t -73.27 124.76 26.31 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.903 0.382 . . . . 0.0 110.399 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 57.3 m -150.18 123.89 9.19 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.61 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 51.8 t0 51.54 55.16 9.82 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.123 0.487 . . . . 0.0 110.999 -179.237 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.61 ' HD2' ' O ' ' A' ' 24' ' ' ASP . 0.0 OUTLIER 60.01 5.55 0.78 Allowed 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.074 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.666 HG23 ' HE1' ' A' ' 28' ' ' TYR . 2.7 m -134.6 145.21 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 O-C-N 121.682 -0.637 . . . . 0.0 112.072 178.68 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 73.9 m -81.37 126.41 31.57 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -179.101 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.666 ' HE1' HG23 ' A' ' 26' ' ' VAL . 30.0 m-85 -112.43 142.6 44.77 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 177.568 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.599 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 3.7 tt -104.22 88.79 3.07 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.533 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 . . . . . 0 C--N 1.326 -0.443 0 CA-C-N 114.959 -1.019 . . . . 0.0 111.356 -178.839 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.809 0 CA-C-O 120.001 -0.333 . . . . 0.0 112.98 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.535 HG23 ' HB3' ' A' ' 29' ' ' LEU . 4.9 t -100.57 119.81 57.7 Favored Pre-proline 0 C--O 1.221 -0.424 0 CA-C-N 117.758 0.779 . . . . 0.0 111.742 -179.158 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -50.22 131.43 31.23 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 123.098 2.532 . . . . 0.0 113.002 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.686 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 8.8 m -90.61 22.71 3.36 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.825 -178.84 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.23 35.69 88.72 Favored Glycine 0 C--N 1.331 0.291 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.105 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.599 ' OE2' HG12 ' A' ' 14' ' ' ILE . 44.7 tt0 -146.1 153.24 40.47 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -179.533 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -135.02 150.19 50.27 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.225 0.536 . . . . 0.0 111.436 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -100.44 51.89 0.88 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.073 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.406 HG12 ' CD1' ' A' ' 10' ' ' TYR . 16.3 t -63.61 -40.08 87.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.424 -179.268 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.406 ' CD1' HG12 ' A' ' 9' ' ' VAL . 40.4 m-85 -142.58 -42.25 0.32 Allowed 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.772 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 37.2 pt -103.26 152.68 38.71 Favored Pre-proline 0 C--N 1.324 -0.531 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.785 -179.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo -68.87 154.42 71.04 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.726 2.284 . . . . 0.0 111.62 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 20.6 m -64.26 122.37 16.5 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.554 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.599 HG12 ' OE2' ' A' ' 6' ' ' GLU . 33.4 pt -74.12 -28.14 23.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.14 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.1 p -78.73 2.4 19.82 Favored 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.507 179.017 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -56.51 -33.77 62.82 Favored Glycine 0 C--N 1.333 0.394 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.625 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 25.6 t -61.63 -27.31 41.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.394 0.616 . . . . 0.0 110.767 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 37.4 mm -78.15 -18.71 13.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.521 179.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 125.97 -7.97 7.67 Favored Glycine 0 N--CA 1.447 -0.57 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.778 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.513 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 60.4 m -63.68 124.89 22.59 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.377 0.608 . . . . 0.0 110.916 -179.774 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 8.8 m -112.21 147.09 36.93 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.371 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.8 t -75.0 123.53 25.32 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.868 0.366 . . . . 0.0 110.15 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.2 m -145.66 121.85 10.83 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 53.67 44.29 29.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.871 0.843 . . . . 0.0 110.754 -179.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.501 ' HG2' ' O ' ' A' ' 25' ' ' LYS . 11.4 ttpp 65.49 10.77 6.88 Favored 'General case' 0 CA--C 1.544 0.723 0 CA-C-N 114.338 -1.301 . . . . 0.0 112.098 179.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.402 ' HB ' ' HE1' ' A' ' 28' ' ' TYR . 49.9 t -127.4 138.42 54.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 O-C-N 121.838 -0.539 . . . . 0.0 110.447 179.713 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 17.8 m -82.02 122.5 27.89 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.771 0.319 . . . . 0.0 111.071 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.446 ' O ' ' HA ' ' A' ' 20' ' ' CYS . 25.2 m-85 -116.75 139.99 49.94 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-O 121.165 0.507 . . . . 0.0 110.862 179.514 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.686 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 55.3 tp -91.59 83.89 5.42 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 177.73 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 3.6 m120 . . . . . 0 C--N 1.327 -0.391 0 CA-C-N 114.704 -1.135 . . . . 0.0 111.299 -178.497 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.795 0 CA-C-O 120.2 -0.222 . . . . 0.0 113.064 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.434 ' HA ' ' HD2' ' A' ' 3' ' ' PRO . 20.4 m -101.21 112.71 65.41 Favored Pre-proline 0 C--O 1.22 -0.489 0 CA-C-N 117.392 0.596 . . . . 0.0 111.041 -179.396 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.596 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 8.5 Cg_endo -49.35 130.32 24.76 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 123.031 2.487 . . . . 0.0 112.626 -179.719 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.654 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 32.4 m -83.26 11.16 6.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.285 -179.167 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 66.1 28.62 73.82 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 121.08 -0.581 . . . . 0.0 112.269 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.627 ' HG3' ' HB2' ' A' ' 27' ' ' CYS . 17.2 pt-20 -134.45 155.08 50.96 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.998 0.428 . . . . 0.0 109.86 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 26' ' ' VAL . 2.8 p -124.19 154.28 40.34 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.613 0.72 . . . . 0.0 112.302 -178.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.8 p -127.25 46.1 2.59 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 114.385 -1.279 . . . . 0.0 109.791 179.654 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.848 HG22 ' HB3' ' A' ' 25' ' ' LYS . 16.3 t -70.6 -48.4 58.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.899 -178.662 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 9.2 m-85 -101.18 -47.92 4.57 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.379 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 31.5 pt -126.95 154.92 76.37 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.397 -179.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -65.48 154.6 72.97 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.46 2.106 . . . . 0.0 111.885 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.46 ' HB3' ' OE1' ' A' ' 6' ' ' GLU . 71.1 m -66.58 128.08 34.85 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.803 -179.314 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 11.5 tt -71.73 126.84 32.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.219 179.481 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.562 ' O ' HG12 ' A' ' 18' ' ' ILE . 21.6 m 67.07 14.58 9.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.648 -0.705 . . . . 0.0 111.844 -179.465 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -56.15 -16.23 13.22 Favored Glycine 0 C--N 1.339 0.706 0 C-N-CA 121.229 -0.51 . . . . 0.0 112.666 179.059 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 16.6 t -56.23 -17.84 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.235 0 C-N-CA 122.95 0.5 . . . . 0.0 111.272 179.172 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.562 HG12 ' O ' ' A' ' 15' ' ' SER . 47.2 mm -57.9 -29.16 35.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.613 0.72 . . . . 0.0 111.044 178.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 155.99 -22.85 0.53 Allowed Glycine 0 C--N 1.312 -0.782 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 179.787 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.496 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 60.1 m -67.35 120.49 13.95 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.644 0.735 . . . . 0.0 110.723 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.487 ' O ' ' HA ' ' A' ' 27' ' ' CYS . 17.9 m -110.62 139.97 45.39 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.713 -179.597 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 49.1 t -67.51 109.66 3.32 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.015 0.436 . . . . 0.0 110.08 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.0 m -120.26 103.54 9.32 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.043 -179.563 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.452 ' O ' ' HD2' ' A' ' 25' ' ' LYS . 21.7 t70 47.65 62.05 2.64 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.767 -179.572 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.848 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.6 OUTLIER 70.96 -0.5 3.02 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 115.117 -0.947 . . . . 0.0 113.356 178.71 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 7' ' ' SER . 50.1 t -131.89 128.26 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 118.557 0.617 . . . . 0.0 110.54 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.627 ' HB2' ' HG3' ' A' ' 6' ' ' GLU . 54.5 m -81.32 128.4 33.79 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.467 0.651 . . . . 0.0 112.457 -179.532 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.596 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 4.2 m-85 -114.46 144.21 43.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.307 -0.861 . . . . 0.0 109.941 179.258 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.654 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 53.1 tp -92.4 81.67 4.9 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.505 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 115.057 -0.974 . . . . 0.0 111.516 -179.188 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.725 0 CA-C-O 120.115 -0.269 . . . . 0.0 113.085 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 21.9 m -97.72 112.48 61.6 Favored Pre-proline 0 C--O 1.222 -0.384 0 CA-C-N 117.484 0.642 . . . . 0.0 111.355 -179.245 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 28' ' ' TYR . 75.5 Cg_exo -50.4 131.85 33.22 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.843 2.362 . . . . 0.0 112.486 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.601 ' SG ' ' HB2' ' A' ' 29' ' ' LEU . 35.5 m -85.15 18.5 2.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.472 -179.201 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.03 33.1 77.74 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.482 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -153.0 151.56 30.41 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.65 ' HB2' HG23 ' A' ' 9' ' ' VAL . 0.6 OUTLIER -132.87 146.36 51.74 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.669 0.747 . . . . 0.0 112.097 -179.284 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.483 ' HA ' ' O ' ' A' ' 11' ' ' ILE . 2.1 p -101.37 45.39 0.97 Allowed 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.389 179.549 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.65 HG23 ' HB2' ' A' ' 7' ' ' SER . 16.3 t -70.9 -35.65 60.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.042 -179.491 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -128.93 -50.8 1.22 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.504 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.483 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 2.4 pp -104.95 151.08 39.37 Favored Pre-proline 0 C--N 1.324 -0.529 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.738 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -71.15 150.07 59.13 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.194 1.93 . . . . 0.0 111.609 179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 98.5 m -69.37 -39.68 77.9 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.923 -179.272 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 76.1 mt 71.48 -44.91 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 122.764 0.426 . . . . 0.0 111.346 -179.63 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.5 p -71.02 10.46 0.54 Allowed 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 122.88 0.472 . . . . 0.0 111.753 179.274 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.456 ' HA2' ' O ' ' A' ' 20' ' ' CYS . . . -57.66 -25.7 56.06 Favored Glycine 0 C--O 1.227 -0.292 0 CA-C-N 116.143 -0.48 . . . . 0.0 113.086 179.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 29.8 m -61.73 -20.91 24.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.994 0.426 . . . . 0.0 111.889 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 16.9 mt -78.63 -14.13 13.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.599 0.714 . . . . 0.0 110.47 179.647 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.87 -14.75 6.3 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.505 ' HB3' ' HB3' ' A' ' 27' ' ' CYS . 60.0 m -63.05 125.84 25.34 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.26 0.552 . . . . 0.0 110.775 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 17.9 m -129.35 140.56 51.34 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.08 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 53.0 m -62.62 111.18 1.97 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.384 0.611 . . . . 0.0 111.345 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.8 m -124.43 107.09 10.73 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.585 179.474 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.416 ' O ' ' HB2' ' A' ' 25' ' ' LYS . 45.1 t0 54.4 50.37 16.37 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.817 0.818 . . . . 0.0 110.248 -178.326 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.615 ' HB3' HG22 ' A' ' 9' ' ' VAL . 0.1 OUTLIER 72.04 -7.71 1.26 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.698 -1.137 . . . . 0.0 113.105 179.692 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 41.3 t -115.25 132.03 65.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 O-C-N 122.06 -0.4 . . . . 0.0 110.464 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.505 ' HB3' ' HB3' ' A' ' 20' ' ' CYS . 39.5 m -78.65 120.37 23.23 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.512 0.672 . . . . 0.0 112.67 -179.11 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.498 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 2.5 m-85 -110.35 143.71 40.18 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.171 -0.922 . . . . 0.0 109.372 178.429 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.601 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 2.9 tt -97.98 84.85 3.38 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 178.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 72.1 m-80 . . . . . 0 C--N 1.326 -0.454 0 CA-C-N 114.898 -1.047 . . . . 0.0 111.196 -179.053 . . . . . . . . 0 0 . 1 stop_ save_